


Drug Utilization Review Board

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
DHCA Board Room

Wednesday

March 12, 2008

@ 6:00 p.m.



THE UNIVERSITY OF
OKLAHOMA



THE UNIVERSITY OF OKLAHOMA

MEMORANDUM

TO: Drug Utilization Review Board Members
FROM: Shellie Gorman, Pharm.D.
SUBJECT: Packet Contents for Board Meeting – March 12, 2008
DATE: March 5, 2008
NOTE: THE DUR BOARD WILL MEET AT 6:00 P.M.

Enclosed are the following items related to the March meeting. Material is arranged in order of the Agenda.

Call to Order

Public Comment Forum

Action Item – Approval of DUR Board Meeting Minutes – **See Appendix A.**

Update on DUR / MCAU Program – **See Appendix B.**

Action Item – Vote to Prior Authorize Combigan™ – **See Appendix C.**

30 Day Notice to Prior Authorize Narcotic Analgesics – **See Appendix D.**

30 Day Notice to Prior Authorize Tekturna HCT® – **See Appendix E.**

Fiscal Year 2007 Annual Review – **See Appendix F.**

Utilization Review of Topical Antibiotics – **See Appendix G**

Action Item – Vote on New Quantity Limits and Annual Review of Osteoporosis Medications / Bone Resorption Suppression Agents – **See Appendix H.**

Action Item – Annual Review of Nasal Allergy Products – **See Appendix I.**

FDA and DEA Updates – **See Appendix J.**

Future Business

Adjournment

Drug Utilization Review Board

(DUR Board)

Meeting – March 12, 2008 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. February 13, 2008 DUR Minutes – Vote
 - B. February 14, 2008 DUR Recommendations Memorandum

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman:

4. **Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for November 2007
 - B. Retrospective Drug Utilization Review Response for August 2007
 - C. Medication Coverage Activity Audit for February 2008
 - D. Help Desk Activity Audit for February 2008

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman

5. **Vote to Prior Authorize Combigan™ – See Appendix C.**
 - A. Product Summary
 - B. Cost Comparison
 - C. COP Recommendations

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman:

6. **30 Day Notice to Prior Authorize Narcotic Analgesics – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Browning, Dr. McNeill, Chairman

7. **30 Day Notice to Prior Authorize Tekturna HCT[®] – See Appendix E.**
 - A. Product Summary
 - B. Cost Comparison
 - C. COP Recommendations

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

8. **Fiscal Year 2007 Annual Review – See Appendix F.**
 - A. Pharmacy Claims by Therapeutic Category
 - B. Top 100 Medications by Pharmacy Reimbursement
 - C. Top 50 Medications by Claims

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

9. **Utilization Review of Topical Antibiotics – See Appendix G.**
 - A. Utilization Review
 - B. Cost Comparison
 - C. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman

10. **Vote on New Quantity Limits and Annual Review of Osteoporosis Medications / Bone Resorption Suppression Agents – See Appendix H.**
 - A. Introduction / Product Overview
 - B. Current PA Criteria
 - C. Utilization Review
 - D. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

11. **Annual Review of Nasal Allergy Products – See Appendix I.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

12. **FDA and DEA Updates – See Appendix J.**

13.

Future Business

- A. Oral Allergy Follow-Up
- B. Methylphenidate Follow-Up
- C. Qualaquin Annual Review
- D. Oral Antifungals
- E. New Product Reviews

14.

Adjournment



Appendix A

**OKLAHOMA HEALTH CARE AUTHORITY
DRUG UTILIZATION REVIEW BOARD MEETING
MINUTES of MEETING of FEBRUARY 13, 2008**

BOARD MEMBERS:	PRESENT	ABSENT
Brent Bell, D.O., D.Ph.	X	
Jay D. Cunningham, D.O.		X
Mark Feightner, D.Ph.	X	
Dorothy Gourley, D.Ph.	X	
Evelyn Knisely, Pharm.D.	X	
Thomas Kuhls, M.D.	X	
Dan McNeill, Ph.D., PA-C; Chairman	X	
Cliff Meece, D.Ph.; Vice-Chairman		X
John Muchmore, M.D., Ph.D.	X	
James Rhymer, D.Ph	X	

COLLEGE of PHARMACY STAFF:	PRESENT	ABSENT
Leslie Browning, D.Ph.; PA Coordinator	X	
Metha Chonlahan, D.Ph.; Clinical Pharmacist	X	
Karen Egesdal, D.Ph.; SMAC-ProDUR Coordinator/OHCA Liaison	X	
Kelly Flannigan, Pharm.D.; Operations Manager	X	
Shellie Gorman, Pharm.D.; DUR Manager	X	
Ronald Graham, D.Ph.; Pharmacy Director	X	
Chris Le, Pharm.D.; Clinical Pharmacist/Coordinator		X
Carol Moore, Pharm.D.; Clinical Pharmacist		X
Neeraj Patel, Pharm.D.; Clinical Pharmacist	X	
Lester A. Reinke, Ph.D.; Principal Investigator		X
Visiting Pharmacy Students: Megan Raney, CheWah Tse	X	

OKLAHOMA HEALTH CARE AUTHORITY STAFF:	PRESENT	ABSENT
Mike Fogarty, J.D., M.S.W.; Chief Executive Officer		X
Nico Gomez; Director of Gov't and Public Affairs		X
Lynn Mitchell, M.D., M.P.H.; Director of Medical Services	X	
Nancy Nesser, Pharm.D., J.D.; Pharmacy Director	X	
Howard Pallotta, J.D.; Director of Legal Services		X
Lynn Rambo-Jones, J.D.; Deputy General Counsel III		X
Rodney Ramsey; Drug Reference Coordinator	X	
Jill Ratterman, D.Ph.; Pharmacy Specialist	X	
Kerri Wade, Senior Pharmacy Financial Analyst	X	

OTHERS PRESENT:		
David Williams, Forest Pharm.	Daniel Garcia, Takeda Pharm.	Jim Dunlap, Eli Lilly
Rachelle Wan, Amgen	M. Patty Laster, Genentech	Vince Morrison, Forest Pharm.
Laura Mitchell, Purdue Pharm.	Amie Gardiner, Purdue	Aaron Mays, Alcon Labs
Janie Huff, TAP Pharm.	Tim Sinn, Takeda Pharm.	Joseph Medina, Sepracor
L. Stewart, Merck	Jorge Nassar, BMS	Richard Ponder, J&J
Rebecca King, Taro	Dan Huffman, Astra Zeneca	Justin Springfield, Sepracor
Jim Fowler, Astra Zeneca		

PRESENT FOR PUBLIC COMMENT:	
James Lieurance, Endo Pharmaceuticals	Agenda Item No. 5

AGENDA ITEM NO. 1: CALL TO ORDER

1A: Roll Call

Dr. Meece called the meeting to order. Roll call by Dr. Graham established a quorum.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 2: PUBLIC COMMENT FORUM

James Lieurance, Endo Pharmaceuticals, for Agenda Item 5.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 3: APPROVAL OF DUR BOARD MINUTES

3A: January 9, ~~2007~~ 2008 DUR Minutes

Dr. Gourley moved to approve minutes as submitted; seconded by Dr. Kuhls.

ACTION: MOTION CARRIED.

AGENDA ITEM NO. 4: UPDATE ON DUR/MCAU PROGRAM

4A: Retrospective Drug Utilization Review Report: October 2007

4B: Retrospective Drug Utilization Review Response: July 2007

4C: Medication Coverage Activity Audit: January 2008

4D: Help Desk Activity Audit: January 2008

Reports included in agenda packet; presented by Dr. Flannigan.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 5: 60-DAY NOTICE TO PRIOR AUTHORIZE NARCOTIC ANALGESICS

For Public Comment, James Lieurance: Well first of all, for clarification, I'm not a doctor; however I am an Enid, Oklahoma native, so I'll play that card in this room. I'm actually the account executive for Endo Pharmaceuticals, the manufacturers of Opana ER and the reason I'm here is because my Texas clinical liaison called me this morning and had a family emergency and wasn't able to make the event, so I hopped in the car and drove down here. So I will do my best to present some things with some brevity. After reviewing the agenda recommendations for the long-acting opioid class, one of the things that I wanted to do was to ask you to turn to the first blue path where you'll see the molecular structure of morphine and oxycodone. And the reason I want to focus on this slide is just so that we're very clear that these are two different chemical agents. When treating long-acting analgesics in the class, you really have three different buckets. You have a Fentanyl bucket obviously, you have the morphine sulfate bucket, and you have oxycodone which is a unique agent. The reason I point this is these agents all hypothetically, exert a chemical on the mu receptor and each one has a specific chain of events that it creates. The reason I want to bring this up is because of the fact that it's often viewed as a morphine sulfate and it's not. When you exert that different effect on the mu receptor, you in essence, justify the need for opioid rotation. So I wanted to stress that fact. I also wanted to make you aware of the fact that Opana ER currently, does not have a branded alternative. It does not have a generic alternative. However, out of the class of random long-acting opioids, it is scheduled to be the first long-acting opioid to be generic, which would be mid-March, so I wanted to make you aware of that. In addition, I wanted to also make you aware of that. In addition, I wanted to also make you aware of the fact that this drug is not metabolized by the cytochrome P450 3A4 metabolite system. So when you look at pain, where you would have other agents commonly used such as tricyclic antidepressants and SSRI's, you avoid the potential for drug-to-drug interactions and last year in the U.S., we spent over \$2 billion dollars treating drug-to-drug interactions in the emergency room. So I wanted to just highlight those two facts relevant to the drug. Other than that, I agree with the assessment in the Agenda, that all these drugs have excellent efficacy and durability. I just remind the Board that it's not always excellent efficacy and durability for all patients all the time. So each one of these agents is specific to the patient and the patient's response. At this point in time, are there any questions? OK, one last comment. I would just note that in the recommendation in the packet, that it was recommended that generic Fentanyl as well as generic morphine sulfate be Tier One; however I am a little concerned with the Kadian and Avniza in the Tier Two recommendation, simply because those drugs are also morphine sulfates, so I would put forth the argument and beseech you guys to consider Opana ER as a second tier option, simply because it is a chemically unique and different agent, and may provide pain relief to the patients that are not responding to the generic morphine sulfates. Thank you.

Materials included in agenda packet; presented by Dr. Gorman.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 6: 30-DAY NOTICE TO PRIOR AUTHORIZE COMBIGAN™

Materials included in agenda packet; presented by Dr. Chonlahan.

Revise PA criteria per Board request: Remove second sentence from #2 criteria, and make the second sentence criteria #5 or #6.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 7: BETA BLOCKERS UTILIZATION REVIEW

Materials included in agenda packet; presented by Dr. Chonlahan.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 8: ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION REVIEW

Materials included in agenda packet; presented by Dr. Flannigan.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 9: ANNUAL REVIEW OF INSOMNIA PRODUCTS

Materials included in agenda packet; presented by Dr. Browning.

Dr. Feightner made a motion to move Lunesta, Rozerem, Ambien CR, Sonata and Restoril brand name to Tier 3; seconded by Dr. Bell.

ACTION: MOTION CARRIED.

AGENDA ITEM NO. 10: ANNUAL REVIEW OF GLUMETZA™ AND FORTAMET®

Materials included in agenda packet; presented by Dr. Patel.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 11: FDA & DEA UPDATES

Materials included in agenda packet; presented by Dr. Graham.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 12: FUTURE BUSINESS

Materials included in agenda packet; submitted by Dr. Graham.

12A: FY07 Annual Review (Presented in March 2008)

12B: Osteoporosis Utilization Review

12C: Oral Allergy Follow-Up

12D: Non-Hypnotic Benzodiazepine Review

12E: Nasal Allergy PBPA Review

12F: New Product Reviews

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 13: ADJOURNMENT

The meeting was adjourned.

Items in red are corrections to 02-13-2008 agenda.



The University of Oklahoma College of Pharmacy



Pharmacy Management Consultants
ORI W-4403; PO Box 26901
Oklahoma City, OK 73190
(405)-271-9039

Memorandum

Date: February 14, 2008

To: Nancy Nesser, Pharm.D., J.D.
Pharmacy Director
Oklahoma Health Care Authority

From: Shellie Gorman, Pharm.D., M.S.
Drug Utilization Review Manager
Pharmacy Management Consultants

Subject: DUR Board Recommendations from Meeting of February 13, 2008.

Recommendation 1: Annual Review of Insomnia Products

MOTION CARRIED by unanimous approval.

The DUR Board made the following recommendation:

Tier 1 ^a	Tier 2	Tier 3
estazolam temazepam flurazepam triazolam zolpidem*		Sonata [®] Restoril [®] 7.5 and 22.5 mg Lunesta [®] Rozerem [®] Ambien CR [®]

*Brand products would still require a brand name override.

Insomnia Approval Criteria:

1. In order to receive a Tier 2 product (or a Tier 3 product if no Tier 2 products exists) a minimum trial of 30 days with at least two Tier 1 products (including zolpidem) should be attempted. Also, clinical documentation of attempts to correct any primary cause for insomnia should be provided.
2. In order to receive a Tier 3 product, all available Tier 2 products should be attempted for a minimum of 30 days each. All other Tier 2 criteria should also be met.

3. FDA approved diagnosis (Ambien CR[®] only covered for sleep maintenance insomnia).
4. No concurrent anxiolytic benzodiazepine therapy greater than TID dosing and no concurrent ADHD medications.
5. Approvals granted for 6 months.

The DUR Board also recommends increased strictness with all current age restrictions and increased efforts to reduce the elderly to the lowest benzodiazepine doses possible.

Recommendation 2: Annual Review of Glumetza™ and Fortamet®

NO ACTION REQUIRED.

The College of Pharmacy does not recommend any changes at this time.



Appendix B

Retrospective Drug Utilization Review Report
Claims Reviewed for November 2007


Module	Drug Interaction	Duplication of Therapy	Drug-Disease Precautions	Dosing & Duration
Total # of messages returned by system when no limits were applied	41,469	64,728	967,474	33,714
Limits which were applied	Established, Major, Males and Females, Age 0-18	Narcotics, Males and Females, Age 19-21	Contraindicated, Males and Females, Age 22-35, Asthma	High Dose only, 22-43 year old, male and females, Abilify and Geodon
Total # of messages after limits were applied	28	141	76	13
Total # of members reviewed after limits were applied	28	96	57	13
LETTERS				
Prescribers		Pharmacies		
Sent	Responded	Sent	Responded	
68		47		

Retrospective Drug Utilization Review Report


Claims Reviewed for August 2007

Module	Drug Interaction	Duplication of Therapy	Drug-Disease Precautions	Dosing & Duration
Limits which were applied	Established, Major, Males and Females, Age 41-50	Narcotics, Males and Females, Age 0-10	Contraindicated, Chronic Ischemic Heart Disease, Males and Females, Age 0-150	High Dose only, Antitussives, Males and Females, Age 0-6
Response Summary (Prescriber) Letters Sent: 62 Response Forms Returned: 36 The response forms returned yielded the following results:				
4 (11%)	<i>Record Error—Not my patient.</i>			
3 (8%)	<i>No longer my patient.</i>			
1 (3%)	<i>Medication has been changed prior to date of review letter.</i>			
10 (28%)	<i>I was unaware of this situation & will consider making appropriate changes in therapy.</i>			
14 (39%)	<i>I am aware of this situation and will plan to continue monitoring therapy.</i>			
4 (11%)	<i>Other</i>			
Response Summary (Pharmacy) Letters Sent: 67 Response Forms Returned: 52 The response forms returned yielded the following results:				
1 (2%)	<i>Record Error—Not my patient.</i>			
7 (13%)	<i>No longer my patient.</i>			
6 (12%)	<i>Medication has been changed prior to date of review letter.</i>			
15 (29%)	<i>I was unaware of this situation & will consider making appropriate changes in therapy.</i>			
13 (25%)	<i>I am aware of this situation and will plan to continue monitoring therapy.</i>			
10 (19%)	<i>Other</i>			

PRIOR AUTHORIZATION ACTIVITY REPORT February 2008



PRIOR AUTHORIZATION REPORT February 2007 – February 2008



Activity Audit for
February 01, 2008 Through February 29, 2008

	Average Length of Approvals in Days	Approved	Denied	Total
ACE Inhibitors	108	8	9	17
Angiotensin Receptor Antagonist	354	33	58	91
Antidepressant	270	191	288	479
Antihistamine	95	638	331	969
Antiulcers	18	11	1	12
Anxiolytic	93	2,759	349	3,108
Calcium Channel Blockers	131	7	1	8
Growth Hormones	173	20	1	21
HTN Combos	319	6	7	13
Insomnia	92	37	15	52
Nsaids	295	23	64	87
Plavix	179	179	11	190
Stimulant	210	712	311	1,023
Others	103	1,023	818	1,841
Emergency PAs		0	0	0
Total		5,647	2,264	7,911
Overrides				
Brand	176	46	25	71
Dosage Change	22	297	16	313
High Dose	365	5	0	5
Ingredient Duplication	18	9	0	9
Lost/Broken Rx	13	97	10	107
Nursing Home Issue	14	51	2	53
Other	15	34	8	42
Quantity vs. Days Supply	216	331	175	506
Stolen	3	2	1	3
Wrong D.S. on Previous Rx	0	0	4	4
Overrides Total		863	241	1,104


Denial Reasons

Lack required information to process request.	2,268
Unable to verify required trials.	824
Considered duplicate therapy. Member has a prior authorization for similar medication.	145
Not an FDA approved indication/diagnosis.	105
Does not meet established criteria.	70
Requested dose exceeds maximum recommended FDA dose.	51
Member has active PA for requested medication.	34
Medication not covered as pharmacy benefit.	7
Duplicate Requests	503
* Changes to existing	589

* Changes to existing PA's: Backdates, changing units, end dates, etc.

CALL VOLUME MONTHLY REPORT

February 2007 – February 2008



04-06 thru 03-07: corrected totals



Appendix C

Vote to Prior Authorize

Combigan^(TM) (brimonidine tartrate and timolol maleate)

Oklahoma Health Care Authority

March 2008

Manufacturer Allergan
Classification Alpha² Agonist/Nonselective Beta-Blocker; Anti-Glaucoma
Status: prescription only

Summary

Combigan^(TM) (brimonidine tartrate and timolol maleate) 0.2%/0.5% received FDA approval on October 31, 2007 for the treatment of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. Both active ingredients are commercially available as single-agent products. The IOP-lowering of COMBIGAN^(TM) ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution 0.2% dosed three times per day.⁽²⁾

Brimonidine 0.2% is selective agonist for alpha₂-receptors which causes reduction of aqueous humor formation and increased uveoscleral outflow. Timolol maleate blocks both beta₁- and beta₂-adrenergic receptors which reduce intraocular pressure by reducing aqueous humor production or possibly outflow. In addition, this component reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, producing a negative chronotropic and inotropic activity by blocking beta₁-adrenergic receptors.

Cost Comparison

	EAC / mL	SMAC / mL	Daily Dose*	Cost (5 mL)
Brimonidine tartrate 0.2%	\$5.73	\$3.05	1 drop TID	\$15.25
Timolol maleate 0.5%	\$3.89	\$0.62	1 drop BID	\$ 3.10
Brimonidine tartrate 0.2%/timolol maleate 0.5%	\$12.45	n/a	1 drop BID	\$62.25

* Based on # drops per mL of solution and average daily dose (brimonidine=25 drops/mL, timolol=32 drops/mL, Combigan=29.6)

Recommendations

The College of Pharmacy recommends placement of Combigan^(TM) (brimonidine tartrate and timolol maleate) 0.2%/0.5% into the tier-2 products in the Anti-Glaucoma PBPA category. Information regarding need for use of combination product over single ingredient products must also be provided.

Current Anti-Glaucoma PA Criteria

1. FDA approved diagnosis.
2. Member must attempt at least one Tier 1 trial of a minimum of 4 weeks duration within the last 90 days. Tier 1 trial may be from any pharmacologic class.
3. Approval may be granted if there is a documented adverse effect, drug interaction, or contraindication to Tier 1 products.
4. Approval may be granted if there is a unique FDA approved indication not covered by Tier 1 products.
5. Member must have had a comprehensive dilated eye exam within the last 365 day period as recommended by the National Institute of Health.
6. Approval duration will be for 1 year.

Tier 1	Tier 2
Beta-Blockers	
Betagan 0.25%,0.5% (Levobunolol) Optipranolol 0.3% (Metipranolol) Timoptic, Betimol, Istalol, Timoptic Ocudose, Timoptic XE 0.25,0.5% (Timolol Maleate) Cartrol, Ocupress 1% (Carteolol) Betoptic-S 0.5% (betaxolol)	Betoptic-S (betaxolol) Cosopt (Dorzolamide and Timolol)** Timoptic 0.5% Dropperette
Prostaglandin Analogs	
Xalatan (Latanoprost)* Travatan, Travatan Z (Travoprost)	Lumigan (Bimatoprost)
Adrenergic Agonists	
Propine (Dipivefrin)	
Alpha-2 Adrenergic Agonists	
Brimonidine 0.2%	Alphagan P 0.1, 0.15% (Brimonidine) lopidine 1% Apraclonidine
Carbonic Anhydrase Inhibitor	
Cosopt (Dorzolamide and Timolol)*	Azopt (Brinzolamide) Trusopt (Dorzolamide)
Cholinergic Agonists¹/Cholinesterase Inhibitors²	
Isopto Carpine, Pilopine HS 0.5,1,2,4,6 %(Pilocarpine)	Isopto, Miostat 1.5, 3% (Carbachol) ¹ Phospholine Iodide (Echothiophate Iodide) ²
Combination Products	
	Brimonidine 0.2%/timolol maleate 0.5% (Combigan)**

Blue indicates Tier-1 due to Supplemental Rebate Participation

*Current portfolio supplemental rebate agreement participation

**Must also provide information regarding need for combination product.



Appendix D

30 Day Notice to Prior Authorize Narcotic Analgesics

Oklahoma HealthCare Authority, March 2008

This category was introduced for possible inclusion in the Product Based Prior Authorization program in September 2007. See the September DUR packet for a more complete discussion of the category. This notice and statement of potential economic impact are presented to meet the statutory requirements of 63 O.S. Sec. 5030.5.

Recommendations

The College of Pharmacy recommends adding the Narcotic Analgesics to the Product Based Prior Authorization Program.

Tier 1	Tier 2	Tier 3	Oncology Only
All Immediate Release Narcotics Not Listed in Higher Tier*	Long-Acting		
	Morphine ER*	Kadian®	Avinza®
	Duragesic® Patches†	Opana® ER	Oxycontin®
	Short Acting		
	Xodol® Opana®		Actiq® Fentora®

*Branded products will require a brand name override.

†Product would move to Tier 3 if current manufacturer's federal rebate status changes.

Recommended Criteria:

1. Members with an oncology related diagnosis will be exempt from the prior authorization process, quantity and dosage limits would still apply.
2. Only 1 long-acting and 1 short-acting agent can be used concurrently regardless of diagnosis.
3. Tier 2 agents will only be approved after:
 - a. A minimum 30 day documented trial/titration period of at least two Tier 1 agents in the past 90 days or
 - b. Clinically appropriate pain therapy requiring time-released medication.
 In either case, diagnosis should be for pain related to a chronic condition.
4. Tier 3 agents will only be approved after:
 - a. A minimum 30 day documented trial period of at least two Tier 2 agents in different classes in the past 90 days or
 - b. Documented allergy or contraindication to all Tier 2 agents.
5. Actiq® and Fentora® are only approved for oncology related diagnoses.



Appendix E

30 Day Notice to Prior Authorize Tekturna HCT[®] (aliskiren and hydrochlorothiazide)

Oklahoma Health Care Authority
March 2008

Manufacturer Novartis Pharmaceuticals
Classification Direct Renin Inhibitor and Diuretic Combination
Status: Prescription Only

Summary

Tekturna HCT[®] is a combination dose form of the direct renin inhibitor aliskiren and the diuretic hydrochlorothiazide. It was approved by the FDA on January 23, 2008. It is indicated for the treatment of hypertension. Because it is a fixed dose combination, it is not recommended for initial therapy. Tekturna HCT[®] is dosed once daily and may be titrated up to a maximum dose of 300/25mg a day. It may be administered with other antihypertensive medications.

Tekturna HCT[®] is contraindicated in patients with anuria or hypersensitivity to sulfonamide-derived drugs. The most common side effects of therapy are dizziness and diarrhea. The usual warnings and concerns seen with HCTZ monotherapy also apply with Tekturna HCT[®].

Cost Comparison

	Strength	SMAC	EAC
HCTZ tab	12.5mg	\$0.19725	-
HCTZ tab	25mg	\$0.13741	-
Tekturna [®] cap	150mg	-	\$2.27362
Tekturna HCT [®] tab	150/12.5mg	-	\$2.27362
Tekturna HCT [®] tab	150/25mg	-	\$2.27362
Tekturna [®] cap	300mg	-	\$2.86850
Tekturna HCT [®] tab	300/12.5mg	-	\$2.86850
Tekturna HCT [®] tab	300/25mg	-	\$2.86850

Recommendations

The College of Pharmacy recommends adding Tekturna HCT[®] to the PBPA category as a Tier 3 agent with the following criteria, similar to Tekturna[®]:

1. FDA approved indication.
2. Recent trial, within the previous 6 months and at least 4 weeks in duration, of an ACE inhibitor (or an ARB if previous trial of an ACEI) and a diuretic, used concomitantly at recommended doses, that did not yield adequate blood pressure control.

Direct Renin Inhibitors		
Tier-1	Tier-2	Tier-3
Tier-1 ACE inhibitor + diuretic	ARB + Diuretic	aliskiren (Tekturna [®]) aliskiren/HCTZ (Tekturna HCT [®])

Reference

Tekturna HCT[®] Product Information. Novartis Pharmaceuticals. January 2008.



Appendix F

Pharmacy Claims by Therapeutic Category Fiscal Year Comparison

(01) PENICILLINS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Penicillins (0100)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Natural Penicillins (0110)	15,016	\$162,535.85	20,681	\$205,463.92	19,110	\$181,127.84	17,959	\$159,807.79
Ampicillins (0120)	139,971	\$1,235,447.95	181,325	\$1,609,096.94	170,600	\$1,628,221.34	184,434	\$1,609,828.58
Penicillinase-resistant (0130)	1,119	\$51,355.59	1,246	\$79,001.81	986	\$41,522.95	640	\$47,728.59
Extended Spectrum (0140)	42	\$7,134.13	41	\$6,931.19	16	\$7,281.95	4	\$718.56
Penicillin Combinations (0199)	55,265	\$3,719,408.64	68,326	\$4,206,846.47	59,418	\$3,106,167.94	62,191	\$2,823,735.03

(01) PENICILLINS TOTAL	211,413	\$5,175,882.16	271,619	\$6,107,340.33	250,130	\$4,964,322.02	265,228	\$4,641,818.55
-------------------------------	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------

(02) CEPHALOSPORINS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Cephalosporins (0200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Cephalosporins - 1st Generation (0210)	63,939	\$1,082,825.30	79,987	\$1,271,247.28	64,658	\$987,159.69	53,670	\$722,448.52
Cephalosporins - 2nd Generation	27,522	\$1,560,531.23	29,697	\$1,606,821.27	24,307	\$1,288,157.03	24,167	\$1,112,150.10
Cephalosporins - 3rd Generation (0230)	20,524	\$1,744,658.55	32,417	\$2,922,553.10	35,403	\$3,178,732.82	43,648	\$3,942,682.94
Cephalosporins - 4th Generation (0240)	128	\$42,326.11	166	\$56,136.66	66	\$24,507.54	60	\$25,316.65

(02) CEPHALOSPORINS TOTAL	112,113	\$4,430,341.19	142,267	\$5,856,758.31	124,434	\$5,478,557.08	121,545	\$5,802,598.21
----------------------------------	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------

(03) MACROLIDE ANTIBIOTICS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Macrolide antibiotics (0300)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Erythromycins (0310)	9,817	\$115,347.70	10,976	\$115,626.46	8,658	\$89,551.52	7,048	\$76,885.24				
Not Classified (0320)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Not Classified (0330)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Azithromycin (0340)	106,754	\$4,521,756.75	139,799	\$6,192,433.23	132,559	\$5,751,795.62	142,453	\$4,696,990.29				
Clarithromycin (0350)	6,323	\$494,876.07	7,216	\$585,051.91	5,644	\$343,600.04	5,233	\$285,070.77				
Dirithromycin (0352)	33	\$2,316.98	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(03) MACROLIDE ANTIBIOTICS TOTAL	122,927	\$5,134,297.50	157,991	\$6,893,111.60	146,861	\$6,184,947.18	154,734	\$5,058,946.30				
---	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------	--	--	--	--

(04) TETRACYCLINES

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Tetracyclines (0400)	20,439	\$402,458.36	27,505	\$584,346.61	23,784	\$450,148.52	20,948	\$325,202.36				

(04) TETRACYCLINES TOTAL	20,439	\$402,458.36	27,505	\$584,346.61	23,784	\$450,148.52	20,948	\$325,202.36				
---------------------------------	---------------	---------------------	---------------	---------------------	---------------	---------------------	---------------	---------------------	--	--	--	--

(05) FLUOROQUINOLONES

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Fluoroquinolones (0500)	45,653	\$3,865,282.24	58,157	\$3,521,405.88	41,964	\$2,318,268.33	25,740	\$1,386,411.11				

(05) FLUOROQUINOLONES TOTAL	45,653	\$3,865,282.24	58,157	\$3,521,405.88	41,964	\$2,318,268.33	25,740	\$1,386,411.11				
------------------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	--	--	--	--

(07) AMINOGLYCOSIDES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Aminoglycosides (0700)	1,189	\$1,114,025.39	1,596	\$1,282,563.02	1,297	\$1,269,531.82	1,152	\$1,406,876.98

(07) AMINOGLYCOSIDES TOTAL	1,189	\$1,114,025.39	1,596	\$1,282,563.02	1,297	\$1,269,531.82	1,152	\$1,406,876.98
-----------------------------------	--------------	-----------------------	--------------	-----------------------	--------------	-----------------------	--------------	-----------------------

(08) SULFONAMIDES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Sulfonamides (0800)	81	\$2,543.98	92	\$2,419.56	59	\$5,857.66	52	\$5,788.88

(08) SULFONAMIDES TOTAL	81	\$2,543.98	92	\$2,419.56	59	\$5,857.66	52	\$5,788.88
--------------------------------	-----------	-------------------	-----------	-------------------	-----------	-------------------	-----------	-------------------

(09) ANTIMYCOBACTERIAL AGENTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antimycobacterial agents (0900)	660	\$44,913.22	1,201	\$74,531.87	1,230	\$96,225.23	815	\$55,540.09
Anti TB Combinations (0999)	5	\$701.35	0	\$0.00	0	\$0.00	0	\$0.00

(09) ANTIMYCOBACTERIAL AGENTS	665	\$45,614.57	1,201	\$74,531.87	1,230	\$96,225.23	815	\$55,540.09
--------------------------------------	------------	--------------------	--------------	--------------------	--------------	--------------------	------------	--------------------

(11) ANTIFUNGALS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antifungals (1100)	5,170	\$951,157.79	7,261	\$1,332,714.67	6,636	\$1,166,561.51	5,602	\$944,482.93
Imidazole-Related Antifungals (1140)	16,611	\$1,425,806.64	22,818	\$803,066.26	19,707	\$592,873.85	17,482	\$456,807.57
Antifungal - Glucan Synthesis Inhibitors	19	\$16,147.21	17	\$28,715.02	17	\$32,939.93	33	\$131,362.89

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
(11) ANTIFUNGALS TOTAL	21,800	\$2,393,111.64	30,096	\$2,164,495.95	26,360	\$1,792,375.29	23,117	\$1,532,653.39
(12) ANTIVIRAL								
Antiviral (1200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiretrovirals (1210)	9,967	\$4,662,946.37	12,922	\$6,568,726.05	10,049	\$5,638,168.69	5,699	\$3,585,992.72
CMV Agents (1220)	218	\$340,980.93	280	\$438,916.30	260	\$373,702.43	172	\$257,925.81
Hepatitis Agents (1235)	1,837	\$2,597,657.24	1,981	\$2,681,447.63	1,697	\$2,287,180.97	2,077	\$2,621,211.43
Herpes Agents (1240)	6,796	\$479,497.57	9,667	\$740,112.94	9,560	\$773,449.29	9,811	\$940,683.35
Influenza Agents (1250)	5,785	\$308,538.24	3,662	\$222,249.27	5,065	\$313,868.93	9,921	\$679,412.93
Respiratory Syncytial Virus (RSV)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiviral Combinations (1299)	11	\$14,101.56	4	\$3,919.14	0	\$0.00	0	\$0.00

(12) ANTIVIRAL TOTAL	24,614	\$8,403,721.91	28,516	\$10,655,371.33	26,631	\$9,386,370.31	27,680	\$8,085,226.24
----------------------	--------	----------------	--------	-----------------	--------	----------------	--------	----------------

(13) ANTIMALARIAL

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antimalarial (1300)	11,295	\$277,359.49	14,187	\$234,198.89	9,642	\$143,147.36	3,420	\$69,101.75
Antimalarial Combinations (1399)	20	\$2,726.18	15	\$2,436.62	21	\$3,897.13	20	\$2,969.66

(13) ANTIMALARIAL TOTAL	11,315	\$280,085.67	14,202	\$236,635.51	9,663	\$147,044.49	3,440	\$72,071.41
-------------------------	--------	--------------	--------	--------------	-------	--------------	-------	-------------

(14) AMEBICIDES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Amebicides (1400)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(14) AMEBICIDES TOTAL	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
-----------------------	---	--------	---	--------	---	--------	---	--------

(15) ANTHELMINTIC

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Anthelmintic (1500)	2,380	\$41,805.21	3,275	\$58,884.15	3,322	\$57,294.04	3,374	\$53,076.85

(15) ANTHELMINTIC TOTAL	2,380	\$41,805.21	3,275	\$58,884.15	3,322	\$57,294.04	3,374	\$53,076.85
--------------------------------	--------------	--------------------	--------------	--------------------	--------------	--------------------	--------------	--------------------

(16) MISC. ANTI-INFECTIVES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Misc. anti-infectives (1600)	14,180	\$560,530.36	19,628	\$742,445.06	18,181	\$694,563.99	17,117	\$549,080.05
Polymyxins (1610)	15	\$1,675.23	6	\$176.16	5	\$118.09	0	\$0.00
Carbapenems (1615)	180	\$176,672.67	344	\$275,731.98	252	\$228,086.16	196	\$211,501.58
Chloramphenicols (1620)	1	\$232.84	1	\$688.22	0	\$0.00	1	\$294.43
Ketolides (1621)	0	\$0.00	2,831	\$165,482.98	3,154	\$187,146.90	675	\$43,055.59
Lincosamides (1622)	4,822	\$143,865.67	7,784	\$228,749.91	8,696	\$217,408.28	9,596	\$384,308.44
Oxazolidinones (1623)	320	\$471,980.80	681	\$1,043,224.43	645	\$974,728.81	471	\$697,447.89
Streptogramins (1625)	2	\$25,480.29	0	\$0.00	1	\$4,068.49	1	\$555.28
Cyclic Lipopeptides (1627)	6	\$12,593.30	5	\$8,478.81	9	\$23,704.63	22	\$37,088.82
Not Classified (1629)	0	\$0.00	0	\$0.00	2	\$452.10	1	\$997.25
Leprostatics (1630)	460	\$4,564.45	651	\$6,421.95	403	\$3,796.65	297	\$2,593.15
Antiprotozoal Agents (1640)	94	\$40,418.88	178	\$59,658.60	166	\$39,369.14	101	\$37,674.58
Sepsis Syndrome Agents (1660)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc. Anti-infective Combinations	38,769	\$425,688.54	57,104	\$544,106.66	62,950	\$535,357.54	68,127	\$690,116.41

(16) MISC. ANTI-INFECTIVES TOTAL	58,849	\$1,863,703.03	89,213	\$3,075,164.76	94,464	\$2,908,800.78	96,605	\$2,654,713.47
---	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------

(17) VACCINES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Vaccines (1700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Viral Vaccines (1710)	2,696	\$65,345.25	481	\$21,972.31	2,834	\$58,461.73	688	\$33,679.87
Bacterial Vaccines (1720)	475	\$14,914.66	730	\$26,885.93	636	\$26,174.42	84	\$3,843.29
Mixed Vaccine Combinations (1799)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(17) VACCINES TOTAL	3,171	\$80,259.91	1,211	\$48,858.24	3,470	\$84,636.15	772	\$37,523.16
----------------------------	--------------	--------------------	--------------	--------------------	--------------	--------------------	------------	--------------------

(18) TOXOIDS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Toxoids (1800)	5	\$234.19	15	\$2,067.88	7	\$1,074.49	14	\$349.38
Toxoid Combinations (1899)	89	\$2,339.99	98	\$3,937.54	36	\$1,249.78	19	\$1,113.86

(18) TOXOIDS TOTAL	94	\$2,574.18	113	\$6,005.42	43	\$2,324.27	33	\$1,463.24
---------------------------	-----------	-------------------	------------	-------------------	-----------	-------------------	-----------	-------------------

(19) PASSIVE IMMUNIZING AGENTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Passive immunizing agents (1900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Immune Serums (1910)	332	\$392,434.71	429	\$475,683.79	387	\$443,217.40	519	\$493,899.39
Antitoxins-Antivenins (1920)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Monoclonal Antibodies (1950)	4,243	\$5,324,252.88	5,826	\$7,033,947.85	5,427	\$6,945,161.43	4,750	\$6,080,364.04

(19) PASSIVE IMMUNIZING AGENTS	4,575	\$5,716,687.59	6,255	\$7,509,631.64	5,814	\$7,388,378.83	5,269	\$6,574,263.43
---------------------------------------	--------------	-----------------------	--------------	-----------------------	--------------	-----------------------	--------------	-----------------------

(20) BIOLOGICALS MISC

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Biologicals misc (2000)	13	\$236,597.95	13	\$257,154.75	16	\$283,262.60	26	\$480,763.90

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Allergenic Extracts (2010)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
(20) BIOLOGICALS MISC TOTAL	13	\$236,597.95	13	\$257,154.75	16	\$283,262.60	26	\$480,763.90

(21) ANTINEOPLASTICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antineoplastics (2100)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alkylating Agents (2110)	356	\$372,106.45	321	\$179,207.07	351	\$367,855.99	344	\$466,897.42
Antineoplastic Antibiotics (2120)	3	\$189.79	2	\$4,039.57	5	\$441.78	1	\$126.41
Antineoplastic Enzymes (2125)	0	\$0.00	1	\$60.15	0	\$0.00	0	\$0.00
Antimetabolites (2130)	3,986	\$348,834.65	5,791	\$317,872.95	5,058	\$442,398.31	3,128	\$411,460.21
Antineoplastic - Angiogenesis Inhibitors	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antineoplastic - Antibodies (2135)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antineoplastic - Hormonal Agents	19,910	\$3,184,187.98	22,634	\$3,610,400.38	14,830	\$2,423,423.84	6,176	\$1,492,512.18
Antineoplastic - Immunomodulators	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Mitotic Inhibitors (2150)	22	\$14,185.54	15	\$14,396.48	30	\$21,989.49	45	\$20,386.35
Antineoplastic Enzyme Inhibitors	261	\$551,435.56	507	\$1,206,694.53	359	\$973,426.58	238	\$802,375.35
Topoisomerase I Inhibitors (2155)	0	\$0.00	0	\$0.00	22	\$14,608.57	3	\$475.38
Antineoplastic Radiopharmaceuticals	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antineoplastics Misc. (2170)	672	\$332,909.65	791	\$445,835.58	542	\$287,875.61	307	\$321,160.34
Chemotherapy Rescue/Antidote Agents	59	\$3,747.36	114	\$16,682.12	139	\$27,569.93	94	\$25,324.31
Chemotherapy Adjuvants (2176)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antineoplastic Combinations (2199)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
(21) ANTINEOPLASTICS TOTAL	25,269	\$4,807,596.98	30,176	\$5,795,188.83	21,336	\$4,559,590.10	10,336	\$3,540,717.95

(22) CORTICOSTEROIDS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Corticosteroids (2200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Glucocorticosteroids (2210)	75,538	\$739,889.23	103,387	\$1,068,831.81	94,632	\$996,161.75	96,880	\$1,032,644.56				
Mineralocorticoids (2220)	1,606	\$54,025.75	1,863	\$57,789.76	1,262	\$35,344.56	729	\$19,639.20				

(22) CORTICOSTEROIDS TOTAL	77,144	\$793,914.98	105,250	\$1,126,621.57	95,894	\$1,031,506.31	97,609	\$1,052,283.76				
-----------------------------------	---------------	---------------------	----------------	-----------------------	---------------	-----------------------	---------------	-----------------------	--	--	--	--

(23) ANDROGEN-ANABOLIC

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Androgen-anabolic (2300)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Androgens (2310)	770	\$114,892.99	1,077	\$148,621.78	894	\$138,787.95	571	\$81,812.81				
Anabolic Steroids (2320)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(23) ANDROGEN-ANABOLIC TOTAL	770	\$114,892.99	1,077	\$148,621.78	894	\$138,787.95	571	\$81,812.81				
-------------------------------------	------------	---------------------	--------------	---------------------	------------	---------------------	------------	--------------------	--	--	--	--

(24) ESTROGENS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Estrogens (2400)	37,348	\$1,666,396.95	39,371	\$1,803,879.21	25,883	\$1,179,522.27	14,062	\$645,378.68				
Estrogen Combinations (2499)	6,988	\$411,908.21	7,140	\$448,294.66	4,916	\$309,164.51	2,806	\$167,483.71				

(24) ESTROGENS TOTAL	44,336	\$2,078,305.16	46,511	\$2,252,173.87	30,799	\$1,488,686.78	16,868	\$812,862.39				
-----------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	---------------------	--	--	--	--

(25) CONTRACEPTIVES

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Contraceptives (2500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Progestin OC's (2510)	2,569	\$123,483.17	4,107	\$186,263.55	4,591	\$189,392.70	4,639	\$175,212.87
Progestin Contraceptives - Injectable	5,092	\$336,896.53	6,937	\$430,824.11	6,404	\$347,399.77	6,592	\$358,660.46
Progestin IUD (2520)	2	\$838.80	29	\$10,157.32	25	\$11,095.22	56	\$25,256.50
Progestin Implants (2530)	0	\$0.00	0	\$0.00	0	\$0.00	10	\$5,753.00
Emergency Contraceptives (2540)	54	\$1,297.07	372	\$10,314.02	593	\$18,184.15	810	\$27,411.09
Combination Contraceptives -	11,431	\$540,226.13	15,540	\$779,830.73	12,335	\$675,531.50	6,098	\$371,263.75
Combination Contraceptives - Vaginal	841	\$39,291.91	2,028	\$92,966.54	3,614	\$186,513.77	5,876	\$330,018.13
Combination Contraceptives -	1	\$27.90	1	\$27.90	0	\$0.00	0	\$0.00
Combinations OC's (2599)	34,567	\$1,436,284.89	46,343	\$2,001,596.12	50,288	\$2,210,485.73	60,418	\$2,853,113.54

(25) CONTRACEPTIVES TOTAL	54,557	\$2,478,346.40	75,357	\$3,511,980.29	77,850	\$3,638,602.84	84,499	\$4,146,689.34
----------------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------

(26) PROGESTINS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Progestins (2600)	3,612	\$67,638.17	4,586	\$107,418.33	4,215	\$205,391.30	3,403	\$184,390.59

(26) PROGESTINS TOTAL	3,612	\$67,638.17	4,586	\$107,418.33	4,215	\$205,391.30	3,403	\$184,390.59
------------------------------	--------------	--------------------	--------------	---------------------	--------------	---------------------	--------------	---------------------

(27) ANTIDIABETIC

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antidiabetic (2700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Insulin (2710)	64,570	\$4,808,605.60	83,362	\$6,579,949.13	64,064	\$5,979,274.72	40,710	\$4,729,782.30
Not Classified (2715)	0	\$0.00	1	\$91.60	28	\$6,905.33	46	\$13,627.29
Not Classified (2717)	0	\$0.00	9	\$1,498.33	796	\$181,601.22	979	\$208,551.54
Sulfonylureas (2720)	53,732	\$1,404,156.69	60,879	\$1,542,753.39	39,642	\$754,380.47	16,917	\$210,814.54
Antidiabetic - Amino Acid Derivatives	1,682	\$155,461.41	1,860	\$186,694.32	1,219	\$129,300.82	337	\$39,730.26
Biguanides (2725)	42,039	\$1,088,329.72	56,993	\$989,158.03	46,234	\$582,525.26	27,665	\$256,328.50
Meglitinide Analogues (2728)	1,287	\$128,142.57	1,165	\$123,661.25	612	\$69,742.65	161	\$19,443.85

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Diabetic Other (2730)	1,028	\$121,020.93	1,317	\$171,249.22	1,333	\$207,774.86	1,221	\$185,713.92
Alpha-Glucosidase Inhibitors (2750)	609	\$36,887.14	744	\$50,385.25	458	\$31,604.15	221	\$17,809.19
Not Classified (2755)	0	\$0.00	0	\$0.00	0	\$0.00	368	\$76,591.60
Insulin Sensitizing Agents (2760)	30,789	\$5,680,922.39	40,242	\$7,701,958.97	31,428	\$6,155,497.19	14,145	\$3,031,057.43
Antidiabetic Combinations (2799)	14,152	\$1,382,202.27	17,469	\$1,747,123.55	10,341	\$738,911.69	6,100	\$550,870.33

(27) ANTIDIABETIC TOTAL	2004	2005	2006	2007
	209,888	\$14,805,728.72	196,155	\$14,837,518.36

(28) THYROID

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Thyroid (2800)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Thyroid Hormones (2810)	84,567	\$1,559,003.40	103,142	\$1,762,380.99	69,612	\$1,122,841.12	32,725	\$457,989.00
Antithyroid Agents (2830)	739	\$21,857.75	1,161	\$29,679.78	876	\$19,664.93	551	\$13,067.11

(28) THYROID TOTAL	2004	2005	2006	2007
	85,306	\$1,580,861.15	104,303	\$1,792,060.77

(29) OXYTOCICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Oxytocics (2900)	636	\$7,093.36	894	\$10,223.56	965	\$10,781.54	926	\$11,428.53
Abortifacients/Agents for Cervical	1	\$204.84	0	\$0.00	1	\$839.06	0	\$0.00

(29) OXYTOCICS TOTAL	2004	2005	2006	2007
	637	\$7,298.20	894	\$10,223.56

(30) MISC. ENDOCRINE

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Misc. endocrine (3000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Adrenal Steroid Inhibitors (3002)	0	\$0.00	0	\$0.00	8	\$2,000.40	5	\$311.79
Calcium Regulators (3004)	35,433	\$3,166,968.40	45,030	\$3,744,565.98	27,835	\$2,442,056.50	7,499	\$681,605.19
Hormone Receptor Modulators (3005)	7,339	\$782,610.82	7,505	\$880,476.72	3,957	\$495,665.10	806	\$103,693.34
Fertility Regulators (3006)	8	\$1,258.63	9	\$1,571.61	8	\$496.16	6	\$263.84
Luteinizing Hormone Releasing-	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
LHRH/GnRH Agonist Analog Pituitary	32	\$17,776.32	34	\$17,016.42	35	\$21,531.65	41	\$27,238.59
GnRH/LHRH Antagonists (3009)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Growth Hormone (3010)	1,088	\$2,272,885.02	1,815	\$3,727,299.74	1,650	\$3,567,367.26	1,607	\$3,499,088.25
Growth Hormone Releasing Hormone	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Growth Hormone (3016)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Somatostatic Agents (3017)	76	\$249,877.42	84	\$244,514.51	102	\$269,078.07	56	\$101,002.44
Growth Hormone Receptor Antagonist	8	\$30,047.20	1	\$4,952.15	0	\$0.00	0	\$0.00
Posterior Pituitary (3020)	8,627	\$1,599,459.47	11,010	\$2,294,496.68	11,164	\$2,309,162.21	11,659	\$2,008,336.71
Corticotropin (3030)	5	\$10,420.45	18	\$37,852.49	8	\$16,556.96	55	\$144,728.55
Prolactin Inhibitors (3040)	85	\$42,021.60	120	\$56,562.34	98	\$50,341.18	73	\$26,651.92
Not Classified (3045)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Progesterone Receptor Antagonists	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Uterine Relaxants (3080)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Metabolic Modifiers (3090)	512	\$64,108.02	1,414	\$480,415.54	1,468	\$612,864.88	967	\$419,385.76
(30) MISC. ENDOCRINE TOTAL	53,213	\$8,237,433.35	67,040	\$11,489,724.18	46,333	\$9,787,120.37	22,774	\$7,012,306.38

(31) CARDIOTONICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Cardiotonics (3100)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Phosphodiesterase Inhibitors (3110)	0	\$0.00	3	\$5,776.45	0	\$0.00	0	\$0.00
Cardiac Glycosides (3120)	39,691	\$408,208.52	40,958	\$384,835.68	22,648	\$234,626.50	5,535	\$70,211.35
(31) CARDIOTONICS TOTAL	39,691	\$408,208.52	40,961	\$390,612.13	22,648	\$234,626.50	5,535	\$70,211.35

(32) ANTIANGINAL AGENTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antianginal agents (3200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Nitrates (3210)	50,587	\$1,208,743.66	55,271	\$943,075.01	31,369	\$435,037.61	8,448	\$113,701.74
Not Classified (3220)	0	\$0.00	0	\$0.00	3	\$550.95	70	\$12,295.86

(32) ANTIANGINAL AGENTS TOTAL	50,587	\$1,208,743.66	55,271	\$943,075.01	31,372	\$435,588.56	8,518	\$125,997.60
--------------------------------------	---------------	-----------------------	---------------	---------------------	---------------	---------------------	--------------	---------------------

(33) BETA BLOCKERS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Beta blockers (3300)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Beta Blockers Non-Selective (3310)	15,971	\$521,356.53	19,339	\$485,726.35	14,938	\$359,592.62	10,038	\$209,361.51
Beta Blockers Cardio-Selective (3320)	84,158	\$1,631,776.96	112,145	\$2,384,907.91	79,610	\$1,729,040.26	40,525	\$851,958.78
Alpha-Beta Blockers (3330)	15,238	\$1,326,857.56	22,136	\$2,020,992.46	17,198	\$1,573,983.00	8,534	\$761,010.27

(33) BETA BLOCKERS TOTAL	115,367	\$3,479,991.05	153,620	\$4,891,626.72	111,746	\$3,662,615.88	59,097	\$1,822,330.56
---------------------------------	----------------	-----------------------	----------------	-----------------------	----------------	-----------------------	---------------	-----------------------

(34) CALCIUM BLOCKERS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Calcium blockers (3400)	92,816	\$5,342,911.34	103,016	\$5,775,414.25	62,909	\$3,366,092.31	23,983	\$1,228,942.73

(34) CALCIUM BLOCKERS TOTAL	92,816	\$5,342,911.34	103,016	\$5,775,414.25	62,909	\$3,366,092.31	23,983	\$1,228,942.73
------------------------------------	---------------	-----------------------	----------------	-----------------------	---------------	-----------------------	---------------	-----------------------

(35) ANTIARRHYTHMIC

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antiarrhythmic (3500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiarrhythmics Type I - Nonspecific	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiarrhythmics Type I-A (3510)	1,127	\$63,459.14	972	\$57,389.18	490	\$26,627.15	68	\$2,666.28				
Antiarrhythmics Type I-B (3520)	186	\$9,188.51	131	\$3,933.65	63	\$1,600.56	22	\$582.53				
Antiarrhythmics Type I-C (3530)	1,128	\$118,597.29	1,200	\$83,325.57	769	\$44,843.75	250	\$11,347.92				
Antiarrhythmics Type III (3540)	6,710	\$177,495.11	7,732	\$156,959.45	4,603	\$76,820.73	1,439	\$31,872.79				
Misc. Antiarrhythmic (3550)	0	\$0.00	0	\$0.00	1	\$69.01	1	\$69.01				
(35) ANTIARRHYTHMIC TOTAL	9,151	\$368,740.05	10,035	\$301,607.85	5,926	\$149,961.20	1,780	\$46,538.53				

(36) ANTIHYPERTENSIVE

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antihypertensive (3600)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
ACE Inhibitors (3610)	123,470	\$2,496,805.84	155,344	\$2,380,877.79	104,685	\$1,465,734.99	50,781	\$602,891.32				
Angiotensin II Receptor Antagonist	28,421	\$2,145,746.15	35,899	\$2,816,852.73	24,463	\$1,976,786.83	8,087	\$682,124.96				
Not Classified (3617)	0	\$0.00	0	\$0.00	0	\$0.00	20	\$1,705.51				
Antiadrenergic Antihypertensives	61,471	\$1,384,739.59	76,010	\$1,591,071.62	60,603	\$1,094,423.26	48,112	\$678,247.00				
Selective Aldosterone Receptor	15	\$2,445.25	140	\$21,276.24	166	\$24,892.82	85	\$14,391.79				
Agents for Pheochromocytoma (3630)	3	\$249.00	0	\$0.00	3	\$341.52	1	\$53.07				
Vasodilators (3640)	3,906	\$68,495.31	5,090	\$107,825.83	3,475	\$85,098.80	1,472	\$35,256.23				
Misc. Antihypertensives (3660)	11	\$1,555.45	4	\$555.80	0	\$0.00	0	\$0.00				
Antihypertensive Combinations (3699)	45,267	\$2,893,100.96	57,083	\$3,706,254.62	41,303	\$2,840,548.33	20,485	\$1,327,660.21				
(36) ANTIHYPERTENSIVE TOTAL	262,564	\$8,993,137.55	329,570	\$10,624,714.63	234,698	\$7,487,826.55	129,043	\$3,342,330.09				

(37) DIURETICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Diuretics (3700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Carbonic Anhydrase Inhibitors (3710)	1,104	\$29,922.83	1,253	\$30,519.11	880	\$28,383.75	532	\$24,382.21
Loop Diuretics (3720)	120,407	\$1,367,373.80	143,110	\$1,455,923.76	88,469	\$765,817.90	28,308	\$226,022.66
Osmotic Diuretics (3740)	0	\$0.00	2	\$19.58	1	\$7.28	0	\$0.00
Potassium Sparing Diuretics (3750)	14,534	\$325,037.52	18,113	\$396,677.22	12,089	\$246,091.05	5,376	\$118,805.97
Thiazides and Thiazide-Like Diuretics	40,518	\$559,603.21	56,101	\$634,365.01	39,774	\$366,351.07	21,418	\$152,596.05
Miscellaneous Diuretics (3790)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Combination Diuretics (3799)	17,280	\$170,320.85	19,535	\$149,713.54	12,112	\$90,721.48	4,512	\$36,346.48
(37) DIURETICS TOTAL	193,843	\$2,452,258.21	238,114	\$2,667,218.22	153,325	\$1,497,372.53	60,146	\$558,153.37

(38) PRESSORS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Pressors (3800)	874	\$183,158.12	1,075	\$195,520.69	719	\$106,464.88	249	\$28,844.28
Anaphylaxis Therapy Agents (3890)	1,258	\$90,463.61	2,161	\$159,540.70	2,408	\$196,663.48	2,816	\$235,513.61
(38) PRESSORS TOTAL	2,132	\$273,621.73	3,236	\$355,061.39	3,127	\$303,128.36	3,065	\$264,357.89

(39) ANTIHYPERLIPIDEMIC

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antihyperlipidemic (3900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bile Sequestrants (3910)	2,336	\$163,157.45	2,867	\$196,807.28	2,044	\$128,990.71	1,159	\$58,688.22
Fibric Acid Derivatives (3920)	9,148	\$545,248.92	12,920	\$829,974.95	9,487	\$636,909.41	5,523	\$372,304.47
Intestinal Cholesterol Absorption	2,394	\$271,001.37	4,697	\$554,022.22	3,763	\$440,982.11	1,298	\$156,386.31
HMG CoA Reductase Inhibitors (3940)	87,902	\$12,563,013.24	118,739	\$16,937,005.98	84,610	\$12,296,770.22	40,245	\$4,738,002.62
Nicotinic Acid Derivatives (3945)	969	\$73,319.55	1,450	\$128,032.47	1,145	\$119,008.63	621	\$65,225.79

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Misc. Antihyperlipidemics (3950)	0	\$0.00	0	\$0.00	127	\$13,149.64	422	\$45,174.10				
Antihyperlipidemic Combinations	0	\$0.00	3,624	\$418,999.49	6,778	\$824,587.95	4,263	\$531,121.39				
(39) ANTIHYPERLIPIDEMIC TOTAL	102,749	\$13,615,740.53	144,297	\$19,064,842.39	107,954	\$14,460,398.67	53,531	\$5,966,902.90				

(40) MISC. CARDIOVASCULAR

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Misc. cardiovascular (4000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Peripheral Vasodilators (4010)	539	\$9,673.42	524	\$9,242.66	249	\$4,534.23	50	\$869.70				
Not Classified (4014)	0	\$0.00	0	\$0.00	55	\$24,171.22	188	\$105,035.49				
Pulmonary Hypertension - Endothelin	76	\$216,698.30	97	\$301,130.35	82	\$282,404.00	128	\$508,050.25				
Prostaglandin Vasodilators (4017)	19	\$98,045.78	54	\$409,452.79	76	\$679,234.62	91	\$575,004.66				
Vasoactive Natriuretic Peptides (4018)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Cardioplegic Soln (4020)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Impotence Agents (4030)	103	\$6,601.81	132	\$11,341.64	92	\$9,389.72	10	\$301.10				
Misc. Cardiovascular Combinations	7	\$1,270.37	973	\$186,439.18	2,232	\$409,216.92	1,586	\$288,889.79				
(40) MISC. CARDIOVASCULAR TOTAL	744	\$332,289.68	1780	\$917,606.62	2786	\$1,408,950.71	2,043	\$1,478,150.99				

(41) ANTIHISTAMINES

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antihistamines (4100)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antihistamines - Alkylamines (4110)	36	\$1,084.86	119	\$4,289.28	135	\$5,399.77	88	\$4,225.10				
Antihistamines - Ethanalamines (4120)	456	\$3,301.12	1,072	\$12,239.99	1,013	\$13,200.27	977	\$10,799.54				
Antihistamines - Ethylenediamines	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Antihistamines - Phenothiazines (4140)	53,043	\$1,160,521.71	70,203	\$1,118,512.44	64,251	\$972,763.66	56,486	\$809,486.56				
Antihistamines - Piperidines (4150)	3,909	\$68,369.86	5,002	\$74,608.07	3,820	\$53,939.84	2,939	\$42,770.12				
Antihistamines - Non-Sedating (4155)	43,151	\$1,383,729.90	109,236	\$2,742,737.29	118,750	\$2,994,012.43	137,802	\$3,020,633.78				

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antihistamines - Combinations (4199)	4	\$108.39	14	\$360.70	11	\$217.68	2	\$81.46
(41) ANTIHISTAMINES TOTAL	100,599	\$2,617,115.84	185,646	\$3,952,747.77	187,980	\$4,039,533.65	198,294	\$3,887,996.56

(42) SYSTEMIC AND TOPICAL NASAL PRODUCTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Systemic and topical nasal products	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Sympathomimetic Decongestants	498	\$11,307.99	191	\$5,051.74	13	\$390.76	1,165	\$8,871.29
Nasal Steroids (4220)	44,855	\$3,043,979.38	66,547	\$4,581,182.43	63,305	\$4,640,511.36	59,024	\$4,134,844.91
Nasal Anti-infectives (4225)	172	\$12,078.30	354	\$28,550.31	211	\$17,236.43	294	\$24,300.01
Nasal Anticholinergics (4230)	673	\$29,450.20	806	\$23,547.90	820	\$21,168.67	579	\$12,532.32
Nasal Antiallergy (4240)	1,483	\$87,410.11	2,732	\$169,438.04	2,604	\$177,693.40	2,405	\$180,067.05
Misc. Nasal Preparations (4250)	3	\$34.88	2	\$9.52	1	\$13.17	7	\$96.30
Nasal Combinations (4299)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
(42) SYSTEMIC AND TOPICAL NASAL	47,684	\$3,184,260.86	70,632	\$4,807,779.94	66,954	\$4,857,013.79	63,474	\$4,360,711.88

(43) COUGH/COLD/ALLERGY

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Cough/cold/allergy (4300)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antitussives (4310)	164	\$23,307.35	168	\$17,630.85	103	\$7,700.51	2,637	\$27,954.28
Expectorants (4320)	10	\$60.24	18	\$92.60	20	\$109.78	1,088	\$9,154.18
Mucolytics (4330)	241	\$13,932.10	222	\$15,339.07	250	\$20,099.75	193	\$22,084.65
Misc. Respiratory Inhalants (4340)	1,315	\$20,214.93	993	\$28,672.17	730	\$12,068.89	736	\$13,300.58
Cough/Cold/Allergy Combinations	572	\$11,816.56	959	\$17,644.46	478	\$7,907.36	6,731	\$55,801.08
(43) COUGH/COLD/ALLERGY TOTAL	2,302	\$69,331.18	2,360	\$79,379.15	1,581	\$47,886.29	11,385	\$128,294.77

(44) ANTI-ASTHMATIC

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antiasthmatic (4400)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiasthmatics - Anticholinergics	11,637	\$553,638.90	18,073	\$1,361,480.64	15,723	\$1,342,111.78	11,251	\$967,810.30
Anti-Inflammatory Agents (4415)	1,565	\$83,116.17	1,582	\$77,448.09	1,140	\$62,141.92	1,076	\$67,603.68
Sympathomimetics (4420)	214,887	\$11,091,256.46	299,563	\$16,463,394.12	277,040	\$16,025,316.58	269,005	\$16,974,649.64
Xanthines (4430)	9,587	\$225,589.56	9,947	\$225,964.12	5,811	\$130,400.60	2,156	\$59,370.09
Steroid Inhalants (4440)	32,931	\$3,799,779.30	43,916	\$5,471,220.33	43,556	\$6,044,555.23	48,487	\$7,102,372.11
Leukotriene Modulators (4450)	64,698	\$6,720,455.22	109,725	\$9,869,799.77	122,680	\$11,592,386.95	139,409	\$13,878,800.63
Antiasthmatic - Monoclonal Antibodies	90	\$147,027.15	42	\$65,927.04	49	\$88,130.02	98	\$200,661.44
Asthma Combinations (4499)	315	\$7,575.58	333	\$7,704.75	229	\$4,019.80	212	\$2,942.95

(44) ANTI-ASTHMATIC TOTAL	335,710	\$22,628,438.34	483,181	\$33,542,938.86	466,228	\$35,289,062.88	471,694	\$39,254,210.84
----------------------------------	----------------	------------------------	----------------	------------------------	----------------	------------------------	----------------	------------------------

(45) MISC. RESPIRATORY

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Misc. respiratory (4500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alpha-Proteinase Inhibitor (Human)	12	\$76,486.03	58	\$305,300.39	32	\$173,116.84	10	\$84,041.31
Cystic Fibrosis Agents (4530)	551	\$799,571.04	683	\$1,068,870.86	721	\$1,159,508.76	835	\$1,228,414.10
Pleural Sclerosing Agents (4550)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(45) MISC. RESPIRATORY TOTAL	563	\$876,057.07	741	\$1,374,171.25	753	\$1,332,625.60	845	\$1,312,455.41
-------------------------------------	------------	---------------------	------------	-----------------------	------------	-----------------------	------------	-----------------------

(46) LAXATIVES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Laxatives (4600)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Saline Laxatives (4610)	1	\$41.63	275	\$14,207.94	270	\$17,258.30	187	\$10,821.44

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Stimulant Laxatives (4620)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Laxatives (4630)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Lubricant Laxatives (4640)	5	\$32.60	0	\$0.00	0	\$0.00	0	\$0.00
Surfactant Laxatives (4650)	0	\$0.00	0	\$0.00	1	\$28.77	0	\$0.00
Miscellaneous Laxatives (4660)	28,605	\$811,728.70	37,675	\$1,080,725.74	30,282	\$764,378.75	22,175	\$601,499.73
Laxative Combinations (4699)	2,043	\$44,202.82	2,662	\$194,819.92	2,018	\$566,427.73	1,459	\$39,560.19

(46) LAXATIVES TOTAL	30,654	\$856,005.75	40,612	\$1,289,753.60	32,571	\$1,348,093.55	23,821	\$651,881.36
-----------------------------	---------------	---------------------	---------------	-----------------------	---------------	-----------------------	---------------	---------------------

(47) ANTIDIARRHEALS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antidiarrheals (4700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiperistaltic Agents (4710)	10,304	\$80,606.48	12,233	\$100,572.92	8,209	\$59,846.99	3,849	\$32,103.85
GI Adsorbents (4720)	0	\$0.00	5	\$37.01	0	\$0.00	0	\$0.00
Misc. Antidiarrheal Agents (4730)	0	\$0.00	4	\$36.78	2	\$17.21	3	\$17.61
Antidiarrheal Combinations (4799)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(47) ANTIDIARRHEALS TOTAL	10,304	\$80,606.48	12,242	\$100,646.71	8,211	\$59,864.20	3,852	\$32,121.46
----------------------------------	---------------	--------------------	---------------	---------------------	--------------	--------------------	--------------	--------------------

(48) ANTACIDS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antacids (4800)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antacids - Aluminum Salts (4810)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antacids - Bicarbonate (4820)	0	\$0.00	9	\$548.09	2	\$112.21	0	\$0.00
Antacids - Calcium Salts (4830)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antacids - Magnesium Salts (4840)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antacids - Sodium Citrate (4850)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antacid Combinations (4899)	21	\$824.97	191	\$1,668.22	324	\$3,066.64	286	\$2,456.02

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
(48) ANTACIDS TOTAL	21	\$824.97	200	\$2,216.31	326	\$3,178.85	286	\$2,456.02

(49) ULCER DRUGS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Ulcer drugs (4900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antispasmodics (4910)	17,657	\$331,522.17	22,046	\$418,376.54	19,897	\$332,606.69	16,783	\$276,018.59
H-2 Antagonists (4920)	108,407	\$1,944,136.84	110,091	\$2,036,518.79	71,796	\$1,606,323.27	46,814	\$1,524,858.03
Ulcer Drugs - Prostaglandins (4925)	704	\$40,090.15	616	\$31,324.96	340	\$13,166.71	201	\$4,251.28
Proton Pump Inhibitors (4927)	83,339	\$11,820,821.60	176,291	\$18,616,961.08	154,893	\$16,662,872.87	92,436	\$8,963,810.13
Misc. Anti-Ulcer (4930)	8,504	\$319,746.31	9,632	\$369,633.01	6,876	\$272,458.03	3,551	\$150,753.33
Ulcer Therapy Combinations (4999)	896	\$232,707.83	870	\$226,829.54	1,076	\$249,628.81	1,754	\$320,570.14
(49) ULCER DRUGS TOTAL	219,507	\$14,689,024.90	319,546	\$21,699,643.92	254,878	\$19,137,056.38	161,539	\$11,240,261.50

(50) ANTIEMETICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antiemetics (5000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiemetics - Antidopaminergic (5010)	2	\$29.90	2	\$32.51	1	\$13.91	0	\$0.00
Antiemetics - Anticholinergic (5020)	10,844	\$147,653.79	14,118	\$212,532.25	8,979	\$145,006.62	3,933	\$85,176.16
5-HT3 Receptor Antagonists (5025)	2,917	\$1,657,705.52	4,915	\$1,694,389.43	4,760	\$1,708,182.03	6,481	\$1,779,704.22
Substance P/Neurokinin 1 (NK1)	13	\$6,308.26	56	\$15,829.58	172	\$52,317.92	264	\$76,597.76
Antiemetics Miscellaneous (5030)	677	\$231,746.74	835	\$335,820.01	705	\$383,791.05	514	\$319,549.82
(50) ANTIEMETICS TOTAL	14,453	\$2,043,444.21	19,926	\$2,258,603.78	14,617	\$2,289,311.53	11,192	\$2,261,027.96

(51) DIGESTIVE AIDS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Digestive aids (5100)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Digestive Enzymes (5120)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Gastric Acidifiers (5130)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Digestive Aids - Mixtures (5199)	2,566	\$658,781.31	2,934	\$838,272.57	2,195	\$827,585.32	1,485	\$710,109.66				

(51) DIGESTIVE AIDS TOTAL	2,566	\$658,781.31	2,934	\$838,272.57	2,195	\$827,585.32	1,485	\$710,109.66				
----------------------------------	--------------	---------------------	--------------	---------------------	--------------	---------------------	--------------	---------------------	--	--	--	--

(52) MISC. GI

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Misc. gi (5200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Gallstone Solubilizing Agents (5210)	1,187	\$174,622.24	1,519	\$160,471.27	1,100	\$88,197.78	715	\$66,941.26				
GI Antiallergy Agents (5216)	12	\$6,013.61	8	\$3,207.62	73	\$8,435.24	78	\$13,463.91				
Antiflatulents (5220)	0	\$0.00	2	\$7.62	0	\$0.00	2	\$9.20				
GI Stimulants (5230)	28,262	\$274,464.51	34,826	\$334,895.16	25,610	\$267,393.60	17,746	\$138,280.10				
Intestinal Acidifiers (5240)	10,894	\$167,184.03	10,423	\$171,351.60	6,831	\$97,050.97	3,442	\$34,378.54				
Not Classified (5245)	0	\$0.00	0	\$0.00	4	\$413.68	47	\$7,720.47				
Inflammatory Bowel Agents (5250)	3,415	\$437,230.53	4,173	\$591,764.45	2,960	\$429,012.47	1,736	\$352,706.54				
Irritable Bowel Syndrome (IBS) Agents	2,601	\$382,543.78	4,412	\$697,160.40	4,002	\$620,712.31	368	\$66,130.12				
Phosphate Binder Agents (5280)	4,883	\$781,192.76	6,163	\$1,129,465.58	4,287	\$882,876.37	1,218	\$298,771.09				

(52) MISC. GI TOTAL	51,254	\$2,223,251.46	61,526	\$3,088,323.70	44,867	\$2,394,092.42	25,352	\$978,401.23				
----------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	---------------------	--	--	--	--

(53) URINARY ANTI-INFECTIVES

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Urinary anti-infectives (5300)	20,597	\$907,039.62	26,026	\$875,342.40	21,855	\$623,887.43	17,727	\$402,650.90				
Combination Urinary Anti-infectives	1,507	\$41,314.00	1,870	\$50,477.41	1,387	\$32,543.14	566	\$14,579.38				

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
(53) URINARY ANTI-INFECTIVES	22,104	\$948,353.62	27,896	\$925,819.81	23,242	\$656,430.57	18,293	\$417,230.28

(54) URINARY ANTISPASMODICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Urinary antispasmodics (5400)	35,635	\$3,376,474.50	42,326	\$4,277,496.38	28,224	\$2,911,196.57	11,231	\$949,763.81
Urinary Antispasmodic Combinations	116	\$4,482.25	161	\$7,468.64	102	\$4,475.00	81	\$1,884.80

(54) URINARY ANTISPASMODICS	35,751	\$3,380,956.75	42,487	\$4,284,965.02	28,326	\$2,915,671.57	11,312	\$951,648.61
-----------------------------	--------	----------------	--------	----------------	--------	----------------	--------	--------------

(55) VAGINAL PRODUCTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Vaginal products (5500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Vaginal Anti-infectives (5510)	5,407	\$256,535.50	7,628	\$379,471.77	7,634	\$387,141.69	7,534	\$326,546.17
Vaginal Anti-inflammatory Agents	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Douche Products (5520)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Spermicides (5530)	8	\$59.81	15	\$137.77	40	\$362.97	34	\$298.83
Vaginal Estrogens (5535)	2,292	\$153,409.37	2,985	\$209,401.48	2,205	\$156,580.85	1,389	\$112,820.55
Vaginal Progestins (5537)	13	\$1,598.96	29	\$6,134.74	14	\$3,649.46	17	\$4,361.05
Miscellaneous Vaginal Products (5540)	85	\$2,114.94	124	\$2,833.38	107	\$2,330.02	51	\$1,210.48

(55) VAGINAL PRODUCTS TOTAL	7,805	\$413,718.58	10,781	\$597,979.14	10,000	\$550,064.99	9,025	\$445,237.08
-----------------------------	-------	--------------	--------	--------------	--------	--------------	-------	--------------

(56) MISCELLANEOUS GENITOURINARY PRODUCTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Miscellaneous genitourinary products	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Acidifiers (5610)	11	\$195.03	3	\$46.05	3	\$47.72	1	\$19.43
Alkalinizers (5620)	968	\$33,993.30	1,149	\$40,787.61	937	\$29,265.71	739	\$20,296.74

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Urinary Analgesics (5630)	3,837	\$49,002.51	5,243	\$54,345.37	4,361	\$22,320.18	3,959	\$21,398.82
Cystinosis Agents (5640)	0	\$0.00	2	\$478.98	2	\$324.28	0	\$0.00
Interstitial Cystitis Agents (5650)	173	\$36,431.34	289	\$61,265.79	246	\$61,076.19	194	\$48,523.64
Urinary Stone Agents (5660)	19	\$970.67	35	\$2,239.56	22	\$1,834.55	18	\$1,631.91
G U Irrigants (5670)	4,589	\$132,245.87	4,151	\$58,356.19	2,248	\$65,282.27	812	\$18,699.73
Prostatic Hypertrophy Agents (5685)	12,470	\$1,002,719.57	14,796	\$1,219,662.76	9,882	\$875,292.66	3,340	\$316,490.78

(56) MISCELLANEOUS	22,067	\$1,255,558.29	25,668	\$1,437,182.31	17,701	\$1,055,443.56	9,063	\$427,061.05
--------------------	--------	----------------	--------	----------------	--------	----------------	-------	--------------

(57) ANTIANXIETY AGENTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antianxiety agents (5700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Benzodiazepines (5710)	102,449	\$1,026,376.33	137,291	\$1,303,041.73	142,581	\$1,169,542.09	148,581	\$1,190,863.05
Misc. Antianxiety Agents (5720)	49,628	\$1,151,455.08	64,381	\$1,364,607.98	53,931	\$906,727.19	44,756	\$600,162.23

(57) ANTIANXIETY AGENTS TOTAL	152,077	\$2,177,831.41	201,672	\$2,667,649.71	196,512	\$2,076,269.28	193,337	\$1,791,025.28
-------------------------------	---------	----------------	---------	----------------	---------	----------------	---------	----------------

(58) ANTIDEPRESSANTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antidepressants (5800)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alpha-2 Receptor Antagonists	28,720	\$1,378,991.05	31,449	\$884,003.46	20,292	\$520,012.81	10,385	\$232,991.40
MAO Inhibitors (5810)	38	\$2,422.25	66	\$4,739.95	45	\$4,530.75	48	\$17,531.38
Modified Cyclics (5812)	36,436	\$453,779.93	49,483	\$512,993.55	40,084	\$375,633.75	32,403	\$286,799.22
Selective Serotonin Reuptake Inhibitors	215,699	\$18,421,347.10	254,775	\$18,472,747.31	199,530	\$12,726,310.25	140,493	\$6,522,645.65
Serotonin-Norepinephrine Reuptake	30,244	\$4,315,210.20	42,511	\$6,288,865.78	39,512	\$5,221,329.72	28,123	\$3,736,948.71
Tricyclic Agents (5820)	41,025	\$472,713.13	52,226	\$537,685.92	37,846	\$407,603.32	24,944	\$326,110.74
Misc. Antidepressants (5830)	20,875	\$2,153,692.95	29,445	\$2,855,646.34	25,735	\$2,579,248.63	21,884	\$2,161,451.69
Not Classified (5899)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
(58) ANTIDEPRESSANTS TOTAL	373,037	\$27,198,156.61	459,955	\$29,556,682.31	363,044	\$21,834,669.23	258,280	\$13,284,478.79

(59) ANTIPSYCHOTICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antipsychotics (5900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Benzisoxazoles (5907)	67,795	\$15,188,675.28	77,937	\$19,227,432.99	60,877	\$14,553,769.24	48,999	\$12,732,221.77
Butyrophenones (5910)	11,322	\$428,742.15	12,599	\$410,136.60	9,203	\$281,027.67	5,614	\$172,750.36
Dibenzapines (5915)	105,599	\$32,774,289.25	117,177	\$37,381,478.73	89,035	\$27,414,916.89	62,202	\$20,173,056.26
Dihydroindolones (5916)	239	\$43,183.76	262	\$50,996.15	188	\$32,096.76	66	\$16,533.10
Phenothiazines (5920)	14,104	\$366,782.72	15,523	\$309,436.98	11,269	\$197,717.99	7,319	\$118,077.04
Quinolone Derivatives (5925)	12,082	\$4,711,667.57	29,425	\$12,181,743.41	33,714	\$12,854,171.17	32,028	\$12,817,366.63
Thioxanthenes (5930)	1,552	\$34,770.78	1,684	\$36,527.79	1,289	\$26,479.43	703	\$14,075.48
Misc. Antipsychotics (5940)	8,427	\$2,347,050.73	14,838	\$4,462,736.41	15,109	\$3,937,139.58	13,127	\$3,453,950.80
Lithium (5950)	9,204	\$204,386.09	11,860	\$238,770.38	9,917	\$189,955.21	7,392	\$127,932.47
(59) ANTIPSYCHOTICS TOTAL	230,324	\$56,099,548.33	281,305	\$74,299,259.44	230,601	\$59,487,273.94	177,450	\$49,625,963.91

(60) HYPNOTICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Hypnotics (6000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Barbiturate Hypnotics (6010)	14,432	\$105,478.67	16,138	\$121,715.13	14,482	\$109,045.79	14,587	\$103,506.62
Non-Barbiturate Hypnotics (6020)	41,398	\$2,061,084.96	55,354	\$2,864,351.85	61,670	\$3,381,054.52	46,469	\$2,405,728.76
Not Classified (6025)	0	\$0.00	0	\$0.00	771	\$56,476.14	1,735	\$144,061.18
Antihistamine Hypnotics (6030)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Not Classified (6099)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
(60) HYPNOTICS TOTAL	55,830	\$2,166,563.63	71,492	\$2,986,066.98	76,923	\$3,546,576.45	62,791	\$2,653,296.56

(61) ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Paid	
Adhd/anti-narcolepsy/anti-	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	
Amphetamines (6110)	38,052	\$2,755,410.71	52,150	\$3,721,183.95	57,800	\$4,258,160.17	64,310	\$5,196,492.25				
Anorexiants Non-Amphetamine (6120)	11	\$443.91	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	
Anti-Obesity Agents (6125)	8	\$869.71	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	
Analeptics (6130)	74	\$33,999.56	181	\$89,347.56	178	\$81,635.48	269	\$214,831.66				
Attention-Deficit/Hyperactivity Disorder	19,258	\$2,148,556.89	25,306	\$3,016,410.31	22,584	\$3,011,107.84	20,108	\$2,757,417.64				
Misc. Stimulants (6140)	38,776	\$2,557,549.56	55,418	\$3,904,535.01	67,570	\$5,219,331.35	82,631	\$7,512,579.59				
(61) ADHD/ANTI-NARCOLEPSY/ANTI-	96,179	\$7,496,830.34	133,055	\$10,731,476.83	148,132	\$12,570,234.84	167,318	\$15,681,321.14				

(62) MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Paid	
Misc psychotherapeutic and	486	\$35,567.65	446	\$36,661.03	329	\$28,253.72	278	\$21,231.36				
Antidementia (6205)	35,612	\$5,112,015.96	52,845	\$7,557,644.14	31,661	\$4,562,885.69	3,518	\$503,387.67				
Smoking Deterrents (6210)	1,306	\$119,429.81	4,924	\$611,526.98	7,744	\$688,124.00	13,372	\$1,230,892.26				
Not Classified (6220)	102	\$7,386.46	50	\$5,041.30	6	\$1,082.32	1	\$123.98				
Multiple Sclerosis Agents (6240)	2,256	\$3,130,663.84	2,671	\$3,633,108.27	1,883	\$2,673,545.49	1,030	\$1,639,843.87				
Anti-Catataptic Agents (6245)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Agents for Chemical Dependency	50	\$2,694.40	134	\$10,496.97	362	\$35,123.05	316	\$33,412.84				
Combination Psychotherapeutics	2,320	\$225,841.89	3,539	\$710,599.75	1,906	\$323,208.48	801	\$172,642.78				
(62) MISC PSYCHOTHERAPEUTIC AND	42,132	\$8,633,600.01	64,609	\$12,565,078.44	43,891	\$8,312,222.75	19,316	\$3,601,534.76				

(64) ANALGESICS - NonNarcotic

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Analgesics - nonnarcotic (6400)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Salicylates (6410)	2,004	\$73,660.38	2,524	\$89,932.73	1,677	\$43,884.61	834	\$24,155.39
Analgesics-Peptide Channel Blockers	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Analgesics Other (6420)	0	\$0.00	0	\$0.00	1	\$8.17	6,581	\$50,779.15
Analgesic Combinations (6499)	10,701	\$203,408.85	14,993	\$212,089.20	12,963	\$165,968.22	12,498	\$162,117.88

(64) ANALGESICS - NonNarcotic	12,705	\$277,069.23	17,517	\$302,021.93	14,641	\$209,861.00	19,913	\$237,052.42
-------------------------------	--------	--------------	--------	--------------	--------	--------------	--------	--------------

(65) ANALGESICS - Narcotic

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Analgesics - narcotic (6500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Narcotic Agonists (6510)	90,432	\$14,035,231.24	127,420	\$18,824,596.82	108,457	\$12,678,633.90	79,914	\$7,671,375.61
Narcotic Partial Agonists (6520)	2,812	\$232,935.06	3,307	\$182,356.77	2,710	\$132,930.53	2,348	\$166,207.38
Not Classified (6540)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Narcotic Combinations (6599)	351,595	\$5,162,771.96	491,730	\$6,781,671.08	424,854	\$5,302,199.41	342,804	\$3,870,368.97

(65) ANALGESICS - Narcotic TOTAL	444,839	\$19,430,938.26	622,457	\$25,788,624.67	536,021	\$18,113,763.84	425,066	\$11,707,951.96
----------------------------------	---------	-----------------	---------	-----------------	---------	-----------------	---------	-----------------

(66) ANALGESICS - ANTI-INFLAMMATORY

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Analgesics - anti-inflammatory (6600)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
NSAIA's (6610)	146,440	\$6,603,103.95	190,487	\$7,824,436.19	142,755	\$4,386,361.54	115,735	\$1,733,023.02
Gold Compounds (6620)	50	\$9,351.74	39	\$7,544.85	22	\$5,115.64	2	\$491.71
Antirheumatic Antimetabolite (6625)	5	\$91.55	11	\$456.48	1	\$77.86	14	\$1,317.14
Interleukin-1 Receptor Antagonist (IL-	196	\$233,218.19	167	\$204,162.08	77	\$91,335.01	18	\$23,780.88
Anti-TNF-alpha - Monoclonal	410	\$646,083.62	629	\$985,751.75	499	\$831,368.58	370	\$674,932.98
Pyrimidine Synthesis Inhibitors (6628)	589	\$276,029.15	1,137	\$470,705.51	671	\$157,579.67	305	\$12,782.45
Soluble Tumor Necrosis Factor	1,267	\$1,590,648.60	1,909	\$2,458,165.74	1,734	\$2,435,549.60	1,329	\$1,982,029.34

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Not Classified (6640)	0	\$0.00	0	\$0.00	0	\$0.00	3	\$7,431.45
Not Classified (6699)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(66) ANALGESICS - ANTI-	148,957	\$9,358,526.80	194,379	\$11,951,222.60	145,759	\$7,907,387.90	117,776	\$4,435,788.97
-------------------------	---------	----------------	---------	-----------------	---------	----------------	---------	----------------

(67) MIGRAINE PRODUCTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Migraine products (6700)	48	\$15,508.11	90	\$21,209.41	109	\$23,085.72	103	\$25,546.02
Carboxylic Acid Derivatives (6730)	15	\$1,961.24	13	\$1,734.54	35	\$3,560.69	43	\$6,034.77
Serotonin Agonists (6740)	6,027	\$1,294,292.71	9,967	\$1,669,352.53	9,987	\$1,693,135.84	9,513	\$1,710,437.01
Migraine Combinations (6799)	363	\$13,563.97	527	\$16,242.04	575	\$10,414.12	407	\$9,900.32

(67) MIGRAINE PRODUCTS TOTAL	6,453	\$1,325,326.03	10,597	\$1,708,538.52	10,706	\$1,730,196.37	10,066	\$1,751,918.12
------------------------------	-------	----------------	--------	----------------	--------	----------------	--------	----------------

(68) GOUT

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Gout (6800)	10,234	\$95,236.51	13,437	\$110,879.46	8,518	\$62,490.30	2,773	\$19,954.48
Uricosurics (6810)	344	\$12,477.58	359	\$11,295.48	243	\$6,028.53	53	\$1,389.19
Combination Gout Drugs (6899)	226	\$9,950.53	253	\$10,490.66	152	\$6,124.09	16	\$738.07

(68) GOUT TOTAL	10,804	\$117,664.62	14,049	\$132,665.60	8,913	\$74,642.92	2,842	\$22,081.74
-----------------	--------	--------------	--------	--------------	-------	-------------	-------	-------------

(69) LOCAL ANESTHETICS-Parenteral

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Local anesthetics-parenteral (6900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

Local Anesthetics - Amides (6910)	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
	1,670	\$9,521.88	1,940	\$10,698.56	1,170	\$6,144.93	463	\$2,620.18
Local Anesthetics - Esters (6920)	54	\$635.81	22	\$289.60	40	\$272.98	210	\$995.09
Local Anesthetic Combinations (6999)	3	\$17.70	4	\$57.89	1	\$6.57	5	\$35.42

(69) LOCAL ANESTHETICS-Parenteral	1,727	\$10,175.39	1,966	\$11,046.05	1,211	\$6,424.48	678	\$3,650.69
-----------------------------------	-------	-------------	-------	-------------	-------	------------	-----	------------

(70) GENERAL ANESTHETICS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
General anesthetics (7000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Barbiturate Anesthetics (7010)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Volatile Anesthetics (7020)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc. Anesthetics (7040)	16	\$2,901.23	6	\$664.35	0	\$0.00	0	\$0.00

(70) GENERAL ANESTHETICS TOTAL	16	\$2,901.23	6	\$664.35	0	\$0.00	0	\$0.00
--------------------------------	----	------------	---	----------	---	--------	---	--------

(72) ANTICONVULSANT

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Anticonvulsant (7200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Anticonvulsant - Benzodiazepines	30,224	\$776,466.86	42,342	\$1,082,948.16	46,034	\$1,282,316.89	50,505	\$1,561,932.14
Carbamates (7212)	510	\$144,258.32	589	\$170,838.10	566	\$169,157.01	574	\$162,391.22
GABA Modulators (7217)	1,963	\$254,718.29	2,730	\$373,988.13	1,584	\$291,121.75	789	\$167,021.18
Hydantoin (7220)	39,322	\$1,316,188.66	43,802	\$1,505,839.84	30,232	\$1,057,720.03	16,564	\$591,361.36
Succinimides (7240)	709	\$63,624.99	890	\$75,664.54	847	\$71,264.64	795	\$63,199.03
Valproic Acid (7250)	51,837	\$5,970,366.26	63,100	\$7,886,064.69	51,028	\$6,552,233.65	38,235	\$5,025,593.22
Misc. Anticonvulsants (7260)	114,676	\$15,179,779.88	149,079	\$20,259,486.95	127,458	\$16,306,101.68	103,241	\$15,447,321.76

(72) ANTICONVULSANT TOTAL	239,241	\$23,705,403.26	302,532	\$31,354,830.41	257,749	\$25,729,915.65	210,703	\$23,018,819.91
---------------------------	---------	-----------------	---------	-----------------	---------	-----------------	---------	-----------------

(73) ANTIPARKINSONIAN

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Paid
Antiparkinsonian (7300)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	\$0.00
Antiparkinsonian Anticholinergic (7310)	18,844	\$224,205.72	23,362	23,362	\$278,505.88	17,651	17,651	\$191,320.86	11,781	11,781	\$129,750.96	\$129,750.96
Antiparkinsonian COMT Inhibitors	776	\$123,243.20	687	687	\$119,895.10	325	325	\$62,772.46	75	75	\$15,460.65	\$15,460.65
Antiparkinsonian Dopaminergic (7320)	24,837	\$1,488,116.28	24,800	24,800	\$1,615,428.31	15,812	15,812	\$1,050,426.63	7,980	7,980	\$527,588.67	\$527,588.67
Antiparkinsonian Monoamine Oxidase	383	\$14,897.69	392	392	\$7,166.31	142	142	\$2,508.57	42	42	\$7,142.30	\$7,142.30
Antiparkinsonian Adjuvants (7340)	27	\$1,330.86	22	22	\$1,045.45	16	16	\$787.11	1	1	\$61.07	\$61.07

(73) ANTIPARKINSONIAN TOTAL	44,867	\$1,851,793.75	49,263	\$2,022,041.05	33,946	\$1,307,815.63	19,879	\$680,003.65
------------------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	---------------------

(74) NEUROMUSCULAR AGENTS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Paid
Neuromuscular agents (7400)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	\$0.00
Depolarizing Muscle Relaxants (7410)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	\$0.00
Nondepolarizing Muscle Relaxants	1	\$885.71	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	\$0.00
Neuromuscular Blocking Agent -	2	\$655.84	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	\$0.00
ALS Agents (7450)	73	\$62,966.07	74	74	\$56,470.44	47	47	\$37,735.98	36	36	\$27,304.78	\$27,304.78

(74) NEUROMUSCULAR AGENTS	76	\$64,507.62	74	\$56,470.44	47	\$37,735.98	36	\$27,304.78
----------------------------------	-----------	--------------------	-----------	--------------------	-----------	--------------------	-----------	--------------------

(75) MUSCULOSKELETAL THERAPY AGENTS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Paid
Musculoskeletal therapy agents (7500)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	\$0.00
Central Muscle Relaxants (7510)	84,373	\$2,443,638.96	121,750	121,750	\$3,144,710.23	104,835	104,835	\$2,489,741.21	71,740	71,740	\$1,545,527.70	\$1,545,527.70
Direct Muscle Relaxants (7520)	712	\$85,589.09	702	702	\$92,825.04	592	592	\$65,601.58	341	341	\$35,155.64	\$35,155.64
Viscosupplements (7580)	26	\$17,446.68	27	27	\$20,792.21	34	34	\$33,926.79	15	15	\$9,212.55	\$9,212.55

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Articular Cartilage Repair Therapy	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Muscle Relaxant Combinations (7599)	707	\$24,189.32	869	\$21,307.94	680	\$22,241.80	253	\$11,214.59

(75) MUSCULOSKELETAL THERAPY	85,818	\$2,570,864.05	123,348	\$3,279,635.42	106,141	\$2,611,511.38	72,349	\$1,601,110.48
-------------------------------------	--------	----------------	---------	----------------	---------	----------------	--------	----------------

(76) ANTIMYASTHENIC AGENTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antimyasthenic agents (7600)	355	\$25,847.89	528	\$34,275.40	356	\$20,251.24	171	\$11,679.40
Antimyasthenic Combinations (7699)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(76) ANTIMYASTHENIC AGENTS	355	\$25,847.89	528	\$34,275.40	356	\$20,251.24	171	\$11,679.40
-----------------------------------	-----	-------------	-----	-------------	-----	-------------	-----	-------------

(77) VITAMINS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Vitamins (7700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Water Soluble Vitamins (7710)	0	\$0.00	10	\$485.42	0	\$0.00	13	\$660.94
Oil Soluble Vitamins (7720)	1,508	\$85,731.68	1,904	\$112,802.82	1,550	\$95,541.21	1,041	\$66,613.87
Misc. Nutritional Factors (7730)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(77) VITAMINS TOTAL	1,508	\$85,731.68	1,914	\$113,288.24	1,550	\$95,541.21	1,054	\$67,274.81
----------------------------	-------	-------------	-------	--------------	-------	-------------	-------	-------------

(78) MULTIVITAMINS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Multivitamins (7800)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Vitamin Mixtures (7810)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
B-Complex Vitamins (7811)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
B-Complex w/ C (7812)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
B-Complex w/ Folic Acid (7813)	2	\$36.78	0	\$0.00	0	\$0.00	0	\$0.00
B-Complex w/ Iron (7814)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
B-Complex w/ Minerals (7815)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bioflavonoid Products (7816)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Multivitamins (7820)	2	\$14.16	5	\$29.08	1	\$4.73	0	\$0.00
Multiple Vitamins w/ Iron (7821)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Multiple Vitamins w/ Minerals (7831)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Multiple Vitamins w/ Calcium (7835)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Multiple Vitamins w/ Minerals &	20	\$318.96	77	\$1,421.23	92	\$2,418.06	14	\$277.64
Not Classified (7837)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Pediatric Vitamins (7840)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Pediatric Multiple Vitamins (7841)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Ped Multiple Vitamins w/ Minerals	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Ped MV w/ Iron (7843)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Ped MV w/ Fluoride (7844)	2,028	\$26,443.22	2,510	\$31,025.20	1,936	\$23,752.15	1,967	\$23,235.40
Ped Multi Vitamins w/FI & FE (7845)	855	\$11,012.83	592	\$6,632.11	630	\$6,626.07	711	\$7,038.47
Specialty Vitamins Products (7850)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Prenatal Vitamins (7851)	28,860	\$675,604.89	40,495	\$1,060,256.44	41,226	\$1,382,460.68	47,926	\$1,886,070.24
Vitamins w/ Lipotropics (7852)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Iron w/ Vitamins (7861)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Iron & B12 w/ Vitamins (7863)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(78) MULTIVITAMINS TOTAL	31,767	\$713,430.84	43,679	\$1,099,364.06	43,885	\$1,415,261.69	50,618	\$1,916,621.75
---------------------------------	---------------	---------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------

(79) MINERALS & ELECTROLYTES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Minerals & electrolytes (7900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bicarbonates (7905)	146	\$2,282.92	367	\$6,064.68	446	\$9,299.80	510	\$14,187.81
Calcium (7910)	25	\$2,197.29	28	\$964.10	17	\$758.69	20	\$403.05
Chloride (7920)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Fluoride (7930)	1,642	\$14,215.81	2,397	\$20,505.23	2,278	\$18,615.54	2,245	\$16,919.43
Iodine Products (7935)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Magnesium (7940)	103	\$1,355.12	30	\$977.28	19	\$260.43	17	\$150.18
Manganese (7950)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Phosphate (7960)	222	\$3,177.62	268	\$4,402.68	155	\$2,680.63	84	\$1,935.65
Potassium (7970)	104,298	\$1,803,466.07	121,649	\$1,921,414.05	75,762	\$1,029,175.78	23,963	\$287,465.00
Sodium (7975)	2,826	\$133,838.45	2,924	\$128,164.03	2,299	\$127,697.23	1,630	\$108,462.84
Zinc (7980)	22	\$1,937.92	21	\$1,901.25	17	\$1,416.36	0	\$0.00
Mineral Combinations (7985)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Trace Minerals (7990)	21	\$5,325.13	8	\$2,295.63	0	\$0.00	0	\$0.00
Electrolyte Mixtures (7999)	243	\$6,754.45	373	\$11,482.64	255	\$9,075.25	196	\$5,716.81

(79) MINERALS & ELECTROLYTES	109,548	\$1,974,550.78	128,065	\$2,098,171.57	81,248	\$1,198,979.71	28,665	\$435,240.77
------------------------------	---------	----------------	---------	----------------	--------	----------------	--------	--------------

(80) NUTRIENTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Nutrients (8000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Carbohydrate (8010)	536	\$15,176.88	457	\$14,797.47	344	\$10,151.50	310	\$9,606.71
Lipids (8020)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Protein (8030)	0	\$0.00	0	\$0.00	0	\$0.00	16	\$9,623.72
Lipotropics (8040)	0	\$0.00	0	\$0.00	0	\$0.00	13	\$58.34
Misc. Nutritional Substances (8050)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(80) NUTRIENTS TOTAL	536	\$15,176.88	457	\$14,797.47	344	\$10,151.50	339	\$19,288.77
----------------------	-----	-------------	-----	-------------	-----	-------------	-----	-------------

(81) DIETARY PRODUCTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Dietary products (8100)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Infant Foods (8110)	0	\$0.00	20	\$5,739.45	19	\$3,792.06	29	\$5,999.52

	2004			2005			2006			2007		
	Total Claims	Total Paid		Total Claims	Total Paid		Total Claims	Total Paid		Total Claims	Total Paid	
Nutritional Supplements (8120)	0	\$0.00	36	\$13,670.23	62	\$26,408.96	106	\$54,770.04				
Nutritional Substitutes (8140)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
(81) DIETARY PRODUCTS TOTAL	0	\$0.00	56	\$19,409.68	81	\$30,201.02	135	\$60,769.56				

(82) HEMATOPOIETIC AGENTS

	2004			2005			2006			2007		
	Total Claims	Total Paid		Total Claims	Total Paid		Total Claims	Total Paid		Total Claims	Total Paid	
Hematopoietic agents (8200)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	
Cobalamins (8210)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	
Folic Acid/Folates (8220)	9,192	\$61,915.77	12,247	\$78,244.30	11,308	\$66,975.43	10,891	\$63,401.93				
Iron (8230)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	
Hematopoietic Growth Factors (8240)	2,146	\$2,623,732.48	3,080	\$3,914,638.62	2,325	\$3,348,712.53	1,073	\$1,902,297.88				
Agents for Gaucher Disease (8270)	36	\$129,599.60	47	\$170,451.43	5	\$27,360.85	35	\$156,782.60				
Agents for Sickle Cell Anemia (8280)	4	\$113.52	9	\$257.98	0	\$0.00	4	\$288.34				
Hematopoietic Mixtures (8299)	69	\$2,295.02	199	\$6,451.31	515	\$14,332.25	275	\$6,507.60				
(82) HEMATOPOIETIC AGENTS TOTAL	11,447	\$2,817,656.39	15,582	\$4,170,043.64	14,153	\$3,457,381.06	12,278	\$2,129,278.35				

(83) ANTICOAGULANTS

	2004			2005			2006			2007		
	Total Claims	Total Paid		Total Claims	Total Paid		Total Claims	Total Paid		Total Claims	Total Paid	
Anticoagulants (8300)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	
Heparins And Heparinoid-Like Agents	4,038	\$1,364,724.56	4,555	\$2,066,057.65	3,662	\$1,594,701.57	3,181	\$1,897,463.48				
Coumarin Anticoagulants (8320)	38,543	\$926,892.66	43,771	\$721,534.10	26,544	\$341,316.94	8,724	\$111,540.60				
Not Classified (8330)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	
Thrombin Inhibitors (8333)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	
In Vitro Anticoagulants (8340)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00		0	\$0.00	

(83) ANTICOAGULANTS TOTAL	42,581	\$2,291,617.22	48,326	\$2,787,591.75	30,206	\$1,936,018.51	11,905	\$2,009,004.08	
(84) HEMOSTATICS									
	2004			2005			2006		2007
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	
Hemostatics (8400)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
Hemostatics - Systemic (8410)	29	\$8,310.32	24	\$5,464.30	39	\$11,850.45	48	\$24,626.07	
Hemostatics - Topical (8420)	2	\$482.65	0	\$0.00	0	\$0.00	0	\$0.00	
(84) HEMOSTATICS TOTAL	31	\$8,792.97	24	\$5,464.30	39	\$11,850.45	48	\$24,626.07	
(85) MISC. HEMATOLOGICAL									
	2004			2005			2006		2007
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	
Misc. hematological (8500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
Antihemophilic Products (8510)	349	\$8,669,884.29	572	\$13,710,266.03	686	\$14,872,638.31	716	\$18,887,080.48	
Platelet Aggregation Inhibitors (8515)	37,283	\$5,240,269.16	47,639	\$6,805,088.04	32,751	\$4,629,945.65	10,772	\$1,625,716.10	
Hematorheological (8520)	5,891	\$93,758.76	5,256	\$71,443.46	2,837	\$36,697.65	610	\$8,753.58	
Hemin (8525)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
In Vitro Hematologic Agents (8527)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
Plasma Expanders (8530)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
Plasma Proteins (8540)	15	\$6,457.25	19	\$8,001.36	48	\$9,680.10	19	\$2,441.17	
Protamine (8550)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
Thrombolytic Enzymes (8560)	1	\$274.07	7	\$683.31	13	\$108,922.00	14	\$94,895.41	
(85) MISC. HEMATOLOGICAL TOTAL	43,539	\$14,010,643.53	53,493	\$20,595,482.20	36,335	\$19,657,883.71	12,131	\$20,618,886.74	
(86) OPHTHALMIC									
	2004			2005			2006		2007
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	
Ophthalmic (8600)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00	
Ophthalmic Anti-infectives (8610)	33,215	\$713,374.37	43,163	\$874,348.40	40,818	\$929,114.90	38,943	\$907,740.09	

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Paid	
Artificial Tears and Lubricants (8620)	0	\$0.00	1	\$58.40	3	\$94.64	13	\$357.54				
Beta-blockers - Ophthalmic (8625)	9,409	\$412,083.97	9,433	\$447,854.58	5,363	\$278,928.87	1,255	\$89,467.61				
Ophthalmic Steroids (8630)	10,397	\$374,908.14	11,308	\$399,006.52	8,792	\$334,763.66	6,240	\$276,955.27				
Prostaglandins - Ophthalmic (8633)	11,640	\$782,890.31	14,070	\$1,042,092.56	8,910	\$679,134.15	2,469	\$220,502.72				
Cycloplegics (8635)	859	\$11,999.44	985	\$12,108.77	841	\$10,459.93	777	\$8,876.32				
Ophthalmic Decongestants (8640)	21	\$196.71	55	\$602.01	36	\$333.05	68	\$501.30				
Miotics (8650)	866	\$13,512.79	792	\$13,363.25	416	\$6,727.62	84	\$2,833.59				
Adrenergic Agents (8660)	5,595	\$407,496.66	5,944	\$424,775.66	3,223	\$238,200.89	810	\$63,852.30				
Ophthalmic - Angiogenesis Inhibitors	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Ophthalmic Photodynamic Therapy	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Ophthalmic Immunomodulators (8672)	531	\$48,736.71	1,212	\$118,701.28	1,069	\$109,972.77	313	\$38,218.33				
Ophthalmic Local Anesthetics (8675)	41	\$451.57	180	\$1,159.17	55	\$373.09	63	\$400.45				
Ophthalmic Surgical Aids (8678)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Misc. Ophthalmics (8680)	8,636	\$1,244,719.55	12,422	\$1,130,095.53	10,632	\$957,283.80	7,464	\$949,049.72				
Contact Lens Solutions (8690)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				

(86) OPHTHALMIC TOTAL	81,210	\$4,010,370.22	99,565	\$4,464,166.13	80,158	\$3,545,387.37	58,499	\$2,558,755.24
------------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------

(87) OTIC

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Paid	
Otic (8700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Otic Anti-infectives (8710)	7,293	\$382,800.60	9,336	\$533,089.71	9,562	\$594,263.12	9,773	\$735,767.43				
Otic Analgesics (8720)	43	\$675.89	57	\$883.47	34	\$525.32	36	\$518.63				
Otic Steroids (8730)	417	\$10,680.88	479	\$11,216.31	414	\$9,432.10	382	\$8,150.01				
Otic Miscellaneous (8740)	331	\$7,398.91	323	\$9,637.50	226	\$6,715.25	187	\$6,367.45				
Otic Agents - For External Ear (8770)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00				
Otic Combinations (8799)	26,300	\$715,664.64	36,069	\$1,181,051.75	34,111	\$1,241,570.69	35,663	\$1,479,226.40				

(87) OTIC TOTAL	34,384	\$1,117,220.92	46,264	\$1,735,878.74	44,347	\$1,852,506.48	46,041	\$2,230,029.92
------------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------	---------------	-----------------------

(88) MOUTH & THROAT (Local)

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Mouth & throat (local) (8800)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Anti-infectives - Throat (8810)	11,466	\$251,723.96	14,626	\$420,492.87	13,188	\$321,701.01	13,637	\$336,563.05
Antiseptics - Mouth/Throat (8815)	2,563	\$26,647.01	2,982	\$28,832.97	2,664	\$22,390.50	2,223	\$17,741.63
Lozenges (8820)	0	\$0.00	4	\$26.87	20	\$99.31	86	\$381.06
Steroids - Mouth (8825)	542	\$9,005.17	618	\$11,050.58	602	\$9,908.05	495	\$9,152.91
Antiallergy Agents (8827)	55	\$1,269.06	29	\$645.08	23	\$502.96	3	\$66.56
Mouthwashes (8830)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Anesthetics Topical Oral (8835)	1,460	\$10,900.08	2,268	\$21,514.54	2,200	\$17,688.56	2,109	\$16,548.00
Dental Products (8840)	791	\$9,910.93	1,206	\$14,693.24	1,318	\$16,474.99	1,916	\$21,302.18
Periodontal Products (8845)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc. Throat Products (8850)	411	\$58,221.14	469	\$62,554.41	323	\$41,525.05	70	\$8,236.13
(88) MOUTH & THROAT (Local) TOTAL	17,288	\$367,677.35	22,202	\$559,810.56	20,338	\$430,290.43	20,539	\$409,991.52

(89) ANORECTAL

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Anorectal (8900)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Rectal Steroids (8910)	1,177	\$13,476.30	1,515	\$20,758.29	1,128	\$14,941.70	829	\$9,278.89
Intrarectal Steroids (8915)	31	\$5,175.25	82	\$11,936.44	58	\$7,105.74	53	\$6,403.15
Rectal Local Anesthetics (8920)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc. Rectal Products (8930)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Rectal Protectants-Emollients (8940)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Rectal Combinations (8999)	938	\$46,102.92	1,401	\$68,449.03	1,226	\$68,643.16	882	\$54,798.14
(89) ANORECTAL TOTAL	2,146	\$64,754.47	2,998	\$101,143.76	2,412	\$90,690.60	1,764	\$70,480.18

(90) DERMATOLOGICAL

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Dermatological (9000)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Acne Products (9005)	5,240	\$438,992.10	7,720	\$705,607.02	8,580	\$778,748.54	8,307	\$791,545.65
Rosacea Agents (9006)	999	\$64,360.47	1,237	\$83,450.26	926	\$67,575.15	268	\$22,419.33
Analgesics (9007)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antibiotics - Topical (9010)	18,498	\$761,400.51	25,619	\$942,448.35	26,030	\$950,342.29	25,188	\$894,780.91
Antifungals - Topical (9015)	43,678	\$1,093,480.04	54,087	\$1,320,980.24	47,659	\$1,080,972.99	41,631	\$764,278.90
Antihistamines-Topical (9020)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antipruritics (9022)	174	\$8,308.45	165	\$9,120.83	71	\$3,875.92	37	\$2,904.00
Antipsoriatics (9025)	1,526	\$280,217.78	1,812	\$462,987.80	1,820	\$381,626.19	1,882	\$432,833.91
Antiseborrheic Products (9030)	1,416	\$19,478.90	1,639	\$22,783.03	1,316	\$21,809.76	1,057	\$15,611.78
Antiviral - Topical (9035)	2,551	\$191,966.23	3,142	\$265,651.78	3,032	\$258,960.43	2,726	\$275,054.15
Antineoplastic or Premalignant Lesions -	321	\$34,829.03	392	\$49,706.49	255	\$36,937.93	181	\$32,553.68
Bath Products (9040)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Burn Products (9045)	6,533	\$93,367.49	7,830	\$100,555.22	5,917	\$85,349.39	4,036	\$50,100.84
Cauterizing Agents (9050)	2	\$41.01	3	\$34.59	0	\$0.00	1	\$63.20
Tar Products (9052)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Corticosteroids - Topical (9055)	40,032	\$844,695.77	54,892	\$1,199,671.06	51,189	\$1,073,129.09	49,168	\$978,027.46
Diaper Rash Products (9060)	0	\$0.00	0	\$0.00	0	\$0.00	1	\$7.21
Emollients (9065)	1,277	\$61,307.26	2,057	\$62,140.18	2,305	\$50,923.39	3,437	\$195,077.29
Emollient/Keratolytic (9066)	516	\$31,816.89	799	\$63,264.03	772	\$54,471.02	605	\$39,674.81
Enzymes - Topical (9070)	12,499	\$650,388.05	17,566	\$976,529.37	12,069	\$732,346.32	2,709	\$174,718.13
Hair Growth Agents (9073)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Hair Reduction Agents (9074)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Keratolytics/Antimitotics (9075)	144	\$17,407.19	305	\$39,120.63	298	\$38,976.28	370	\$41,147.73
Immunomodulating Agents - Topical	1,317	\$236,368.04	1,801	\$291,024.36	1,777	\$316,327.39	1,579	\$330,542.20
Immunosuppressive Agents - Topical	12,174	\$1,049,041.43	18,529	\$1,885,102.18	12,896	\$1,513,629.54	6,512	\$803,196.84
Liniments (9080)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Local Anesthetics - Topical (9085)	2,605	\$300,857.69	5,715	\$884,854.38	5,796	\$943,854.70	4,713	\$690,876.36
Pigmenting-Depigmenting Agents	93	\$4,972.73	156	\$8,007.33	133	\$7,701.23	55	\$5,925.99
Agents for Facial Wrinkles (9088)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Glabellar Lines (Frown Lines) Agents	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Scabicides & Pediculicides (9090)	15,335	\$1,139,759.93	21,302	\$1,821,020.36	19,970	\$1,531,809.49	19,084	\$1,441,292.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Sunscreens (9092)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Scar Treatment Products (9093)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Wound Care Products (9094)	386	\$159,287.52	389	\$135,197.11	241	\$89,350.86	172	\$30,405.61
Poison Ivy Products (9095)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc. Topical (9097)	240	\$3,248.64	408	\$5,398.14	480	\$5,743.12	408	\$4,473.15
Podiatric Products (9098)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc. Dermatological Products (9099)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
(90) DERMATOLOGICAL TOTAL	167,556	\$7,485,593.15	227,565	\$11,334,654.74	203,532	\$10,024,461.02	174,127	\$8,017,511.13

(92) ANTISEPTICS & DISINFECTANTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antiseptics & disinfectants (9200)	4	\$74.58	14	\$200.03	11	\$424.94	11	\$337.57
Chlorine Antiseptics (9210)	525	\$14,882.50	788	\$22,832.46	833	\$25,109.48	923	\$29,213.35
Iodine Antiseptics (9220)	1	\$5.80	43	\$1,954.47	32	\$1,464.24	3	\$156.45
Mercury Antiseptics (9230)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Silver Antiseptics (9240)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Antiseptic Combinations (9299)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(92) ANTISEPTICS & DISINFECTANTS

	530	\$14,962.88	845	\$24,986.96	876	\$26,998.66	937	\$29,707.37
--	-----	-------------	-----	-------------	-----	-------------	-----	-------------

(93) ANTIDOTES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Antidotes (9300)	152	\$119,774.73	337	\$273,822.25	216	\$224,010.15	12	\$22,197.16
Antidotes - Chelating Agents (9310)	4	\$1,368.28	4	\$1,621.38	99	\$291,767.54	264	\$818,682.32
Benzodiazepine Antagonists (9320)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Narcotic Antagonists (9340)	440	\$67,224.08	466	\$54,786.98	411	\$38,187.00	624	\$48,319.30
Antidote Kits (9399)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
(93) ANTIDOTES TOTAL	596	\$188,367.09	807	\$330,230.61	726	\$553,964.69	900	\$889,198.78

(94) DIAGNOSTIC PRODUCTS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Diagnostic products (9400)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Diagnostic Reagents (9410)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Diagnostic Drugs (9420)	296	\$32,827.91	783	\$85,995.83	354	\$39,689.59	81	\$6,875.01
Diagnostic Biologicals (9430)	68	\$888.32	152	\$1,838.72	83	\$2,858.61	73	\$1,044.04
Diagnostic Radiopharmaceuticals	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Radiographic Contrast Media (9440)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Non-Radiographic Contrast Media	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Diagnostic Products, Misc. (9460)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
(94) DIAGNOSTIC PRODUCTS TOTAL	364	\$33,716.23	935	\$87,834.55	437	\$42,548.20	154	\$7,919.05

(95) ALTERNATIVE MEDICINES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Alternative medicines (9500)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - A's (9503)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - B's (9506)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - C's (9509)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - D's (9512)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - E's (9515)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - F's (9518)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - G's (9521)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - H's (9524)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - K's (9533)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - L's* (9536)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - M's (9539)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Alternative Medicine - N's (9542)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - P's (9548)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - R's (9554)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - S's (9557)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - T's (9560)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - V's (9566)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - W's (9569)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine - Y's (9575)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Alternative Medicine Combinations	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(95) ALTERNATIVE MEDICINES TOTAL	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
---	----------	---------------	----------	---------------	----------	---------------	----------	---------------

(96) CHEMICALS

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Chemicals (9600)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Acids, Bases, & Buffers (9610)	0	\$0.00	1	\$8.05	1	\$11.95	1	\$5.59
Liquids (9620)	5	\$111.68	1	\$344.27	14	\$340.50	36	\$981.98
Solids (9630)	4	\$36.01	55	\$1,633.56	22	\$566.95	14	\$145.32
Semi-Solids (9640)	0	\$0.00	3	\$128.04	1	\$5.10	1	\$6.02
Bulk Chemicals - A's (9642)	2	\$13.16	4	\$34.27	8	\$65.97	1	\$25.15
Bulk Chemicals - B's (9644)	0	\$0.00	1	\$245.80	242	\$9,026.16	0	\$0.00
Bulk Chemicals - C's (9646)	19	\$1,058.45	36	\$5,589.67	14	\$2,040.15	107	\$768.22
Bulk Chemicals - D's (9648)	3	\$145.04	1	\$6.44	3	\$12.80	2	\$7.54
Bulk Chemicals - E's (9650)	0	\$0.00	0	\$0.00	6	\$26.10	0	\$0.00
Bulk Chemicals - F's (9652)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - G's (9654)	2	\$166.00	6	\$325.26	6	\$292.49	3	\$126.35
Bulk Chemicals - H's (9656)	3	\$88.11	7	\$175.33	7	\$68.15	7	\$302.95
Bulk Chemicals - I's (9658)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Not Classified (9660)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - K's (9662)	12	\$4,356.00	15	\$19,775.55	8	\$4,688.58	5	\$96.91
Bulk Chemicals - L's (9664)	9	\$346.85	3	\$203.01	30	\$1,033.49	1	\$46.20

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Bulk Chemicals - M's (9666)	1	\$4.84	6	\$256.50	6	\$250.58	6	\$31.97
Bulk Chemicals - N's (9668)	0	\$0.00	0	\$0.00	1	\$144.41	1	\$284.68
Bulk Chemicals - O's (9670)	0	\$0.00	0	\$0.00	1	\$201.27	47	\$1,646.17
Bulk Chemicals - P's (9672)	4	\$41.31	14	\$1,069.31	2	\$29.53	0	\$0.00
Bulk Chemicals - Q's (9674)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - R's (9676)	0	\$0.00	1	\$18.34	8	\$218.30	2	\$260.66
Bulk Chemicals - S's (9678)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - T's (9680)	39	\$232.42	32	\$427.55	89	\$1,280.02	0	\$0.00
Bulk Chemicals - U's (9682)	1	\$6.57	16	\$1,635.62	23	\$2,285.59	3	\$57.91
Bulk Chemicals - V's (9684)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Not Classified (9686)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - X (9687)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - Y's (9688)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals - Z's (9689)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bulk Chemicals (9690)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(96) CHEMICALS TOTAL	104	\$6,606.44	202	\$31,876.57	492	\$22,588.09	237	\$4,793.62
----------------------	-----	------------	-----	-------------	-----	-------------	-----	------------

(97) MEDICAL DEVICES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Medical devices (9700)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Parenteral Therapy Supplies (9705)	1	\$20.48	0	\$0.00	0	\$0.00	3	\$12.96
Cardiology Supplies (9708)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Respiratory Therapy Supplies (9710)	8,490	\$345,205.66	13,282	\$567,637.19	13,673	\$608,178.83	15,664	\$734,965.04
Respiratory Aids (9712)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Medical Gases (9714)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
GI-GU Ostomy & Irrigation Supplies	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Peritoneal Dialysis (9717)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Diabetic Supplies (9720)	0	\$0.00	1	\$27.50	0	\$0.00	0	\$0.00
Enteral Nutrition Supplies (9725)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Bandages-Dressings-Tape (9730)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	
Elastic Bandages & Supports (9735)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Surgical Supplies (9736)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Heating/Cooling Aids (9737)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Back Plasters (9739)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Contraceptives (9740)	63	\$1,101.79	135	135	\$4,074.99	96	96	\$2,288.00	44	44	\$2,011.66	
Fertility Monitoring Test Supplies	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Female Personal Care Products (9745)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Impotence Aids (9747)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Oral Hygiene Products (9750)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Infant Care Products (9755)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Optical Supplies (9760)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Misc. Devices (9770)	0	\$0.00	11	11	\$76.37	366	366	\$2,532.92	884	884	\$4,919.74	
Blood Pressure Devices (9775)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Foot Care Products (9780)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
First Aid Kits (9785)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	

(97) MEDICAL DEVICES TOTAL	8,554	\$346,327.93	13,429	13,429	\$571,816.05	14,135	14,135	\$612,999.75	16,595	16,595	\$741,909.40
-----------------------------------	--------------	---------------------	---------------	---------------	---------------------	---------------	---------------	---------------------	---------------	---------------	---------------------

(98) PHARMACEUTICAL ADJUVANTS

	2004			2005			2006			2007		
	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	Total Claims	Total Claims	Total Paid	
Pharmaceutical adjuvants (9800)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Alkalinizing Agents (9805)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Antimicrobial Agents (9810)	0	\$0.00	0	0	\$0.00	1	1	\$5.52	8	8	\$375.80	
Coloring Agents (9830)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Flavoring Agents (9833)	0	\$0.00	4	4	\$392.34	0	0	\$0.00	0	0	\$0.00	
Pharmaceutical Excipients (9835)	9	\$207.30	179	179	\$3,068.87	312	312	\$7,342.48	617	617	\$11,852.10	
Internal Vehicle Ingredients/Agents	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Surfactants (9837)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	
Liquid Vehicle (9840)	1,871	\$48,018.89	1,726	1,726	\$58,927.98	1,665	1,665	\$128,004.14	1,852	1,852	\$122,579.29	
Semi Solid Vehicle (9860)	6	\$86.95	9	9	\$235.68	12	12	\$236.13	38	38	\$1,125.29	
Not Classified (9865)	0	\$0.00	0	0	\$0.00	0	0	\$0.00	0	0	\$0.00	

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Gelatin Capsules (Empty) (9870)	0	\$0.00	1	\$6.82	2	\$12.35	0	\$0.00
Not Classified (9871)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Placebo (9880)	191	\$4,579.03	119	\$2,723.59	96	\$2,646.53	54	\$1,056.97
Not Classified (9890)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(98) PHARMACEUTICAL ADJUVANTS	2,077	\$52,892.17	2,038	\$65,355.28	2,088	\$138,247.15	2,569	\$136,989.45
--------------------------------------	--------------	--------------------	--------------	--------------------	--------------	---------------------	--------------	---------------------

(99) ASSORTED CLASSES

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
Assorted classes (9900)	1	\$12.19	0	\$0.00	0	\$0.00	0	\$0.00
Chelating Agents (9920)	69	\$9,074.14	64	\$7,730.93	38	\$5,246.79	28	\$7,183.72
Enzymes (9935)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Immunomodulators (9939)	127	\$304,514.88	138	\$386,014.70	149	\$593,720.99	51	\$309,292.90
Immunosuppressive Agents (9940)	4,503	\$1,718,516.21	4,856	\$1,897,002.95	4,308	\$1,661,976.04	3,809	\$1,563,637.85
K Removing Resin (9945)	503	\$34,925.17	697	\$40,791.99	449	\$23,275.57	161	\$8,265.66
Prostaglandins (9950)	0	\$0.00	0	\$0.00	1	\$200.15	0	\$0.00
Sclerosing Agents (9965)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Peritoneal Dialysis Solutions (9970)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Irrigation Solutions (9975)	334	\$6,098.04	290	\$3,901.27	222	\$2,881.07	161	\$2,816.70
Organ Preservation Solution (9980)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Misc Natural Products (9985)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Homeopathic Products (9987)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00
Not Classified (9990)	0	\$0.00	0	\$0.00	0	\$0.00	0	\$0.00

(99) ASSORTED CLASSES TOTAL	5,537	\$2,073,140.63	6,045	\$2,335,441.84	5,167	\$2,287,300.61	4,210	\$1,891,196.83
------------------------------------	--------------	-----------------------	--------------	-----------------------	--------------	-----------------------	--------------	-----------------------

	2004		2005		2006		2007	
	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid	Total Claims	Total Paid
GRAND TOTAL	5,475,751	\$366,755,159	7,182,130	\$481,870,477	5,958,535	\$402,487,157	4,699,041	\$321,198,284

Top 100 Medications by Pharmacy Reimbursement Fiscal Year Comparison

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
Antiinhibitor Coagulant Complex For Inj	1	\$5,621,551.94	6	\$4,360,408.78	29	\$2,982,223.73	32	\$1,889,465.47
Montelukast Sodium Chew Tab 5 MG (Base Equiv)	2	\$5,270,803.11	9	\$4,001,182.21	25	\$3,121,262.02	27	\$2,037,144.52
Palivizumab IM Soln 100 MG/ML	3	\$4,920,569.19	8	\$4,094,002.87*	5	\$5,049,817.96	13	\$2,874,840.70
MONTELUKAST SODIUM TAB 10 MG (BASE EQUIV)	61	\$1,159,794.85	71	\$1,282,623.23	48	\$1,984,129.89	20	\$2,449,412.18
QUETIAPINE FUMARATE TAB 300 MG	4	\$4,151,515.22	7	\$4,322,183.59	9	\$4,238,739.26	10	\$3,136,109.37
Montelukast Sodium Chew Tab 4 MG (Base Equiv)	5	\$4,113,905.01	1	\$5,024,151.19	11	\$3,864,127.93	29	\$2,020,554.08
OLANZAPINE TAB 20 MG	6	\$3,756,659.36	16	\$2,797,669.48	43	\$2,106,433.96	61	\$1,268,191.84
LANSOPRAZOLE CAP DELAYED RELEASE 30 MG	7	\$3,393,058.08	2	\$4,984,585.96	2	\$5,322,770.38	1	\$5,427,809.26
Quetiapine Fumarate Tab 200 MG	8	\$3,349,953.83	3	\$4,683,034.42	4	\$5,252,051.36	3	\$4,357,272.93
Coagulation Factor VIIa (Recomb) For Inj 4800 MCG	9	\$3,186,961.14	4	\$4,546,999.17	3	\$5,292,996.86	7	\$3,331,072.63
Aripiprazole Tab 10 MG	10	\$3,107,490.09	53	\$1,589,933.61	**	****	**	****
FLUTICASON-SALMETEROL POWDER DISKS 250-50 MCG/DOSE	11	\$3,073,989.66	13	\$3,338,363.46	22	\$3,176,684.65	65	\$1,236,092.04
Aripiprazole Tab 5 MG	12	\$3,028,967.40	11	\$3,576,485.30	15	\$3,474,897.17	28	\$2,026,323.56
RISPERIDONE TAB 2 MG	13	\$2,707,405.04	20	\$2,587,548.17	32	\$2,774,478.15	**	****
Fluticasone-Salmeterol Powder Disks 100-50 MCG/DOSE	14	\$2,505,573.26	15	\$2,813,890.40	14	\$3,498,718.52	12	\$3,036,618.77
Risperidone Tab 1 MG	15	\$2,451,593.52	18	\$2,690,535.29	35	\$2,557,485.06	45	\$1,550,732.78
ARIPIPRAZOLE TAB 15 MG	16	\$2,440,159.99	17	\$2,731,690.89	12	\$3,826,469.67	8	\$3,282,887.26
ARIPIPRAZOLE TAB 30 MG	17	\$2,346,627.59	19	\$2,605,567.69	18	\$3,271,186.65	30	\$1,955,372.33
BUDESONIDE INHALATION SUSP 0.25 MG/2ML	18	\$2,269,797.55	28	\$2,274,258.70	72	\$1,539,966.70	**	****
Budesonide Inhalation Susp 0.5 MG/2ML	19	\$2,171,424.93	44	\$1,785,027.66	69	\$1,598,512.95	78	\$1,002,699.33
	20	\$2,133,826.42	43	\$1,801,830.13	74	\$1,471,064.70	90	\$846,831.95

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
Aripiprazole Tab 20 MG	21	\$2,100,346.59	36	\$1,967,906.90	78	\$1,404,143.76	**	****
Albuterol Sulfate Inhal Aero 108 MCG/ACT (90MCG Base Equiv)	22	\$2,013,596.54	**	****	**	****	**	****
Risperidone Tab 3 MG	23	\$1,961,160.29	21	\$2,519,500.29	30	\$2,930,424.39	16	\$2,645,457.56
Azithromycin For Susp 200 MG/5ML	24	\$1,869,948.85	**	****	**	****	**	****
ZITHROMAX SUS 200/5ML	**	****	31	\$2,064,608.90	47	\$1,999,067.75	49	\$1,500,612.93
Divalproex Sodium Tab Delayed Release 500 MG	25	\$1,849,573.95	22	\$2,507,067.09	23	\$3,173,586.05	17	\$2,506,974.92
METHYLPHENIDATE HCL TAB SA OSM 36 MG	26	\$1,843,383.30	72	\$1,269,123.10	**	****	**	****
Cefdinir For Susp 250 MG/5ML	27	\$1,756,074.29	78	\$1,236,527.02	**	****	**	****
Esomeprazole Magnesium Cap Delayed Release 40 MG	28	\$1,682,794.86	5	\$4,492,096.40	7	\$4,436,902.13	34	\$1,886,229.80
Albuterol Inhal Aerosol 90 MCG/ACT	29	\$1,661,210.52	68	\$1,290,926.53	86	\$1,293,938.32	79	\$996,559.45
Ziprasidone HCl Cap 80 MG	30	\$1,620,750.79	38	\$1,892,827.06	63	\$1,698,678.17	**	****
Antihemophilic Factor (Recombinant) For Inj Kit 1000 Unit	31	\$1,604,514.09	32	\$2,048,482.99	66	\$1,645,785.69	68	\$1,123,450.57
Desmopressin Acetate Tab 0.2 MG	**	****	**	****	62	\$1,716,458.78	67	\$1,152,266.88
QUETIAPINE FUMARATE TAB 100 MG	32	\$1,600,155.51	59	\$1,385,646.97	**	****	**	****
MOMETASONE FUROATE NASAL SUSP 50 MCG/ACT	33	\$1,575,488.27	29	\$2,255,009.19	20	\$3,225,294.33	21	\$2,262,796.34
Topiramate Tab 100 MG	34	\$1,551,987.78	70	\$1,283,671.31	92	\$1,092,632.38	**	****
Risperidone Tab 0.5 MG	35	\$1,550,202.69	47	\$1,736,715.41	46	\$2,008,735.05	53	\$1,466,647.62
INSULIN GLARGINE INJ 100 UNIT/ML	36	\$1,523,834.07	34	\$1,981,408.94	24	\$3,132,329.61	15	\$2,661,922.29
Etanercept Subcutaneous Inj 50 MG/ML	37	\$1,503,576.61	37	\$1,905,703.84	51	\$1,897,008.05	75	\$1,032,303.95
Quetiapine Fumarate Tab 400 MG	38	\$1,434,314.04	55	\$1,496,277.04	**	****	**	****
Risperidone Tab 4 MG	39	\$1,432,210.46	**	****	**	****	**	****
ESCITALOPRAM OXALATE TAB 10 MG (BASE EQUIV)	40	\$1,427,309.55	49	\$1,703,539.19	53	\$1,829,080.91	48	\$1,515,239.36
VENLAFAXINE HCL CAP SR 24HR 150 MG	41	\$1,395,860.87	23	\$2,447,421.15	28	\$3,028,143.97	31	\$1,933,951.15
AMPHETAMINE-DEXTROAMPHETAMINE CAP SR 24HR 20 MG	42	\$1,393,603.89	33	\$2,034,198.34	38	\$2,381,471.25	38	\$1,792,434.02
	43	\$1,382,217.15	85	\$1,131,421.56	**	****	**	****

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
Antihemophilic Factor (Human) For Inj	44	\$1,370,269.15	41	\$1,826,453.05	37	\$2,486,454.90	43	\$1,622,576.55
TOBRAMYCIN NEBU SOLN 300 MG/5ML	45	\$1,354,443.32	81	\$1,188,979.80	87	\$1,202,865.01	77	\$1,026,377.99
Methylphenidate HCl Tab SA OSM 54 MG	46	\$1,351,903.52	**	****	**	****	**	****
PEGINTERFERON ALFA-2A INJ KIT 180	47	\$1,347,937.25	94	\$1,012,645.99	**	****	**	****
Atorvastatin Calcium Tab 20 MG (Base Equivalent)	48	\$1,345,366.24	24	\$2,433,875.18	21	\$3,185,973.14	23	\$2,234,602.69
Olanzapine Tab 10 MG	49	\$1,330,387.36	27	\$2,280,467.83	6	\$4,528,316.55	2	\$5,089,978.46
Fluticasone Propionate Nasal Susp 50 MCG/ACT	**	****	50	\$1,688,994.75	42	\$2,162,406.52	57	\$1,390,872.54
FLUTICASONONE SPR 50MCG	50	\$1,314,992.36	**	****	**	****	**	****
LAMOTRIGINE TAB 100 MG	51	\$1,309,897.49	80	\$1,210,804.77	89	\$1,153,177.62	**	****
Escitalopram Oxalate Tab 20 MG (Base Equivalent)	52	\$1,288,830.49	39	\$1,870,513.24	52	\$1,845,049.10	87	\$878,672.46
Lexapro Tab 20MG	52	\$1,288,830.49	39	\$1,870,513.24	52	\$1,845,049.10	87	\$878,672.46
Divalproex Sodium Tab SR 24 HR 500 MG	53	\$1,271,003.55	60	\$1,385,436.13	80	\$1,358,524.61	**	****
DEPAKOTE ER TAB 500MG	53	\$1,271,003.55	60	\$1,385,436.13	80	\$1,358,524.61	**	****
Olanzapine Tab 15 MG	54	\$1,267,133.59	26	\$2,355,982.80	8	\$4,312,296.07	4	\$4,248,821.58
ZYPREXA TAB 15MG	54	\$1,267,133.59	26	\$2,355,982.80	8	\$4,312,296.07	4	\$4,248,821.58
Amphetamine-Dextroamphetamine Cap SR 24HR 30 MG	55	\$1,247,060.78	93	\$1,020,744.28	**	****	**	****
ADDERALL XR CAP 30MG	55	\$1,247,060.78	93	\$1,020,744.28	**	****	**	****
Levalbuterol HCl Soln Nebu 0.63 MG/3ML (Base Equiv)	56	\$1,245,520.76	77	\$1,240,517.05	90	\$1,138,502.62	**	****
XOPENEX NEB 0.63MG	56	\$1,245,520.76	77	\$1,240,517.05	90	\$1,138,502.62	**	****
Dornase Alfa Inhal Soln 1 MG/ML	57	\$1,228,414.10	83	\$1,159,508.76	93	\$1,068,870.86	93	\$799,571.04
PULMOZYME SOL 1MG/ML	57	\$1,228,414.10	83	\$1,159,508.76	93	\$1,068,870.86	93	\$799,571.04
Azithromycin Tab 250 MG	58	\$1,215,411.27	89	\$1,060,810.52	**	****	**	****
AZITHROMYCIN TAB 250MG	58	\$1,215,411.27	89	\$1,060,810.52	**	****	**	****
ZITHROMAX TAB Z-PAK	**	****	**	****	44	\$2,057,289.37	46	\$1,544,899.59
Levetiracetam Tab 500 MG	59	\$1,176,757.61	61	\$1,378,764.35	77	\$1,405,464.48	84	\$904,965.40
KEPPRA TAB 500MG	59	\$1,176,757.61	61	\$1,378,764.35	77	\$1,405,464.48	84	\$904,965.40
ANTHEMOPHILIC FACTOR (RECOMBINANT) FOR INJ KIT 500 UNIT	60	\$1,172,541.23	58	\$1,437,212.22	**	****	**	****
KOGENATE FS SOL 500UNIT	60	\$1,172,541.23	58	\$1,437,212.22	**	****	**	****
Zolpidem Tartrate Tab 10 MG	62	\$1,156,331.27	46	\$1,737,172.74	58	\$1,772,458.36	64	\$1,239,459.66
Azithromycin For Susp 100 MG/5ML	63	\$1,081,288.96	**	****	**	****	**	****
AZITHROMYCIN SUS 100/5ML	63	\$1,081,288.96	**	****	**	****	**	****
ZITHROMAX SUS 100/5ML	**	****	84	\$1,157,802.11	98	\$1,019,667.16	**	****
Clopidogrel Bisulfate Tab 75 MG (Base Equiv)	64	\$1,070,201.57	10	\$3,923,782.25	1	\$5,392,756.42	5	\$3,963,604.68
PLAVIX TAB 75MG	64	\$1,070,201.57	10	\$3,923,782.25	1	\$5,392,756.42	5	\$3,963,604.68
PANTOPRAZOLE SODIUM EC TAB 40 MG (BASE EQUIV)	65	\$1,066,432.78	14	\$3,067,789.70	16	\$3,440,520.15	39	\$1,763,084.42
PROTONIX TAB 40MG	65	\$1,066,432.78	14	\$3,067,789.70	16	\$3,440,520.15	39	\$1,763,084.42

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
CIPROFLOXACIN-DEXAMETHASONE OTIC SUSP 0.3-0.1%	66	\$1,057,341.80	**	****	**	****	**	****
Oxcarbazepine Tab 300 MG	67	\$1,039,619.19	97	\$986,771.16	**	****	**	****
Albuterol-Ipratropium Nebu Soln 2.5(3)-0.5 MG/3ML	68	\$1,022,231.57	79	\$1,228,212.35	79	\$1,363,603.61	91	\$837,011.86
Lamotrigine Tab 25 MG	69	\$986,148.57	**	****	**	****	**	****
Duloxetine HCl Enteric Coated Pellets Cap 60 MG	70	\$984,929.16	86	\$1,105,074.19	**	****	**	****
Coagulation Factor VIIa (Recomb) For Inj 2400 MCG	71	\$970,539.07	**	****	**	****	**	****
SOMATROPIN INJ 5 MG/ML	72	\$956,388.90	100	\$981,509.15	**	****	**	****
Albuterol-Ipratropium Aerosol 103-18 MCG/ACT (120-20MCG/ACT)	73	\$940,703.79	52	\$1,592,680.09	45	\$2,038,588.50	47	\$1,526,156.91
COAGULATION FACTOR VIIA (RECOMB) FOR INJ 1200 MCG	74	\$934,630.55	**	****	**	****	**	****
Divalproex Sodium Tab Delayed Release 250 MG	75	\$930,664.49	66	\$1,337,922.34	60	\$1,762,607.48	51	\$1,478,909.68
ATOMOXETINE HCL CAP 40 MG (BASE EQUIV)	76	\$930,222.09	57	\$1,465,710.55	71	\$1,553,619.70	71	\$1,091,018.94
FLUTICASON-SALMETEROL POWDER DISKS 500-50 MCG/DOSE	77	\$929,635.34	76	\$1,244,552.75	83	\$1,320,008.83	89	\$854,706.08
Oxycodone HCl Tab SR 12HR 80 MG	100	\$713,859.09	**	****	**	****	**	****
SERTRALINE HCL TAB 100 MG	78	\$926,261.89	45	\$1,755,452.05	70	\$1,553,963.45	**	****
Omeprazole Cap Delayed Release 20 MG	**	****	96	\$992,758.74	50	\$1,904,419.77	18	\$2,450,776.18
	79	\$909,450.60	**	****	**	****	**	****
	**	****	12	\$3,369,009.34	10	\$4,060,474.66	9	\$3,177,063.86
	80	\$907,724.05	30	\$2,253,628.69	13	\$3,767,990.69	50	\$1,484,250.07
Amoxicillin & K Clavulanate For Susp 600-42.9 MG/5ML	81	\$892,490.99	87	\$1,075,596.92	100	\$1,012,562.87	**	****
	**	****	**	****	**	****	62	\$1,249,034.32

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
RABEPRAZOLE SODIUM EC TAB 20 MG	82	\$853,838.03	**	****	**	****	**	****
Topiramate Tab 200 MG	83	\$846,090.17	90	\$1,054,332.52	88	\$1,185,158.92	95	\$786,415.31
Atorvastatin Calcium Tab 10 MG (Base Equivalent)	84	\$843,351.57	35	\$1,981,087.50	31	\$2,858,760.08	22	\$2,258,947.57
Amphetamine-Dextroamphetamine Cap SR 24HR 10 MG	85	\$810,658.21	**	****	**	****	**	****
Fluticasone Propionate HFA Inhal Aerosol 44 MCG/ACT	86	\$807,741.25	**	****	**	****	**	****
Ziprasidone HCl Cap 60 MG	87	\$791,419.92	**	****	**	****	**	****
Lamotrigine Tab 200 MG	88	\$791,343.69	**	****	**	****	**	****
Risperidone Microspheres For Inj 50 MG	89	\$790,684.98	**	****	**	****	**	****
ATORVASTATIN CALCIUM TAB 40 MG (BASE EQUIVALENT)	90	\$783,626.54	63	\$1,350,942.92	67	\$1,642,801.56	74	\$1,051,529.63
Fluticasone Propionate HFA Inhal Aerosol 110 MCG/ACT	91	\$776,564.91	**	****	**	****	**	****
ROSIGLITAZONE MALEATE TAB 8 MG (BASE EQUIV)	92	\$761,690.15	51	\$1,685,002.02	36	\$2,488,001.72	33	\$1,886,812.30
CLOZAPINE TAB 100 MG	93	\$759,348.06	**	****	**	****	99	\$763,189.45
TIOTROPIUM BROMIDE MONOHYDRATE INHAL CAP 18 MCG (BASE EQUIV)	94	\$757,161.69	99	\$983,039.73	**	****	**	****
Ranitidine HCl Syrup 15 MG/ML (75 MG/5ML)	95	\$755,615.10	**	****	94	\$1,029,980.35	96	\$784,206.47
Hydrocodone-Acetaminophen Tab 10-500 MG	96	\$736,470.80	**	****	**	****	**	****
Oxcarbazepine Tab 600 MG	97	\$735,550.47	**	****	**	****	**	****
Venlafaxine HCl Cap SR 24HR 75 MG	98	\$730,989.57	74	\$1,261,908.89	40	\$2,302,155.12	35	\$1,866,519.42
Cetirizine HCl Syrup 1 MG/ML (5 MG/5ML)	99	\$722,039.57	**	****	**	****	**	****
SERTRALINE HCL TAB 50 MG	**	****	25	\$2,430,823.81	17	\$3,374,517.36	14	\$2,736,179.29
Donepezil Hydrochloride Tab 10 MG	**	****	40	\$1,858,008.44	27	\$3,057,216.77	26	\$2,106,470.82
Simvastatin Tab 20 MG	**	****	42	\$1,815,026.24	34	\$2,558,987.05	25	\$2,163,715.81
Simvastatin Tab 40 MG	**	****	48	\$1,728,167.92	39	\$2,328,361.46	41	\$1,694,241.05
Fentanyl TD Patch 72HR 100 MCG/HR	**	****	**	****	55	\$1,804,576.62	36	\$1,857,357.19
FENTANYL DIS 100MCG/H	**	****	54	\$1,504,765.53	**	****	**	****

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
Rosiglitazone Maleate Tab 4 MG (Base Equiv)	**	****	56	\$1,492,336.05	59	\$1,769,368.44	60	\$1,270,807.16
Celecoxib Cap 200 MG	**	****	62	\$1,350,963.88	33	\$2,601,590.27	19	\$2,449,770.84
Olanzapine Tab 5 MG	**	****	64	\$1,344,670.35	26	\$3,094,580.76	6	\$3,422,068.27
TOLTERODINE TARTRATE CAP SR 24HR 4 MG	**	****	65	\$1,337,944.08	49	\$1,977,990.21	55	\$1,433,611.56
Pimecrolimus Cream 1%	**	****	67	\$1,315,451.47	64	\$1,658,839.20	85	\$899,999.52
Oxycodone HCl Tab SR 12HR 40 MG	**	****	69	\$1,284,200.50	**	****	**	****
OXYCONTIN TAB 40MG CR	**	****	**	****	19	\$3,243,960.54	24	\$2,202,822.21
Quetiapine Fumarate Tab 25 MG	**	****	73	\$1,267,009.00	41	\$2,211,457.80	42	\$1,690,772.05
Pioglitazone HCl Tab 30 MG (Base Equiv)	**	****	75	\$1,256,202.69	75	\$1,412,951.41	70	\$1,113,364.85
LEVOFLOXACIN TAB 500 MG	**	****	82	\$1,165,054.83	54	\$1,810,979.40	56	\$1,414,018.10
Pioglitazone HCl Tab 45 MG (Base Equiv)	**	****	88	\$1,062,134.98	84	\$1,307,710.12	82	\$929,103.18
Bupropion HCl Tab SR 24HR 300 MG	**	****	91	\$1,046,079.22	**	****	**	****
MEMANTINE HCL TAB 10 MG	**	****	92	\$1,030,255.30	85	\$1,295,378.74	**	****
Glatiramer Acetate Inj Kit 20 MG/ML	**	****	95	\$1,009,826.20	73	\$1,513,960.52	54	\$1,463,256.13
MEGESTROL ACETATE SUSP 40 MG/ML	**	****	**	****	56	\$1,803,183.82	40	\$1,713,756.32
Etanercept For Subcutaneous Inj Kit 25 MG	**	****	**	****	57	\$1,774,720.32	44	\$1,590,648.60
Oxycodone HCl Tab SR 12HR 20 MG	**	****	**	****	61	\$1,734,633.53	59	\$1,305,299.40
Olanzapine Tab 2.5 MG	**	****	**	****	65	\$1,652,406.31	37	\$1,851,687.25
GABAPENTIN CAP 300 MG	**	****	**	****	68	\$1,628,219.44	**	****
RISPERIDONE TAB 0.25 MG	**	****	**	****	81	\$1,341,076.86	11	\$3,075,890.77
Alendronate Sodium Tab 70 MG	**	****	**	****	76	\$1,411,488.20	63	\$1,243,665.98
Gabapentin Tab 600 MG	**	****	**	****	82	\$1,323,521.50	66	\$1,174,557.33
Amlodipine Besylate Tab 10 MG	**	****	**	****	91	\$1,138,201.36	58	\$1,374,547.05
Paroxetine HCl Tab 20 MG	**	****	**	****	95	\$1,028,464.71	88	\$863,544.56
Paroxetine HCl Tab 20 MG	**	****	**	****	96	\$1,024,175.53	73	\$1,059,372.49

	2007		2006		2005		2004	
	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid	Rank	Amount Paid
Meloxicam Tab 7.5 MG	**	****	**	****	97	\$1,022,887.35	**	****
Linezolid Tab 600 MG	**	****	**	****	99	\$1,012,762.86	**	****
CITALOPRAM HYDROBROMIDE TAB 20 MG (BASE EQUIV)	**	****	**	****	**	****	52	\$1,468,835.83
FENTANYL TD PATCH 72HR 75 MCG/HR	**	****	**	****	**	****	69	\$1,116,794.77
Fentanyl TD Patch 72HR 50 MCG/HR	**	****	**	****	**	****	72	\$1,075,139.14
ROFECOXIB TAB 25 MG	**	****	**	****	**	****	76	\$1,028,184.83
Citalopram Hydrobromide Tab 40 MG (Base Equiv)	**	****	**	****	**	****	80	\$957,553.92
Paroxetine HCl Tab SR 24HR 25 MG	**	****	**	****	**	****	81	\$947,166.17
Bupropion HCl Tab SR 12HR 150 MG	**	****	**	****	**	****	83	\$925,409.39
Gabapentin Cap 400 MG	**	****	**	****	**	****	86	\$889,927.09
Donepezil Hydrochloride Tab 5 MG	**	****	**	****	**	****	92	\$824,898.15
TAMSULOSIN HCL CAP SR 24HR 0.4 MG	**	****	**	****	**	****	94	\$799,551.37
Raloxifene HCl Tab 60 MG	**	****	**	****	**	****	97	\$782,610.82
CALCITONIN (SALMON) NASAL SOLN 200 UNIT/ACT	**	****	**	****	**	****	98	\$774,424.02
Lamivudine-Zidovudine Tab 150-300 MG	**	****	**	****	**	****	100	\$759,519.85

*Total for season also includes an additional \$986,253.04 for old dosage form.

Top 50 Medications by Claims

RANK CLAIMS		GENERIC NAME		BRAND NAME		CLAIMS		UNITS/ DAY		COST/ DAY		PERCENT COST	
RANK	RANK CLAIMS	GENERIC NAME	BRAND NAME	CLAIMS	COST	UNITS/ DAY	COST/ DAY	PERCENT COST					
1	129	Hydrocodone-Acetaminophen Tab 7.5-500 MG	HYDROCO/APAP TAB 7.5-500	90,012	\$607,626.88	4.03	\$0.62	1.28%					
2	28	Albuterol Inhal Aerosol 90 MCG/ACT	ALBUTEROL AFR 90MCG	71,994	\$1,661,003.61	0.87	\$1.00	3.50%					
3	24	Azithromycin For Susp 200 MG/5ML	AZITHROMYCIN SUS 200/5ML	54,300	\$1,869,580.90	4.4	\$6.79	3.94%					
4	2	MONTELUKAST SODIUM CHEW TAB 5 MG (BASE)	SINGULAIR CHW 5MG	52,693	\$5,268,313.23	1	\$3.35	11.11%					
5	183	AMOXICILLIN (TRIHYDRATE) FOR SUSP 250	AMOXICILLIN SUS 250/5ML	51,632	\$391,330.15	16.43	\$0.77	0.83%					
6	246	Hydrocodone-Acetaminophen Tab 5-500 MG	HYDROCO/APAP TAB 5-500MG	51,301	\$265,901.19	4.46	\$0.83	0.56%					
7	22	PROAIR HFA	PROAIR HFA	49,021	\$2,012,500.34	0.43	\$1.76	4.25%					
8	58	Azithromycin Tab 250 MG	AZITHROMYCIN TAB 250MG	46,102	\$1,214,631.59	1.16	\$5.11	2.56%					
9	143	AMOXICILLIN (TRIHYDRATE) FOR SUSP 400	AMOXICILLIN SUS 400/5ML	45,008	\$542,898.11	13.33	\$1.21	1.15%					
10	97	Hydrocodone-Acetaminophen Tab 10-500 MG	HYDROCO/APAP TAB 10-500MG	43,568	\$735,889.90	4.07	\$0.83	1.55%					
11	4	MONTELUKAST SODIUM TAB 10 MG (BASE)	SINGULAIR TAB 10MG	42,119	\$4,150,623.28	0.99	\$3.30	8.76%					
12	172	LORATADINE TAB 10 MG	LORATADINE TAB 10MG	40,793	\$421,764.87	1	\$0.33	0.89%					
13	6	Montelukast Sodium Chew Tab 4 MG (Base Equiv)	SINGULAIR CHW 4MG	37,500	\$3,755,757.57	1	\$3.35	7.92%					
14	287	Amoxicillin (Trihydrate) Cap 500 MG	AMOXICILLIN CAP 500MG	36,318	\$225,990.48	2.98	\$0.70	0.48%					
15	160	Promethazine HCl Tab 25 MG	PROMETHAZINE TAB 25MG	33,856	\$467,516.63	4.09	\$2.02	0.99%					
16	290	Ibuprofen Tab 800 MG	IBUPROFEN TAB 800MG	33,579	\$222,273.23	2.98	\$0.38	0.47%					
17	273	PROPOXYPHENE-N W/ APAP TAB 100-650 MG	PROPO-N/APAP TAB 100-650	32,739	\$233,648.84	4.17	\$0.72	0.49%					
18	236	SULFAMETHOXAZOLE-TRIMETHOPRIM TAB 800-	SMZ/TMP DS TAB 800-160	31,781	\$277,740.88	2.01	\$0.79	0.59%					
19	228	Cyclobenzaprine HCl Tab 10 MG	CYCLOBENZAPR TAB 10MG	31,678	\$295,183.53	2.53	\$0.46	0.62%					
20	266	TRAMADOL HCL TAB 50 MG	TRAMADOL HCL TAB 50MG	31,527	\$246,104.28	4.35	\$0.51	0.52%					
21	81	Omeprazole Cap Delayed Release 20 MG	OMEPRAZOLE CAP 20MG	28,740	\$905,650.83	1.31	\$0.92	1.91%					
22	247	LORATADINE SYRUP 10 MG/10ML	LORATADINE SYP 5MG/5ML	28,573	\$265,656.01	5.12	\$0.35	0.56%					
23	283	CLONIDINE HCL TAB 0.1 MG	CLONIDINE TAB 0.1MG	28,530	\$227,881.85	1.59	\$0.26	0.48%					
24	269	Alprazolam Tab 1 MG	ALPRAZOLAM TAB 1MG	27,924	\$241,504.96	2.85	\$0.31	0.51%					
25	279	Cephalexin Cap 500 MG	CEPHELEXIN CAP 500MG	27,802	\$228,280.59	3.2	\$0.91	0.48%					
26	64	Azithromycin For Susp 100 MG/5ML	AZITHROMYCIN SUS 100/5ML	27,201	\$1,081,213.76	3.97	\$7.94	2.28%					
27	352	Alprazolam Tab 0.5 MG	ALPRAZOLAM TAB 0.5MG	24,281	\$173,030.62	2.61	\$0.27	0.37%					
28	8	LANSOPRAZOLE CAP DELAYED RELEASE 30 MG	PREVACID CAP 30MG DR	23,525	\$3,348,697.29	1.01	\$4.80	7.06%					
29	50	FLUTICASON PROPRIONATE NASAL SUSP 50	FLUTICASON SPR 50MCG	23,213	\$1,314,642.18	0.49	\$1.74	2.77%					
30	396	RANITIDINE HCL TAB 150 MG	RANITIDINE TAB 150MG	23,037	\$142,023.92	1.83	\$0.20	0.30%					
31	179	ALBUTEROL SULFATE SOLN NEBU 0.083%	ALBUTEROL NEB 0.083%	21,503	\$407,696.15	10.46	\$1.12	0.86%					
32	186	PREDNISOLONE SOD PHOSPHATE ORAL SOLN 15	PREDNISOLONE SOL 15MG/5ML	21,310	\$381,348.37	7.04	\$3.02	0.80%					
33	82	AMOXICILLIN & K CLAVULANATE FOR SUSP 600-	AMOX/K CLAV SUS 600/5ML	21,191	\$892,296.65	11.93	\$4.06	1.88%					

RANK CLAIMS	RANK COST	GENERIC NAME	BRAND NAME	CLAIMS	COST	UNITS/ DAY	COST/ DAY	PERCENT COST
34	101	Cetirizine HCl Syrup 1 MG/ML (5 MG/5ML)	ZYRTEC SYP 1MG/ML	21,064	\$721,769.03	4.03	\$1.21	1.52%
35	248	Clonazepam Tab 1 MG	CLONAZEPAM TAB 1MG	20,958	\$265,188.04	2.39	\$0.43	0.56%
36	277	CLONAZEPAM TAB 0.5 MG	CLONAZEPAM TAB 0.5MG	20,698	\$229,954.87	2.2	\$0.39	0.49%
37	442	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	APAP/CODEINE TAB 300-30MG	19,581	\$123,751.38	4.65	\$1.12	0.26%
38	33	Mometasone Furoate Nasal Susp 50 MCG/ACT	NASONEX SPR 50MCG/AC	19,175	\$1,551,391.69	0.51	\$2.42	3.27%
39	438	Acetaminophen w/ Codeine Soln 120-12 MG/5ML	APAP/CODEINE SOL 120-12/5	19,128	\$124,938.03	21.87	\$1.13	0.26%
40	317	SULFAMETHOXAZOLE-TRIMETHOPRIM SUSP 200-	SMZ-TMP SUS 200-40/5	19,038	\$200,556.36	13.51	\$0.92	0.42%
41	403	PREDNISOLONE SYRUP 15 MG/5ML	PREDNISOLONE SYP 15MG/5ML	18,694	\$137,800.45	7.64	\$1.26	0.29%
42	63	CEFDINIR FOR SUSP 125 MG/5ML	OMNICEF SUS 125MG/5	17,450	\$1,144,202.87	8.01	\$6.59	2.41%
43	15	Fluticasone-Salmeterol Powder Disks 100-50	ADV AIR DISKU MIS 100/50	17,213	\$2,450,993.84	1.96	\$4.67	5.17%
44	12	FLUTICASONNE-SALMETEROL POWDER DISKS 250	ADV AIR DISKU MIS 250/50	17,101	\$3,026,746.40	1.98	\$5.85	6.39%
45	509	Oxycodone w/ Acetaminophen Tab 5-325 MG	OXYCOD/APAP TAB 5-325MG	16,662	\$99,970.90	5.96	\$1.03	0.21%
46	41	ESCITALOPRAM OXALATE TAB 10 MG (BASE	LEXAPRO TAB 10MG	16,136	\$1,395,447.72	1.01	\$2.57	2.94%
47	457	Naproxen Tab 500 MG	NAPROXEN TAB 500MG	15,857	\$119,233.88	2.02	\$0.30	0.25%
48	447	Metformin HCl Tab 500 MG	METFORMIN TAB 500MG	15,748	\$122,619.66	2.3	\$0.24	0.26%
49	80	SERTRALINE HCL TAB 100 MG	SERTRALINE TAB 100MG	15,576	\$908,788.27	1.26	\$1.69	1.92%
50	225	Albuterol Sulfate Soln Nebu 0.083% (2.5 MG/3ML)	ALBUTEROL NEB 0.083%	15,542	\$299,755.52	10	\$1.11	0.63%
				1,539,972	\$47,399,311.58	2.98	\$1.66	



Appendix G

Dermatological Topical Antibiotics

Oklahoma Health Care Authority

March 2008

Utilization

Drug	Claims	Units	Days	Members	Cost	Per Diem
Mupirocin Oint 2%	15,181	367,864	165,466	12,081	\$321,285.09	\$1.94
Bactroban Cream 2%	9,053	232,659	101,271	7,544	\$539,080.92	\$5.32
Centany Oint 2%	375	7,930	4,039	330	\$8,013.80	\$1.98
Altanax Oint 1%	222	3,436	1,817	179	\$18,769.69	\$10.33
Gentamicin Oint 0.1%	159	3,806	1,427	128	\$1,190.66	\$0.83
Gentamicin Cream 0.1%	94	2,100	810	67	\$549.09	\$0.68
Cortisporin Oint 1%	43	645	491	36	\$2,552.49	\$5.20
Cortisporin Cream 1%	31	318	380	25	\$1,820.52	\$4.79
Gentamicin Powder	13	972	230	13	\$234.32	\$1.02
Centany Kit 2%	12	274	141	11	\$938.32	\$6.65
Bactroban Oint 2%	3	110	35	1	\$278.73	\$7.96
Polysporin Powder†	1	40	5	1	\$63.41	\$12.68
Triple Antibiotic Oint†	1	60	30	1	\$3.87	\$0.13
	25,188	620,214	276,142	19,551*	\$894,780.91	\$3.24

*unduplicated members

†as of 11/13/2007 there are not any CMS reimbursable NDCs for this medication

Indications

Drug	Indication
Gentamicin	<ul style="list-style-type: none"> ▪ Infection of skin and/or subcutaneous tissue ▪ Staphylococcal infectious disease
Mupirocin	<ul style="list-style-type: none"> ▪ Impetigo ▪ Methicillin resistant Staphylococcus aureus infection, colonization ▪ Secondary infection – skin lesion
Retapamulin	<ul style="list-style-type: none"> ▪ Impetigo due to S. aureus (methacillin – susceptible only) or S. pyogenes
Neomycin/Polymixin B/HC	<ul style="list-style-type: none"> ▪ Treatment of corticosteroid responsive dermatoses with secondary infection.

Antimicrobial Therapy for Impetigo ¹		
Antibiotic Therapy ^a	Adult Dose	Pediatric Dose
Dicloxacillin	250mg po qid	12mg/kg/day in 4 divided doses po
Cephalexin	250mg po qid	25mg/kg/day in 4 divided doses po
Erythromycin	250mg po qid ^b	40mg/kg/day in 4 divided doses po
Clindamycin	300-400mg tid po	10-20mg/kg/day in 3 divided doses po
Amox/Clavulanate	875/125mg bid po	25mg/kg/day of the amoxicillin component in 2 divided doses po
Mupirocin Oint	Apply to lesions tid	Apply to lesions tid

¹infection due to Staphylococcus and Streptococcus species. Duration of therapy is approximately 7 days.

^badult dosage of erythromycin ethylsuccinate is 400mg qid po

Cost Comparison

	Package Size (gm)	Cost per gram (based on EAC or SMAC)	Total Cost
Mupirocin Oint 2%	22	\$0.61561	\$13.54
Gentamicin Oint 0.1%	15	\$0.17681	\$2.65
	30	\$0.17681	\$5.30
Gentamicin Cream 0.1%	15	\$0.33621	\$5.04
	30	\$0.33621	\$10.09
Bactroban (Mupirocin) Oint 2%	22	\$2.71000	\$59.62
Bactroban (Mupirocin) Cream 2%	15	\$2.74032	\$41.10
	30	\$2.32202	\$69.66
Centany (Mupirocin) Oint 2%	15	\$2.32789	\$34.92
	30	\$1.97266	\$59.18
Centany Kit (Mupirocin) 2%	1	\$65.54240/kit	\$65.54
Altabax (Retapamulin) Oint 1%	5	\$7.22128	\$36.11
	10	\$6.11864	\$61.19
	15	\$4.98666	\$74.80
Cortisporin (Neomycin, Polymixin B, HC) Oint 1%	15	\$3.78282	\$56.74
Cortisporin (Neomycin, Polymixin B, HC) Cream 0.5%	7.5	\$5.53109	\$41.48
Gentamicin Powder	5	\$3.13456	\$15.67

Recommendations

The College of Pharmacy recommends creating a prior authorization category for this group of medications with the following tier structure and criteria:

Tier 1	Tier 2	Tier 3
<ul style="list-style-type: none">• Mupirocin Oint 2%• Gentamicin Oint 0.1%• Gentamicin Cream 0.1%• Gentamicin Powder	<ul style="list-style-type: none">• Supplemental Rebated Tier 3	<ul style="list-style-type: none">• Bactroban Cream 2%• Centany Kit 2%• Altabax Oint 1%• Cortisporin Oint 1%• Cortisporin Cream 0.5%

Criteria:

- A 5-day trial of a Tier 1 medication within the last month is required before a Tier 2 medication can be approved.
- Member must have a 5-day trial with a Tier 1 and a Tier 2 medication prior to receiving authorization for a Tier 3 medication.
- Clinical exception for drug allergy or unique indication.
- Prior authorization will be for 10 days.

REFERENCE

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. *Clin Infect Dis* 2005;41:1373-406.



Appendix H

Vote on New Quantity Limits Prior Authorization Annual Review - Fiscal Year 2007 Bone Resorption Suppression Agents

Oklahoma Health Care Authority
March 2008


Summary

Osteoporosis is a major public health issue affecting women and men of all ages. Postmenopausal elderly women of Caucasian or Asian descent are at high risk for development of osteoporosis or osteopenia. This potentially life-threatening disease often goes undiagnosed or untreated due to its asymptomatic presentation upon initial patient assessment. Unfortunately, definitive diagnosis is often determined after a bone fracture has already occurred resulting in high medical costs and decreased quality of life. This review will evaluate utilization among SoonerCare members and summarize current treatment guidelines to assess whether a product based prior authorization would improve the cost-effective use of medications while improving quality of life.

Introduction³

Osteoporosis may develop due to the normal aging process, impaired development, or excess bone loss. Osteoporosis is characterized by deterioration of bone, low bone mass, weak bone strength, and increase risk for bone fractures. The most common fractures occur at the hip, wrist or spine. Fractures may occur with or without the presence of physical trauma.

Osteogenesis and bone remodeling involve both osteoclasts and osteoblasts to constantly break down and rebuild bones. Osteoclasts breakdown old bone, while osteoblasts deposit minerals to help rebuild and strengthen the existing bone. Osteoporosis is a disease that occurs when the balance of mineral depositing does not match the resorption rate. The two main causes of the disease are hormonal changes (type 1) and dietary deficiencies (type 2). Major surgery, corticosteroid drugs, liver disease, Crohn's disease, and cystic fibrosis can also lead to osteoporosis.




New Bone

Osteoporotic Bone

Bone Tissue in Osteoporosis

Facts and Figures^{3,4}

- 10 Million (8 Million women) in the U.S. diagnosed with osteoporosis
- 34 Million have low bone mass density of the hip
- 1.5 Million hip fractures yearly in U.S. (>50 yrs: 50% Female, 13% Male)



- 18 Billion dollars was the estimated impact to health care costs in 2002
- Less than 1/3 diagnosed
- Less than 1/7 receive treatment
- 24% of Hip Fracture patients die within 12 months
- 25% of Hip Fracture patients are placed in long term care facility

Risk Factors for Osteoporosis and Fractures^{3,14}

- Medical history of LOW-TRAUMA fractures
- Low BMD
- Family history of fracture in first-degree relative
- Weight loss, change in height or low body weight(<57.6kg)
- Cigarette smoking
- Prone to falling (due to medication, impaired hearing or vision, frailty)
- High bone turnover
- Older age
- Alcohol >2 drinks/day
- Sedentary
- Low dietary calcium, magnesium, vitamin D, vitamin K, boron, copper, manganese, and zinc.
- Estrogen deficiency at early age (<45years of age)
- Postmenopausal Women (lose approximately 5% of bone per year during 1st year 7 years after menopause)
- Oral Corticosteroid therapy (>3 months)

Secondary Causes of Osteoporosis¹⁴

<i>Endocrine Or Metabolic</i>	<i>Nutritional</i>	<i>Drugs</i>	<i>Disorders of Collagen</i>	<i>Other</i>
Hypogonadism Hyperadrenocorticism Thyrotoxicosis Anorexia nervosa Hyperprolactinemia Porphyria Hypophosphatasia in adults Diabetes mellitus Type 1 Pregnancy Hyperparathyroidism Acromegaly	Malabsorption Malnutrition Chronic Liver Disease Gastric operations Vitamin D deficiency Calcium deficiency Alcoholism	Vitamin D toxicity Phenytoin Glucocorticoids Phenobarbital Excessive thyroid Heparin Gonadotropin releasing hormone antagonists	Osteogenesis Homocystinuria Ehlers-Danlos syndrome Marfan syndrome	Rheumatoid Arthritis Myeloma Immobilization Renal tubular Hypercalciuria COPD Organ transplant Cholestatic Liver Mastocytosis Thalassemia

Diagnosis and Testing¹⁴

Osteoporosis is primarily diagnosed by a standard bone mineral density (BMD) measurement. The World Health Organization (WHO) defines this measurement as a T-score. A T-score represents a patient's bone density expressed as the number of standard deviations (SD) above or below the mean BMD of a normal young adult. (see chart) This score also determines fracture risk. Each 1-SD results in 1.5 to 2.5 -fold increase risk for fracture. Note: Z-score compares bone density with a standard patient matched for age, race and ethnicity.

Diagnosis	BMD Criteria
Normal	BMD within 1 SD
Osteopenia	BMD between -1 and -2.5 SD
Osteoporosis	BMD at least -2.5 SD below

BMD testing should be performed on:

1.	All women aged 65 and older regardless of risk factors.
2.	Younger postmenopausal women with one or more risk factors (other than being white, postmenopausal, and female).
3.	Postmenopausal women who present with fractures (to confirm diagnosis and determine disease severity)

Follow Up Testing¹⁴

Normal BMD (-1.0)	Every 3 to 5 years
Undergoing preventative or therapeutic regimen	Annual Exams

Testing Methods and Physical Assessment¹⁴

- Dual x-ray absorptiometry (DXA) **Preferred** (hip, neck, spine region)
- Peripheral dual x-ray absorptiometry (pDXA) and single-energy x-ray absorptiometry (SXA)
- Quantitative computed tomography (QCT)
- Ultrasound densitometry
- Biochemical markers (serum or urine)
- Height and weight measurement
- Back pain or kyphosis
- Vertebral fracture (height loss of 20%)
- Identify and treat children and adolescents with delay of growth and puberty
- Periodic thyroid monitoring of thyrotropin
- Note: Paget's disease usually occur >40 years of age affecting more men than women results in abnormal bone remodeling and growth. Usually affects skull, the hip, pelvis, and bones in the back and legs. Symptoms include pain and warm sensation in affected area.

Nonpharmacologic Prevention and Treatment¹⁴

- Promote a diet with adequate calcium(1200mg/day) and vitamin D(400-800IU/day) intake
- Weight-bearing exercise
- Discourage tobacco smoking
- Monitor thyroid function
- Identify children and adolescents with constitutional delay of growth and puberty
- Identify patients with predisposition to falling

Goals of Therapy¹⁴

1. *Prevent Fractures*
2. *Stabilize and increase bone mass*
3. *Relieve symptoms of fractures and skeletal deformity*
4. *Maximize physical function to prevent further physical disability*

Treatment ^{Guidelines12,14,15,}

- Regardless of risk factors, initiate therapy in women with BMD T-scores below -2.0 by DXA of Hip.
 - One or more risk factors, initiate therapy with BMD T-scores below -1.5 by DXA of the Hip.
 - Initiate therapy in women with prior vertebral or hip fracture
 - Bisphosphonates are recommended 1st line agents
- All agents approved reduces bone resorption but teriparatide has anabolic effects as well.

Clinical Considerations^{2,15}

- Estrogen therapy no longer recommended for long-term therapy despite reduced fractures according to the Women's Health Initiative Report indicating increased risk for myocardial infarction, stroke, invasive breast cancer, pulmonary emboli and deep vein phlebitis.
- Bisphosphonates potentially associated with dysphagia, esophagitis, and esophageal or gastric ulcer.
- Raloxifene increases the risk of deep vein thrombosis and may potentially increase symptoms of hot flashes.
- Calcitonin treatment may cause rhinitis and rarely epistaxis.
- Parathyroid Hormone treatment may cause leg cramps and dizziness. Contraindicated in the presence of osteosarcoma (Paget's disease, radiation therapy of bone, bone metastases, hypercalcemia)
- Calcium carbonate may cause constipation.
- Precaution for osteonecrosis of jaw with bisphosphonates therapy during dental procedures.

Clinical Update^{1,5,6,7,8,9,10}

Jan 24, 2008 - 5 year randomized placebo-controlled study in New Zealand revealed calcium supplementation in postmenopausal women (mean age 74) may be associated with upward trends in cardiovascular events.

Jan 1, 2008 - FDA alert regarding the possibility of severe and sometimes incapacitating bone, joint, and/or muscle pain in patients taking bisphosphonates.

Dec 26, 2007 - A meta-analysis of osteoporosis medications revealed many agents are effective in preventing osteoporotic fractures, but evidence is insufficient to suggest one agent is superior to another.

Dec 24, 2007 - New selective estrogen receptor modulator, bazedoxifene, receives second FDA approvable letter pending submission of further analysis regarding stroke and venous thrombotic events.

Dec 3, 2007 - Prospective study of 89 premenopausal women with major depressive disorder conducted by NIH suggest low bone density is more prevalent in participants diagnosed with depression.

February 2007 - Dear Healthcare Provider sent by GlaxoSmithKline and Takeda regarding ADOPT study findings suggesting glitazone therapy (rosiglitazone, pioglitazone) may be associated with higher incidence of fractures in women.

Jan 22, 2007 - 5 year cohort study of 5008 men and women 50 years or older (71 % women) suggest a possible association between SSRI use and higher incidence of fractures. Study revealed double the risk for fragility fractures between SSRI users and nonusers.

Dec 27, 2006 - A nested case-control study evaluating proton pump inhibitor use in patients > 50 years of age suggest PPI use greater than 1 year is associated with increase risk of hip fracture. The findings were predominantly found in males.

Current Product Based Prior Authorization and Current Quantity Limits

With respect to the osteoporosis medications, a prior authorization is required for parathyroid hormone analog, Forteo (teriparatide). The bisphosphonate medications do not require a prior authorization unless the requested quantity exceeds the monthly quantity limitation.

Forteo® (teriparatide)

Current PA Criteria:

1. FDA approved diagnosis (Treatment of osteoporosis in postmenopausal women at high risk of fracture; treatment of primary or hypogonadal osteoporosis in men at high risk of fracture)
2. Member must be:
 - A postmenopausal woman at high risk for fracture (T-score at or below -2.5) or who cannot tolerate, is allergic to, or has failed to improve while using other agents, or
 - A man with primary or hypogonadal osteoporosis at high risk for fracture (T-score at or below -2.5) or who cannot tolerate, is allergic to, or has failed to improve while using other agents.
3. No concurrent use of Forteo® with other osteoporosis agents is covered (unless more clinical research information which supports the safety and efficacy of such use becomes available).
4. There must have been at least a 12 month trial with any one other agent (unless contraindicated, intolerant, or allergic) and a BMD (T-score at or below -2.5) test within the last month (results should be indicated on the petition).
5. PA approval should be given for 1 year, with a maximum total coverage period of 2 years (since Forteo has not yet been proven to be safe and efficacious for longer than 2 years).

Quantity limits for bisphosphonates are as follows:

- Ibandronate (**Boniva 150mg**): 3 tabs per 84 days
- Alendronate (**Fosamax 5,10, 40mg**): 30 tablets per 30 days
- Alendronate (**Fosamax 35, 75mg**): 4 tablets per 28 days
- Risedronate (**Actonel 5, 30mg**): 30 tablets per 30 days
- Risedronate (**Actonel 35mg**): 4 tablets per 28 days

Utilization

For the period of July 2006 through June 2007, a total of , members received anti-ulcer products through the SoonerCare program.

FY 2006 versus FY 2007			% Change
Cost FY '07		\$681,605.19	72.1 ↓
	<i>Cost FY '06</i>	\$ 2,442,056.77	
Claims FY '07		7,499	73.1 ↓
	<i>Claims FY '06</i>	27,835	
Per Diem FY '07		\$3.05	0.30 ↑
	<i>Per Diem FY '06</i>	\$3.04	
Members FY '07		1,428	78.8 ↓
	<i>Members FY '06</i>	6,749	

Product Utilization FY '07

2007	Claims	Cost	Cost/Claim	Units	Cost/Day
Alendronate	3,701	\$284,122.87	\$76.77	60,648	\$2.69
Etidronate	17	\$7,604.54	\$447.33	2,520	\$14.91
Ibandronate	1,248	\$124,110.08	\$99.45	1,722	\$2.64
Pamidronate	85	\$22,475.21	\$264.41	838	\$111.82
Risedronate	1,841	\$144,217.31	\$78.34	10,184	\$2.76
Miacalcin	523	\$41,027.97	\$78.45	2,218	\$2.65
Teriparatide	84	\$58,047.21	\$691.04	252	\$24.51
<i>*Selective Estrogen Receptor Modulator (Is not included in overall FY 07 utilization)</i>					
<i>*Raloxifene</i>	806	\$103,693.34	\$128.65	34,542	\$3.01

Dual and Non-Duals Utilization

FY 2007	# of Members	# of Claims	Total Units	Total Days	Total Cost	Per Diem
	1,428	7,499	78,382	223,238	\$681,605.19	\$3.05
% Change -vs- FY '06 (Non-Duals)	16.91% ↑	20.35% ↑	26.04% ↑	23.64% ↑	28.90% ↑	4.10% ↑

FY 2006	# of Members	# of Claims	Total Units	Total Days	Total Cost	Per Diem
<i>Duals</i>	5,529	21,604	141,665	623,464	\$1,913,252.00	\$3.07
<i>Non-Duals</i>	1,220	6,231	62,190	180,562	\$528,804.77	\$2.93
Totals	6,749	27,835	203,855	804,026	\$2,442,056.77	\$3.04


Members Premenopausal Age

	Members	< 35 years of age
FY '06	6,749	192
FY '07	1,428	149


Total petitions submitted for this category during FY07: 128

<i>Approved</i>	49
Denied	34
Incomplete	45


Members Age/Gender FY07 *unduplicated members



Members Age/Gender FY06 *unduplicated members



Top Ten Clinical Specialty by Percent of Claims (n=7,499 claims)



Product News¹³

February 6, 2008 – FDA approved generic Fosamax (alendronate sodium tablets)

April 2007 – FDA approved Reclast (zoledronic acid)

Strontium Ranelate – Unavailable in the U.S. In vitro and animal studies shows increase bone formation and reduce bone resorption

Novel Therapies- Monoclonal Antibodies Against RANK Ligand (osteoclasts), oral calcium-sensing-receptor antagonists, sclerostin inhibitors, antiresorptive agents, integrin antagonists, and cathepsin-K inhibitors.

Conclusion

Effective osteoporosis prevention, detection and treatment has the potential to increase bone mineral density to reduce the risk of fractures. Cost-effective use of osteoporosis medications can minimize overall health care costs associated with fractures and improve overall quality of life. Clinical literature is lacking in regard to duration of therapy with bisphosphonates and greater efficacy with combination therapy.

Recommendations

The College of Pharmacy recommends placing quantity limits on Didronel (etidronate) and Reclast (zoledronic Acid) and consideration of a new Product Based Prior Authorization category for the osteoporosis medications to ensure cost-effective utilization in accordance to current treatment guidelines to optimize therapeutic outcomes while minimizing overall healthcare costs associated with osteoporosis.

Recommended Quantity Limits:

1. Etidronate (Didronel): Maximum of 6 months of treatment per year.
 - a. 200mg tablet 75 tablets per 30 days
 - b. 400mg tablet 150 tablets per 30 days
2. Zoledronic Acid (Reclast): 5mg (100ml) per 365 days.

References

1. Proton pump inhibitors and risk of hip fracture. Pharmacist's Letter/Prescriber's Letter 2007;23(2):230202.
2. Bisphosphonate-associated jaw osteonecrosis. Pharmacist's Letter/Prescriber's Letter 2006;22(8):220801.
3. Fast Facts on Osteoporosis. National Institute of Health.
www.osteoporosis.gov/newfile.asp?doc=fast&doctype=HTML+Fact+Sheet&doctitle=Fast+Facts+on+Osteoporosis. June, 2005.
4. Freeman, Jeanne, and Turner, Lori. Osteoporosis: It's More Than Calcium. California Journal of Health Promotion. January 2004.
5. Glitazones and the risk of fracture. Pharmacist's Letter/Prescriber's Letter 2007;23(4):230407.
6. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008; DOI:10.1136/bmj.39440.525752.BE. Available at: <http://www.bmj.com>.
7. Cizza G. Depression Associated with Low Bone Mineral Density. Arch Intern Med. 2007;167:2329-2336.
8. Richards JB et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007 Jan 22; 167:188-94.
9. FDA Alert. Possibility of severe and sometimes incapacitating bone, joint, and/or muscle (musculoskeletal) pain in patients taking bisphosphonates. Website: <http://www.fda.gov/cder/drug/infopage/bisphosphonates/default.htm>. Accessed January 2008.
10. Reuters health information article. Website: http://www.medscape.com/viewarticle/567921_print. Accessed February 2008.
11. Barclay L, Martin BN, et al. National Osteoporosis Foundation Issues Guidelines for Osteoporosis Management. Medscape Medical News. Website: http://www.medscape.com/viewarticle/570594_print.
12. Barclay L, Vega, Charles, et al. Osteoporosis Guidelines Updated. Medscape Medical News. Website: http://www.medscape.com/viewarticle/533846_print.
13. Mulder JE, Kolatkar NS, LeBoff MS. [Review] Drug Insight: Existing and Emerging Therapies for Osteoporosis. Nat Clin Pract Endocrinol Metab. 2006;2(12):670-680.
14. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the prevention and treatment of postmenopausal osteoporosis: 2001 Edition, with selected updates for 2003. AACE Osteoporosis Task Force. Endocrine Practice December 2003;9(6):544-564.
15. Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. Washington (DC): National Osteoporosis Foundation; 2003 Apr. 37.

Osteoporosis Products

	Role in Treatment	Dosage Form	Product and Dosing	Efficacy	Side Effects	Contraindications	Other
Bisphosphonates	Treatment Paget's Disease Heterotopic ossification due to spinal cord injury or after total hip replacement	Tablets	5-10 mg/kg/day (not to exceed 6 months) or 11-20 mg/kg/day (not to exceed 3 months). Doses >20 mg/kg/day are not recommended; 20mg/kg/day x 2wks then 10mg/kg/day x 10wks OR 20mg/kg/day x 1 mos.(preop.)then same dose x 3 mos. (post-op)	Chemisorbs to calcium hydroxyapatite crystals and their amorphous precursors, blocking the aggregation, growth, and mineralization of these crystals.	Diarrhea , nausea, and bone pain.	Pregnancy Risk factor C. Hypersensitivity to bisphosphonates or any component of the formulation; overt osteomalacia. Possible osteonecrosis of jaw.	Paget's retreatment: Initiate only after etidronate-free period ≥90 days. Monitor patients every 3-6 months. Retreatment regimens are the same as for initial treatment.
	Prevention(recently diagnosed) Treatment(post-menopausal, and glucocorticoid induced) Paget's Disease	Tablets; Tablets with Vitamin D; Solution	Fosamax(Alendronate) 5mg /daily or 35mg/weekly 10mg/daily or 70mg/weekly(shown to be equally effective) 70mg/weekly	Reduce the risk of spine, hip and non spine fractures by 50%. Increase BMD at spine and hip by 5 to 10%.	Dysphagia, esophagitis, esophageal or gastric ulcer. Take with 8 oz. water on empty stomach. Remain sitting or standing for 30 minutes on empty stomach.	Active upper gastrointestinal disease, hypersensitivity, hypocalcemia. Severe renal insufficiency require dose adjustment. Pregnancy C.	Evidence available at 7 year efficacy.
	Prevention(see above) Treatment (see above) (Paget's Disease) (Glucocorticoid induced osteoporosis)	Tablets	Actonel(Risedronate) 5mg/daily, 35mg/weekly, or two 75mg tablets/month. 30mg/daily 2 months, may repeat once 5mg/daily	Reduce risk of spine fractures by 40%; Hip and non spine by 30%.	(see above)	(see above) Avoid if Creatine clearance is <30ml/minute.	Evidence available at 3 year efficacy.
	Treatment(cancer related hypercalcemia) (Osteolytic bone lesions) Paget's Disease	Injection	Aredia(pamidronate) 60 to 90mg/day. 90mg over 2 to 4 hours repeated monthly or every 4 months. 30mg/daily over 4 hours x 3days	Unavailable for treatment of osteoporosis.	(see above) plus fatigue, fever, insomnia, anemia, dyspnea, cough, myalgia.	Hypersensitivity, Pregnancy D.	Patients who cannot tolerate oral products or cannot absorb due to GI disorders.
	Prevention Treatment	Tablets, injection	Boniva(Ibandronate) 2.5mg/day or 150mg once a month.	A reduction in hip fracture risk has not been established in randomized trials.	(see above) plus dyspepsia, back pain. Ibandronate should be taken in an upright position with a full glass (6-8 oz) of plain water and the patient should avoid lying down for 60 minutes to minimize the possibility of GI side effects.	Hypersensitivity, Pregancy risk factor C. Avoid if creatine clearance is <30ml/minute.	
	Treatment(Paget's Disease) (Postmenopausal Osteoporosis)	Injection	Reclast(Zoledronic acid) 5mg/infused over 15minutes. Note: Patients should receive a daily calcium supplement and multivitamin containing vitamin D 5mg every 12 months.	3 yr Horizon Pivotal Trial shown 70% reduction in vertebral fracture and 41 % in hip fracture, compared to placebo.	An acute reaction (eg, arthralgia, fever, flu-like symptoms, myalgia) may occur within the first 3 days following infusion; usually resolves within 3-4 days of onset, although may take up to 14 days to resolve. Hypertension, Fever, headache, arthralgia, myalgia, nausea, dizziness, fatigue, atrial fibrillation.	Pregnancy risk factor D,**Renal deterioration: Single and multiple infusions have been associated with renal deterioration, resulting in renal failure and dialysis; has occurred in patients with normal and impaired renal function. Aspirin-sensitive asthma: Use with caution in patients with aspirin-sensitive asthma; may cause bronchoconstriction.	Maintain adequate hydration (2-3 L/day of fluids) unless instructed to restrict fluid intake. For those that cannot oral bisphosphonates or inability to sit or stand upright.

Continued	Treatment Paget's disease of the bone (osteitis deformans) in patients who have a level of serum alkaline phosphatase (SAP) at least twice the upper limit of normal, or who are symptomatic, or who are at risk for future complications of their disease		Skelid(Tiludronic acid) 400mg/daily for 3months. Evaluate over 3 months. Take with 6-8 oz of plain water. Should not be taken with beverages containing minerals (eg, mineral water), food, or with other medications (may reduce absorption). Do not take within 2 hours of food, aspirin, indomethacin, or calcium-, magnesium-, or aluminum-containing medications.	Unavailable for treatment of osteoporosis.	Nausea, diarrhea, dyspepsia, vomiting, rhinitis, sinusitis, chest pain, hypertension, anxiety, fatigue, hyperparathyroidism, arthrosis, paresthesia, glaucoma, cataracts, infection.	Pregnancy risk factor C . Renal impairment: Use with caution in patients with mild-to-moderate renal impairment (not recommended in patients with a $Cl_{cr} < 30$ mL/minute).	
Calcitonin	Treatment(Paget's disease of bone {osteitis deformans}); adjunctive therapy for hypercalcemia; treatment of osteoporosis in women >5 years postmenopause)	Intranasal Spray or Injection	Miacalcin(Calcitonin) 100IU/day IM or SQ. 4 units/kg q 6 to 12 hours IM, SQ.Nasal spray 200IU per puff daily or 100 units IM/SQ every other day	Reduce the risk of spine fracture by 21%. Increase in BMD.	Rhinitis, epistaxis, nausea, flushing. GI symptoms not as common with nasal route.	Hypersensitivity. Pregnancy risk factor C .	
Hormone Therapy	Prevention(women without hysterectomy, may require dosing with progestins)	Various estrogen products	Estrogen: Used in lowest possible doses and shortest period of time for relief of menopausal symptoms, Considered least preferred.	Reduce the risk of spine and hip fractures by 34%. Treatment >7yrs = 50% lower risk.	Hyperplasia, carcinoma, Irregular vaginal bleeding, cholelithiasis, fluid retention, mastalgia, headache, abdominal pain, thromboembolism.	Pregnancy, breast cancer, neoplasia, undiagnosed genital bleeding, thromboembolic disease, hypersensitivity.Increase in triglycerides.	Increase risk for breast cancer, heart attack, stroke, and venous thromboembolism . (WHI/HERS Study)
	Treatment(parathyroid replacement) (postmenopausal osteoporosis) (idiopathic or hypogonadal osteoporosis with lack of efficacy with other therapy)	Subcutaneous Injection	Forteo(teriparatide) 20ug/day.	Reduce spine fractures by 65% and nonspine fractures by 54% after 19 months of therapy. Increased bone density in lumbar spine and neck in men over 11 months.	Leg cramps and dizziness. Nausea, orthostatic hypotension, arthralgia, depression, vertigo, gastrointestinal dyspepsia, rash, and asthenia.	Contraindicated in Paget's disease, patients with open epiphysis, history of irradiation of skeleton, elevation of alkaline phosphatase of skeletal origin. Pregnancy risk factor C . Caution in patients with urolithiasis, hx of skeletal metastases.	Reduces bone resorption. Anabolic effects resulting in increased bone density. Limit 2 year treatment. Monitor for hypercalcemia or hypercalciuria.
Selective Estrogen Receptor Modulators	Prevention(osteoporosis and breast cancer risk reduction) Treatment	Tablets	Evista(Raloxifene) 60mg/day.	Reduce spine fractures by 50% with 3 year treatment. Increased BMD by 2.7% in spine and 2.4 % neck.	Hot flashes and deep vein thrombosis. Peripheral edema,	Pregnancy, hypersensitivity, current thromboembolic disease. Prolonged immobilization. Avoid ampicillin and cholestyramine use.	Has shown reduction in LDL and total cholesterol by 7 to 11%. MORE study shown 76% reduction in breast cancer. Efficacy and safety up to 3 yrs.



Appendix I

Prior Authorization Annual Review - Fiscal Year 2007
 Nasal Allergy Drugs
 Oklahoma Health Care Authority
 March 2008

Product Based Prior Authorization

The following criteria are required for approval of a Tier-2 product:

1. Documented adverse effect or contraindication to the preferred products.
2. Failure with at least two Tier 1 medications defined as no beneficial response after at least two weeks each of use during which time the drug has been titrated to the recommended dose (at least one trial must be a corticosteroid).
3. Approvals will be for the duration of three months, except for members with chronic diseases such as asthma or COPD, in which case authorizations will be for the duration of one year.

All products have quantity limits in place, based on the FDA approved maximum dose.

Nasal Allergy Products	
<i>Tier 1*</i>	<i>Tier 2</i>
Corticosteroids	Omnaris™ (not on market yet 2-2008)
Fluticasone (Flonase®)	
flunisolide	
Nasonex®	
Veramyst™	
Beconase® AQ	
Nasacort® AQ	
Rhinocort® AQ	
Other	
Astelin®	
Ipratropium bromide	

Supplemental Rebate is indicated by blue color

Utilization

Fiscal Year	Total Members	Total Claims	Total Cost	Cost/Claim	Per-Diem	Total Units	Total Days
2006							
	32,915	66,729	\$4,839,373.43	\$72.52	\$2.24	1,108,452	2,156,538
2007							
	30,733	62,016	\$4,327,729.64	\$69.78	\$2.13	1,010,508	2,034,056
% Change	-6.6%	-7.1%	-10.6%	-3.8%	-4.9%	-8.8%	-5.7%
	-2,182	-4,713	-\$511,643.79	-\$2.74	-\$0.11	-97,944	-122,482

Utilization of Nasal Allergy Products: FY 2007

Product	# of claims	Total Units	Total Days	Unduplicated Members	Per Diem	Total Cost	Market Share
Fluticasone propionate 50 mcg	23,225	371,371	756,264	11,790	1.74	\$1,315,106.62	30.39%
Fluticasone propionate (Flonase) 50 mcg	292	4,657	8,929	196	2.58	\$23,017.15	0.53%
Fluticasone furoate (Veramyst) 27.5 mcg	113	1,112	3,645	107	2.64	\$9,623.27	0.22%
Mometasone furoate (Nasonex) 50 mcg	19,183	325,905	641,112	10,536	2.42	\$1,551,987.78	35.86%
Triamcinolone acetonide (Nasacort AQ) 55 mcg	5,853	97,817	185,286	2,863	2.54	\$470,605.06	10.87%
Budesonide (Rhinocort) 32 mcg	8,206	70,717	277,931	4,401	2.42	\$671,443.91	15.52%
Azelastine HCl (Astelin) 137 mcg	2,405	72,131	75,657	1,447	2.38	\$180,067.05	4.16%
Flunisolide 25 mcg	1,830	45,612	55,949	1,159	1.18	\$65,816.27	1.52%
Flunisolide (Nasarel) 20 mcg	116	2,925	6,000	74	1.04	\$6,245.20	0.14%
Beclomethasone diprop. (Beconase AQ) 0.042%	213	5,342	6,705	88	3.18	\$21,247.59	0.49%
Ipratropium 0.06% 42 mcg	295	4,468	7,890	220	0.72	\$5,660.33	0.13%
Ipratropium 0.03% 21 mcg	284	8,436	8,658	208	0.79	\$6,871.99	0.16%
Total	62,015	1,010,493	2,034,026	30,733	2.13	\$4,327,692.22	


Demographics

Claims were reviewed to determine the age/gender of the members. There were 21 claims with indeterminate age/gender.

Age	Female	Male
0 to 9	4,471	5,804
10 to 19	6,853	6,853
20 to 34	2,335	454
35 to 49	1,649	382
50 to 64	1,270	410
65 to 79	144	49
80 to 94	31	6
95 & over	0	1
Totals	16,753	13,959

News in FY '08

Sepracor acquired exclusive U.S. Rights to Nycomed's Omnaris™ AQ, which was approved in October 2006. It will be marketed in the spring of 2008.



Recommendations

The College of Pharmacy recommends no changes to the current prior authorization criteria for this category.



Appendix J

Advair Diskus, Advair HFA, Brovana, Foradil, Serevent Diskus, and Symbicort Information (Long Acting Beta Agonists)

On November 18, 2005, FDA alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing (bronchospasm) in some people, and requested that manufacturers update warnings in their existing product labeling. This information has now been included in updated labeling.

On March 2, 2006, FDA approved new safety labeling and Medication Guides for patients for Serevent Diskus (salmeterol xinafoate) and Advair Diskus (fluticasone propionate; salmeterol xinafoate). On June 19, 2006, FDA approved new safety labeling and a Medication Guide for patients for Foradil (formoterol fumarate), and also approved Advair HFA. Symbicort Inhalation Aerosol was approved on July 21, 2006.

March 5, 2008 Update: On November 28, 2007, a Pediatric Advisory Committee (PAC) meeting was held. At this meeting, FDA raised concerns about the safety of long-acting beta2 adrenergic agonists (LABAs) in pediatric patients with asthma. The PAC has agreed with an FDA recommendation to continue assessment of the risks of LABAs and seek advice from a future advisory committee (<http://www.fda.gov/ohrms/dockets/ac/oc07.htm#pac>).

In January, 2008 FDA requested manufacturers of Advair Diskus, Advair HFA, Brovana Inhalation Solution, Foradil Aerolizer, Perforomist Inhalation Solution, Serevent Diskus, and Symbicort Inhalation Aerosol to provide information regarding controlled clinical studies conducted with these products in order to further evaluate the safety of LABAs when treating asthma.

The manufacturers have indicated it will take several months to submit the requested information. Following review of this information, FDA plans to bring the issue of the benefit/risk assessment of LABAs in adults and children to an advisory committee in the fall or winter of 2008.

Labels and Medication Guides

- [Advair Diskus Label](#)  (updated 3/2/2006)
- [Advair Diskus Medication Guide for Patients](#) 

- [Advair HFA Label](#)  (6/8/2006)
- [Advair HFA Medication Guide for Patients](#) 

- [Brovana Label](#)  (10/6/2006)
- [Brovana Medication Guide for Patients](#) 

- [Foradil Aerolizer Label](#)  (updated 6/19/2006)
- [Foradil Aerolizer Medication Guide for Patients](#) 

- [Serevent Diskus Label](#)  (updated 3/2/2006)
- [Serevent Diskus Medication Guide for Patients](#) 

- [Symbicort Inhalation Aerosol Label](#) 
- [Symbicort Medication Guide for Patients](#) 

Patient Information Sheets

- Fluticasone propionate; Salmeterol xinafoate (marketed as Advair Diskus) [\[HTML\]](#) [\[PDF\]](#) (updated 5/15/2006)
- Fluticasone propionate; Salmeterol xinafoate (marketed as Advair HFA) [\[HTML\]](#) [\[PDF\]](#) (posted 7/5/2006)
- Formoterol fumarate (marketed as Foradil Aerolizer) [\[HTML\]](#) [\[PDF\]](#) (updated 7/5/2006)
- Salmeterol xinafoate (marketed as Serevent Diskus) [\[HTML\]](#) [\[PDF\]](#) (updated 5/15/2006)

Other Information

- [Historical Information](#)

[↑ Back to Top](#) [↙ Back to Drug Index](#)

 PDF requires the free [Adobe Acrobat Reader](#)

Date created: March 3, 2006, updated March 5, 2008

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research

Public Health Advisory

Important Information on the Correct Use of Spiriva and Foradil Capsules

FDA is issuing this public health advisory to highlight the correct use of Spiriva (tiotropium bromide inhalation powder) and Foradil (formoterol fumarate inhalation powder) capsules. Spiriva and Foradil capsules are to be used in the HandiHaler (Spiriva) and Aerolizer (Foradil) devices to deliver the medicine to the lungs to improve breathing in patients with asthma, and in individuals affected by chronic obstructive lung disease (COPD), including chronic bronchitis and emphysema. The medication in the Spiriva or Foradil capsules is specifically designed to be inhaled through inhalation devices. Both Spiriva and Foradil will not treat a patient's breathing condition if the contents of a capsule are swallowed rather than inhaled.

FDA is highlighting for patients the following information on the correct use of Spiriva and Foradil capsules:

- **Do not swallow the Spiriva or Foradil capsules.**
- **The contents of Spiriva and Foradil capsules are only to be inhaled using their respective inhalation devices.** Remove the capsule from the blister package and place the intact capsule into the inhalation device prior to inhalation.
- **Follow the instructions contained in the patient information leaflet provided with your prescription explaining how to use the Spiriva Handihaler or Foradil Aerolizer**

Doctors, nurses, and pharmacists should discuss with patients how to correctly use the Spiriva HandiHaler or Foradil Aerolizer. If a patient who is prescribed Spiriva or Foradil does not experience breathing improvement, the health care provider should ask the patient if he or she is swallowing the medicine rather than inhaling it.

FDA and the American Association of Poison Control Center's (AAPCC) National Poison Data System have received many reports of patients swallowing Foradil and Spiriva capsules rather than placing the capsules in the inhalation devices. Reports of ingestions indicate that few patients experienced side effects from the swallowed capsules.

The Spiriva HandiHaler and Foradil Aerolizer patient information includes highlighted statements stating that the capsule contents are to be inhaled and not swallowed. FDA will continue to monitor the incorrect use of Spiriva Handihaler and Foradil Aerolizer and, as needed, will continue to work with the manufacturers to improve the medication labeling and promote patient education for the correct use of these medications.

[↑ Back to Top](#) [↩ Back to Public Health Advisories](#)

 PDF requires the free [Adobe Acrobat Reader](#)

Date created: February 29, 2008



[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#)

FDA News

FOR IMMEDIATE RELEASE
February 28, 2008

Media Inquiries:
Rita Chappelle, 301-827-6246
Consumer Inquiries:
888-INFO-FDA

FDA Approves Nexium for Use in Children Ages 1-11 Years

The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD). The agency approved Nexium in two forms, a delayed-release capsule and liquid form. Nexium is approved in 10 milligrams (mg) or 20 mg daily for children 1-11 years old compared to 20 mg or 40 mg recommended for pediatric patients 12 to 17 years of age.

"This approval provides important information for appropriate dosing for children ages 1-11 years with GERD," said Julie Beitz, M.D., director of the FDA's Office of Drug Evaluation III in the Center for Drug Evaluation and Research. "Children prescribed this drug should be monitored by their physicians for any adverse drug reactions."

Nexium is part of a class of drugs known as proton pump inhibitors (PPIs). PPIs decrease the amount of acid produced in the stomach and help heal erosions in the lining of the esophagus known as erosive esophagitis.

FDA approved the use of Nexium in patients 1 to 11 years for short-term treatment of GERD based upon the extrapolation of data from previous study results in adults to the pediatric population, as well as safety and pharmacokinetic studies performed in pediatric patients. In one study, 109 patients 1-11 in age, diagnosed with GERD, were treated with Nexium once-a-day for up to eight weeks to evaluate its safety and tolerability. Most of these patients demonstrated healing of their esophageal erosions after eight weeks of treatment.

The most common adverse reactions in children treated with Nexium were headache, diarrhea, abdominal pain, nausea, gas, constipation, dry mouth and sleepiness. The safety and efficacy of Nexium has not been established in children less than one year of age.

Nexium is manufactured by AstraZeneca of Wilmington, DE.

#

[RSS Feed for FDA News Releases](#) [\[what is RSS?\]](#)

[Get free weekly updates](#) about FDA press releases, recalls, speeches, testimony and more.

[FDA Newsroom](#)

[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#)

[FDA Website Management Staff](#)



Recall -- Firm Press Release

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

PRICARA™ RECALLS 25 mcg/hr DURAGESIC® (fentanyl transdermal system) CII PAIN PATCHES

Contact:

Greg Panico

PriCara™

Office: (908) 927-3715

Mobile: (908) 240-2011

FOR IMMEDIATE RELEASE -- Raritan, NJ – February 12, 2008 – PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. said today that all lots of 25 microgram/hour (mcg/hr) DURAGESIC® (fentanyl transdermal system) CII patches sold by PriCara in the United States and all 25 mcg/hr fentanyl patches sold by Sandoz Inc. in the United States are being voluntarily recalled as a precaution from wholesalers and pharmacies. The recalled patches all have expiration dates on or before December 2009, and all are manufactured by ALZA Corporation, an affiliate of PriCara. The recall is being conducted in cooperation with the U.S. Food and Drug Administration. All 25 mcg/hr fentanyl patches manufactured by ALZA and sold in Canada also are being recalled.

DURAGESIC 25 mcg/hr (fentanyl transdermal system) and Sandoz Inc. 25 mcg/hr fentanyl transdermal system patches being recalled may have a cut along one side of the drug reservoir within the patch. The result is possible release of fentanyl gel from the gel reservoir into the pouch in which the patch is packaged, exposing patients or caregivers directly to fentanyl gel. As per the approved product labeling for DURAGESIC, fentanyl is a potent Schedule II opioid medication. Fentanyl patches that are cut or damaged in any way should not be used. Exposure to fentanyl gel may lead to serious adverse events, including respiratory depression and possible overdose, which may be fatal. Anyone who comes in contact with fentanyl gel should thoroughly rinse exposed skin with large amounts of water only; do not use soap. Immediately dispose of affected patches with cut edges by flushing them down the toilet, using caution not to handle them directly. Patches with a cut edge that have leaked gel will not provide effective pain relief.

Anyone who has 25 mcg/hr DURAGESIC or Sandoz Inc. fentanyl patches should check the box or foil pouch for the expiration date to see if they have patches that are being recalled. The recalled patches all have expiration dates on or before December 2009. The cut edge in affected patches can be seen upon opening the sealed foil pouch that holds the patch. Affected patches should not be handled directly.

Anyone with 25 mcg/hr DURAGESIC patches being recalled should call 800-547-6446.

Anyone with 25 mcg/hr Sandoz Inc. patches being recalled should call 800-901-7236.

Patients using fentanyl patches who have medical questions should contact their health-care providers.

For more information, visit www.DURAGESIC.com.

DURAGESIC is used to manage persistent moderate to severe chronic pain that needs to be treated around the clock and which cannot be treated by: combination narcotic, short-acting, or

non-narcotic pain treatment products. It should only be used by people who are receiving or have developed a tolerance to pain therapy with opioids. DURAGESIC should not be used if patients have pain that will go away in a few days, such as pain from surgery, medical or dental procedures, or short-lasting conditions. Any adverse reactions experienced with the use of fentanyl patches should be reported to the appropriate company using the telephone numbers above. DURAGESIC brand and other fentanyl patches are available by prescription only, through pharmacies, and should be used only under the supervision of a physician.

DUROGESIC™ patches sold in Europe, Latin America and Asia are not affected by this recall.

#

[RSS Feed for FDA Recalls Information](#) [\[what's this?\]](#)

 [Sign up for Recall email updates.](#)

[FDA Newsroom](#)

[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#)

[FDA Website Management Staff](#)

Early Communication about an Ongoing Safety Review Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)

This information reflects FDA's current analysis of available data concerning these drugs.

Posting this information does not mean that FDA has concluded there is a causal relationship between the drug products and the emerging safety issue. Nor does it mean that FDA is advising healthcare professionals to discontinue prescribing these products. FDA is considering, but has not reached a conclusion about whether this information warrants any regulatory action. FDA intends to update this document when additional information or analyses become available.

FDA has received reports of systemic adverse reactions including respiratory compromise and death following the use of botulinum toxins types A and B for both FDA-approved and unapproved uses. The reactions reported are suggestive of botulism, which occurs when botulinum toxin spreads in the body beyond the site where it was injected. The most serious cases had outcomes that included hospitalization and death, and occurred mostly in children treated for cerebral palsy-associated limb spasticity. Use of botulinum toxins for treatment of limb spasticity (severe arm and leg muscle spasms) in children or adults is not an approved use in the U.S.

These serious systemic adverse reactions occurred following treatment of a variety of conditions using a wide range of botulinum toxin doses. FDA is currently reviewing safety data from clinical studies submitted by the manufacturers of Botox, Botox Cosmetic and Myobloc, as well as post-marketing adverse event reports and the medical literature.

Botox (botulinum toxin type A) is approved for treatment of conditions such as blepharospasm (spasm of the eyelids), cervical dystonia (severe neck muscle spasms), and severe primary axillary hyperhidrosis (excess sweating). Botox Cosmetic, also botulinum toxin Type A, is approved for temporary improvement in the appearance of moderate to severe facial frown lines.

Myobloc (botulinum toxin Type B) is approved for the treatment of adults with cervical dystonia; the safety and effectiveness of Myobloc for cervical dystonia in children have not been established.

FDA is aware of the body of literature describing the use of botulinum toxins to treat limb spasticity in children and adults. The safety, efficacy and dosage of botulinum toxins have not been established for the treatment of limb spasticity of cerebral palsy or for use in any condition in children less than 12 years of age.

The current prescribing information (labeling) for Botox, Botox Cosmetic and Myobloc describes adverse reactions occurring in regions near the site of injection for each product's approved uses, such as dysphagia (difficulty swallowing) after injections to treat cervical dystonia, or ptosis (drooping eye lids) after injections for glabellar frown lines or for strabismus and blepharospasm.

The *Warnings* sections of the labeling for both botulinum toxin products note that important systemic adverse effects, including severe difficulty swallowing and difficulty breathing have

occurred in patients with neuromuscular disorders after local injection of typical doses of botulinum toxin. FDA now has evidence that similar, potentially life-threatening systemic toxicity from the use of botulinum toxin products can also result after local injection in patients with other underlying conditions such as those with cerebral palsy associated limb spasticity. Systemic toxicity has been reported in children, several of whom required feeding tubes and/or ventilation (breathing) support.

Until such time that FDA has completed its review, healthcare professionals who use medicinal botulinum toxins should:

- Understand that potency determinations expressed in “Units” or “U” are different among the botulinum toxin products; clinical doses expressed in units are not comparable from one botulinum product to the next
- Be alert to the potential for systemic effects following administration of botulinum toxins such as: dysphagia, dysphonia, weakness, dyspnea or respiratory distress
- Understand that these effects have been reported as early as one day and as late as several weeks after treatment
- Provide patients and caregivers with the information they need to be able to identify the signs and symptoms of systemic effects after receiving an injection of a botulinum toxin
- Tell patients they should receive immediate medical attention if they have worsening or unexpected difficulty swallowing or talking, trouble breathing, or muscle weakness

What does FDA know now about these data?

The FDA has reviewed post-marketing cases from its Adverse Event Reporting System (AERS) database and from the medical literature of pediatric and adult patients diagnosed with botulism following a local injection with a marketed botulinum toxin product.

The pediatric botulism cases occurred in patients less than 16 years old, with reported symptoms ranging from dysphagia to respiratory insufficiency requiring gastric feeding tubes and ventilatory support. Serious outcomes included hospitalization and death. The most commonly reported use of botulinum toxin among these cases was treatment of limb muscle spasticity associated with cerebral palsy. For Botox, doses ranged from 6.25 to 32 Units/kilogram (U/kg) in these cases. For Myobloc, reported doses were from 388 to 625 U/kg.

The reports of adult botulism cases described symptoms including patients experiencing difficulty holding up their heads, dysphagia and ptosis. Some reports described systemic effects that occurred distant from the site of injection and included weakness and numbness of the lower extremities. Among the adult cases that were serious, including hospitalization, none required intubation or ventilatory support. No deaths were reported. The doses for Botox ranged from 100 to 700 Units and for Myobloc from 10,000 to 20,000 U.

This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs. FDA will communicate to the public its conclusions, resulting recommendations, and any regulatory actions after the review of the data are completed.

Report serious adverse events to FDA’s MedWatch reporting system by completing a form on line at <http://www.fda.gov/medwatch/report/hcp.htm>, by faxing (1-800-FDA-0178), by mail using the postage-paid address form provided online (5600 Fishers Lane, Rockville, MD 20853-9787), or by telephone (1-800-FDA-1088)